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Abstract 
Measles virus (MV) is an important human pathogen that still claims almost one 
million lives annually, primarily in the developing world. To date two human 
proteins have been identified that can serve as the receptor for measles virus, namely 
membrane cofactor protein (MCP) and signalling lymphocyte activation molecule 
(SLAM). It is thought that a more through understanding of the sructure and 
behaviour of the interacting regions of these receptors, will facilitate a more detailed 
understanding of the pathogenesis of MV. This thesis describes efforts to clone, 
express and characterise the relevant fragments of these receptors. 
The natural function of MCP is to prevent activation of complement on self cells. 
MCP contains four extracellular complement control protein (CCP) modules. The 
region of MCP that interact with MV has previously been identified to be the first 
two N-terminal CCP modules. MCP carries a functionally critical N-glycan on its 
second module (MCP2) and the crystal structure of MCP12 (expressed in 
mammalian cells) implies a structural role for this carbohydrate moiety. MCP 12 and 
MCP2 were successfully cloned and expressed as secreted proteins in Pichia pastoris 
at levels sufficient for biophysical characterisation. Proton and ' 5N Nuclear 
magnetic resonance spectroscopy (NMR) studies, differential scanning calorimetry 
and mass spectrometry were employed to investigate the recombinant proteins. Both 
the natural sequences of MCP 12 and MCP2 fragments expressed in P. pastoris were 
hyperglycosylated, and therefore these recombinant fragments were investigated in 
both glycosylated and deglycolylated forms in order to study the effect of the glycans 
on module 2 of MCP, and with a view to detailed structural and dynamic studies 
using NMR. The data obtained with the P. pastoris-expressed fragments are not 
inconsistant with the hypothesis that the N-glycan on module 2 of the wild-type MCP 
is required for this module to be properly folded. After extensive investigations, it 
was concluded that the inability of P. pastoris to attach the natural glycan is a barrier 
to more detailed structural studies. In an effort to produce MCP2 with a better 
defined glycosylation profile, efforts were made to express, this fragment in insect 
cells which are known to produce a 'more natural' glycosylation profile on proteins. 
Moreover, the MCP2 fragment was also expressed in E. coli, in order to produce a 
form of MCP2 that had never been glycosylated. 
Following the discovery that SLAM may be the more physiologically relevant 
receptor for MV, it had been established that the first V-type immunoglobulin-type 
domain (SLAM 1) is necessary and sufficient for interaction with the virus. SLAM 1 
was successfully cloned from a human cDNA library using touchdown PCR, and 
efforts were made towards its expression in P. pastoris. Expression levels of 20 mg/i 
of induction medium were achieved, however the recombinant SLAM 1 was also 
hyperglycosyiated by P. pastoris which has hampered its purification. 
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1.1. Measles Virus 
1.1.1. Preliminary remarks 
Measles virus has been anecdotally described as the biggest killer of children in 
history. Whether or not this is true it has undoubtedly been responsible for countless 
millions of deaths. Measles virus is historically significant and is thought to have 
been recognised as a disease distinct from smallpox for over 1000 years (Griffin et 
al., 1994). It is also said that measles is the disease that first introduced the idea of 
lifelong immunity to medicine, after Panum's observations of a measles epidemic in 
the Faroe Islands in 1846 (republished as Panum, 1939). He found that islanders 
who had been infected with measles virus in an earlier measles epidemic remained 
healthy during the current outbreak. Given the historical significance of measles 
virus, it is hardly surprising that it has been the subject of such a significant level of 
research effort. 
1.1.2. Measles vaccination: 
Since the introduction of an effective attenuated live vaccine based on the 
Edmonston strain, the incidence of measles has dramatically declined, especially in 
the developed world (Stalkup, 2002), and the virus is now on the WHO target list for 
eradication (Wild, 1999). Despite thee efforts, however, measles still affects around 
50 million people, and is responsible for around one million deaths annually, 
predominantly in the developing world (Omer, 1999). 
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One of the major failings of the current vaccine is that its period of protection is 
necessarily limited. A neonate's initial measles protection comes from 
transpiacentally transferred maternal antibodies, which persist in the blood stream for 
several months. During this period, vaccination is not a viable option since the 
vaccine would be rapidly cleared from the blood by the same maternal antibodies 
that provide the initial immunity (Osterhaus et al., 1994). It is not until this transient 
immunity has waned that vaccination can proceed, therefore there is inevitably a 
period of almost a year during which there can be no measles vaccination. There 
will probably always be clinical cases of measles under this immunisation regime, 
especially in developing countries, where the incidence of vaccination is lower (El 
Kasmi et al., 2001). The relative success of this vaccination strategy in the 
developed world appears to be due to a combination of factors, not least of which is 
the high rate of vaccination uptake, which over time causes a gradual depletion of the 
viral reservoir, and provides a herd immunity (Schlenker et al., 1992). This 
combined with better isolation and treatment of patients with the clinical disease 
reduces the chances of an individual coming into contact with the virus in the first 
place. 
There also appears to be another problem with the current measles vaccination 
strategy in the UK, namely that of public concern over the safety of the measles 
vaccine (Owens, 2002). In the majority of developed countries, the measles vaccine 
is given in conjunction with those for mumps and rubella as a single dose vaccine 
known as MMR. However since the publication of some studies that have indicated 
(albeit fairly inconclusively) that the MMR vaccine may be linked to autism and 
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bowel disease (Morris et al., 2002; Uhlmann et al., 2002), public confidence in the 
vaccine has declined significantly. This has resulted in a small but significant drop 
in the uptake of the vaccine in the UK, which may result in rising rates of clinical 
measles cases with all the associated problems. The reduction in vaccine uptake also 
appears to be clustered, and it may be that some regions have a rate of vaccination 
below that which is necessary to maintain the herd immunity. These problems could 
be addressed by the use of public information campaigns aiming to reassure parents 
that the vaccine is safe. This could well be the quickest (and probably the cheapest) 
solution to this problem. It may also be wise, however, to try developing a new 
vaccine that has a more favourable distribution of possible times of administration, 
and would not be tainted with public suspicion that it is unsafe. Such a strategy may 
serve both to improve the overall levels of measles immunity, and to improve public 
confidence in the vaccine, and thus help uptake rates to recover to their previous 
levels. Another reason why it is important to maintain public confidence in the 
safety of the MMR vaccine is to prevent the emergence of a widespread suspicion of 
vaccines in general, with all of the associated public health implications. 
1.1.3. Disease Progression 
The clinical course of an uncomplicated measles virus infection generally follows a 
standard pattern (for a review see Katz, 1995): the incubation period, the prodromal 
period, the exanthem period, and the healing of the rash. The incubation period of a 
typical measles virus infection lasts for 10 to 12 days post-infection, during which 
time there are virtually no outward symptoms. During this period the virus infects 
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the endothelial cells of the upper respiratory tract, spreads to the lymph nodes and 
multiplies. It spreads throughout the bloodstream resulting in the primary viraemia. 
followed subsequently by a more intense secondary viraemia several days later. 
Following the incubation period the patient enters the prodromal phase, which is 
when the symptoms first appear. The initial symptoms somewhat resemble those of 
the common cold. Over the next two days, however, they intensify and additional 
symptoms, including nausea, a rasping cough, and conjunctivitis, may often start to 
develop. The initial symptoms are followed by the appearance of Koplik's spots 
shown in Figure 1.1, which are small raised white spots found on the mucous 
membranes of the mouth and throat that resemble grains of salt. The appearance of 
Koplik's spots is a characteristic of all clinical measles cases. 
Figure 1.1 Kopliks spots in the mouth of a measles patient. Koplks spots 
appear like grains of salt on the oral mucosa, and are one of the first noticeable 
manifestations of the disease. Taken from 
vw . dent isirv 
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The next phase of the disease is the exanthem period, during which the characteristic 
measles rash starts to develop. The rash is a consequence of the immune response to 
measles rather that a result of the virus itself, as demonstrated by the lack of 
presentation of the rash in severely immunocompromised patients (Kaplan et al., 
1992; Markowitz et al., 1988). The rash usually appears between 14 and 18 days 
post-infection and develops initially on the face or behind the ears, spreading over 
the next two to three days to include the torso and limbs. During this period the body 
temperature peaks and the Koplik's spots begin to subside. The rash generally lasts 
less than a week and as it fades the skin tends to peel or flake. The cold symptoms 
and conjunctivitis usually disappear shortly after the appearance of the rash, although 
the cough will often persist for several days longer. 
1.1.4. The Genetics of a Measles Virus Infection 
Measles virus is an enveloped negative (-) sense RNA virus of the order 
mononegavirales. It is a member of the paramyxoviridae family, subfamily 
paramyxovirinae and of the genus morbillivirus, and is closely related to several 
other important viruses including canine distemper and rinderpest viruses. The virus 
has a 15.9 Kb minus (-) sense RNA genome (Baczko et al., 1983; Dunlap et al., 
1983), which consists of six genes in the following order: 
N 6OkDa 
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The N gene encodes for the nucleoprotein, which associates tightly with the RNA 
genome to form the nucleocapsid (Lund et al., 1984). The P gene encodes for three 
proteins, (P C and V) (Bellini et al., 1985; Gombart et al., 1992) that when combined 
with the L gene-product provide the viral RNA-dependent RNA polymerase activity 
(Horikami et al., 1994). The V and C proteins have also been demonstrated to act as 
virulence factors (Patterson et al., 2000). The M gene encodes the matrix protein 
(Bellini et al., 1986), and the F (Buckland et al., 1987; Curran et al., 1988) and H 
(Gerald et al., 1986) genes encode for the two viral envelope glycoproteins, i.e. the 
fusion protein and haemagglutinin respectively. The gene order of the measles virus 
genome is: 3' leader - N - P/C/V - M - F - H - L - trailer 5'—. It was originally 
determined by northern analysis of the mRNAs isolated from measles-infected virus 
cells (Dowling et al., 1986) and this was subsequently confirmed by sequencing 
(Takeda et al., 1999). It also appears that the gene order plays a significant role in 
controlling the levels of expression of each gene product. The RNA-dependant RNA 
polymerase generally binds to the 3' end of the genome and transcribes each gene in 
sequence, halting transcription between each gene. A proportion of polymerase 
seems to 'fall off the template after the transcription of each gene is finished, and 
then cannot be replaced. This results in decreased levels of transcription for genes at 
the 5' end of the genome, compared to the levels for genes at the 3' end (Cattaneo et 
al., 1987). This phenomenon may be reflected in differential expression levels for 
the various viral proteins. 
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1.1.5. Structure of a Measles Virus Virion 
Measles virions vary in size from approximately 100 nm to 250 nm in diameter, and 
are roughly spherical in shape, although they do appear to be somewhat pleomorphic 
(Horikami et al., 1995). Figure 1.2 shows an electron micrograph of a measles virion. 
The schematic representation of a measles virion shown in Figure 1.3 shows the 
virus's key features. It consists of a host cell-derived outer lipid bilayer, which 
contains the two envelope glycoproteins haemagglutinin (H) and fusion (F) The H 
protein has a dual role: it both mediates the initial attachment of the virion to the cell 
and it plays an auxiliary role in the fusion process (Nussbaum et al., 1995). Located 
just on the inner side of the membrane is the matrix (M) protein, which provides 
much of the virion's structural stability. The M protein is thought to interact directly 
with the cytoplasmic domains of the envelope glycoproteins. An idea that is 
demonstrated by the ability of M protein to specify polarised sorting of these proteins 
in epithelial cells (Naim et al., 2000). Within the region enclosed by the M protein 
lies the nucleocapsid, which contains the viral genome. Also present inside the 
virion are the proteins that provide the viral RNA polymerase activity - the large (L) 
protein and the phosphoprotein (P). 
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Figure 1.3 Schematic representation of a measles virion structure showing the 
virion's proteins and major features (taken from Schneider-Schaulies et al., 
2002). 
1.1.6. The Infectious Cycle 
The initial interaction between measles virus and a susceptible cell is the adsorption 
of the virus to the cell surface. Following the initial binding, the viral envelope fuses 
with the plasma membrane in a process that appears to require the formation of a 
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ternary complex between the F and H proteins and the cellular receptor. The fusion 
protein is synthesised as a precursor protein termed F0 and is subsequently cleaved 
and disulphide bonded yielding the active heterodimeric form of the protein (F 1 -F2) 
(Bolt et al., 1998). Following binding of the H protein to the cellular receptor, a 
conformational change is induced in F 1 -F2 that facilitates insertion of the 
hydrophobic fusion domain of F 1 -F2 into the host cell. The fusion process has been 
shown to require the action of both the H and F proteins. Subsequent interactions 
between a-helices of the fusion protein result in membrane fusion (Baker et al., 
1999; Samuel et al., 2001). Whilst the action of the fusion protein seems to 
predominate, other host proteins, possibly including moesin, may also be involved in 
viral fusion. Moesin became a candidate since it was demonstrated that it is present 
at the sites of MV infection and can form a complex with MCP; and anti-moesin 
antibodies can block measles infection under certain circumstances; (Schneider-
Schaulies et al., 1995b). The schematic representation of the fusion process 
illustrated in Figure 1.4 shows MV using the protein SLAM as the cellular receptor 
(see below). This general scheme would hold true also for membrane cofactor 
protein (MCP) receptor usage (see below). The overall fusion process is, however, 
still far from fully understood. 
Following membrane fusion the nucleocapsid is released into the cytoplasm where 
the rest of the viral life cycle takes place. The virus initiates the synthesis of its own 
proteins, using the RNA-dependant RNA polymerase packaged within the virion. 
This activity provided by a P-L complex appears to only transcribe encapsidated 
RNAs. The resulting transcripts are processed at the 5' and the 3' ends by the host 
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cell in the usual way. The cellular machinery is also responsible for the translation 
of the processed viral transcripts. 
Binding 	 Conformational 
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Figure 1.4 Schematic representation of the events involved in the fusion of MV 
with the cell membrane (taken from Schneider-Schauljes et al., 2002). 
It would appear that initially the RNA-dependent RNA polymerase produces only 
mRNA transcripts. In order for replication to occur, however, the virus also needs to 
produce a plus (+) sense copy of the complete RNA genome to serve as a template 
for the production of further copies of the minus (-) sense RNA genome. Based on 
data obtained on other organisms including Vesicular Stomatitis Virus (VSV), it is 
thought that the same RNA-dependant RNA polymerase is responsible for the 
synthesis of the mRNA transcripts, and both the (+) and (-) strand genome length 
RNAs (Banerjee, 1987). This seems to be achieved through a switching mechanism, 
whereby the concentration of the viral nucleoprotein upon reaching a critical level 
triggers the synthesis of whole copies of (+) sense genome. Although the nature of 
this switching mechanism is not well understood, it is plausible because genome 
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synthesis appears to be coupled to the encapsidation process. The secondary 
genomes produced by this mechanism also appear able to serve as the templates for 
further rounds of transcription, thus amplifying viral mRNAs as well as facilitating 
viral replication. 
1.1.7. Receptors for Measles Virus 
As has already been suggested, the initial event in any measles infection (attachment 
of the virus to the cell) is achieved by an interaction between the H protein and its 
cellular receptor. Considerable effort was therefore put into identifying the receptor 
because blocking this interaction could potentially provide a very effective treatment. 
The breakthrough finally came when (Naniche et al., 1993) discovered that 
recombinant murine B cells expressing MCP were found to bind measles virus 
(Edmonston Strain), and that anti-MCP antibodies were able to prevent this binding. 
This report was further supported when it was reported almost simultaneously that 
MCP recombinant chinese hamster ovary (CHO) cells could both bind measles virus 
and support infection, whereas mock transfected cells could not (Dorig et al., 1993). 
It was also demonstrated that polyclonal anti-MCP antisera could block this 
infection(Dorig et al., 1993). As further evidence also showed that MCP could act as 
the cellular receptor for measles virus (Dorig et al., 1994; Gerlier et al., 1994), the 
idea became generally accepted. The binding site for MCP was mapped on the 
measles virus H protein, and amino acid 481 was shown to be particularly important 
for this binding (Bartz et al., 1996; Lecouturier et al., 1996). 
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Questions regarding this view began to arise in 1996 (Buckland et al., 1997), 
however, when an accumulation of data indicated that MCP could only act as a 
receptor for certain laboratory-adapted strains of measles virus (typically the vaccine 
strains Hallé and Edmonston), and that so called wild-type measles strains appeared 
to be using a different protein as their receptor (Bartz et al., 1998; Lecouturier et al., 
1999). 
There is considerable and wide ranging evidence that only certain strains of measles 
virus use MCP as a receptor. Human red blood cells don't express MCP although 
African green monkey red blood cells (AGM_RBC) express a simian homologue of 
MCP. Vaccine strains of measles virus have the ability to haemagglutinate 
AGM_RBC, whereas other isolates could not, implying that some measles isolates 
cannot use MCP as a receptor (Saito et al., 1992). Certain MCP transgenic rodents 
and recombinant cell lines are not permissive for measles infection/attachment 
(Blixenkrone-Moller et al., 1998; Horvat et al., 1996; Niewiesk et al., 1997). Whilst 
this could indicate the need for a cofactor, it could also suggest that MCP may not be 
the 'natural receptor' for measles. One of the consequences of a measles infection 
with a vaccine strain is the down-regulation of MCP expression, and the amino acids 
on the H protein responsible for this phenomenon were subsequently identified 
(Bartz et al., 1996). This characteristic of infection is found only for the vaccine 
strains and certain laboratory-adapted strains of measles (Lecouturier et al., 1996). 
This phenomenon is also mirrored in the case of SLAM, since it has been 
demonstrated that MV-H also down regulates SLAM (Tanaka et al., 2002). The 
latter case, however, appears to hold true even for measles strains that are normally 
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associated with MCP receptor usage. Chick embryo fibroblast cultures are thought 
not to have a homologue of MCP, although certain measles isolates have been 
successfully passaged through such cultures. It is interesting to note that these data 
seem to be consistent with one group of isolates using MCP as receptor while 
another group of isolates use another receptor. This other receptor was identified as 
CDw150 (SLAM) during the course of this study (Tatsuo et al., 2000), and this result 
was subsequently supported by similar findings elsewhere (Erlenhoefer et al., 2001; 
Hsu et al., 2001; Ono et al., 2001a; Yanagi, 2001). In each of these cases the strain 
of measles used had not been passaged through Vero cells, and was said to be wild-
type. The use of SLAM as a receptor for measles virus was further validated when 
the measles binding site was mapped to the N-terminal Ig domain (Ono et al., 
2001b). There are, however, discrepancies also in the data that suggest SLAM is the 
'natural' measles virus receptor. Whilst all measles strains tested so far have the 
ability to use SLAM as a receptor, it appears not to possess the expression profile 
that one would expect from observing clinical measles infections. SLAM is 
expressed on activated B and T cells, immature thymocytes and memory cells, but is 
not found on unstimulated monocytes (Minagawa et al., 2001), and is either not 
present on immature dendritic cells, or is expressed at very low levels (Ohgimoto et 
al., 2001). It therefore remains an open question as to how measles viral infections 
can manifest themselves the way they do, given this restricted expression profile. It 
has recently been demonstrated that SLAM expression can be induced on monocytes 
during an inflammatory response (Minagawa et al., 2001), and it may subsequently 
emerge that this induction is indeed associated with the infection of monocytes with 
measles virus. Given that these data appear to be counter-intuitive, alternative 
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hypotheses may be needed, such as invoking the possibility of measles virus using 
co-receptors. 
The problems of receptor identification seem to have arisen from the way in which 
the virus is isolated. The propagation of measles virus is typically achieved by 
passaging through monkey kidney cell lines (Vero). This procedure requires several 
rounds of so called blind passaging when no virus can be propagated. It is only after 
several weeks that cytopathic effects become observable, and virus can be harvested. 
It was later found that the isolation procedure could be considerably (10,000-fold) 
more sensitive if a marmoset lymphoblastic cell line (B95-8, or the adherent relative 
B95-a) was used in place of Vero cells (Kobune et al., 1990). Furthermore it was 
discovered that: (i) there were minor antigenic differences between the two types of 
measles isolate (Kobune et al., 1990); (ii) the B95-8 isolated virus produced disease 
symptoms in experimentally infected moneys which more closely resembled those of 
the human form of the disease; and (iii) that when the B95-8 isolated virus was 
adapted to Vero cells it behaved like the traditional Vero passaged virus. These data 
imply that some fundamental difference exists between the two types of measles 
virus, and that the B95-8 passaged measles isolates may more closely resemble the 
wild type virus than do Vero passaged isolates. 
These differences in isolation also seem to translate into the phenotypic differences 
noted above. Vero-passaged isolates appear to be able to infect MCP recombinant 
cells, have this infection/binding blocked by anti-MCP antibodies, down-regulate 
MCP expression, and haemagglutinate AGM_RBC. Whereas, virus passaged on B 
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cell-derived cell lines on the other hand, appear to display none of those traits 
(Schneider-Schaulies et al., 1995a). The evidence becomes more compelling when 
one considers reports that sequence analysis of the H proteins from certain Vero cell-
adapted and 'Wild Type' virus differ from each other by two amino acids. Moreover 
it was found that the phenotype could be switched between 'wild-type' and 'Vero' by 
mutating E451 and N481 of the H protein in a wild-type Ma93F strain into the valine 
and tyrosine residues respectively found in the vaccine like Hallé strain (Lecouturier 
et al., 1996). A later study showed that the Y451 of Edmonston H protein was 
required for fusion to COS cells, but was unnecessary for binding to the marmoset 
B95-8 cell line (Xie et al., 1999). MCP down-regulation remained unaffected in this 
case. There have also been reports that other H-protein amino acids are involved 
both in MCP down regulation and receptor usage. If G546 is changed to a serine 
then haemadsorption and MCP receptor usage are conferred upon the virus (Woelk et 
al., 2001). Similar results have also been obtained elsewhere (Li et al., 2002). 
Statistical analysis of the sequences of the H protein from a large number of measles 
isolates using the maximum likelihood method has generated some interesting 
findings (Woelk et al., 2001). It was shown that a number of differences in the H 
protein sequences from different isolates were non-random. Of particular interest 
was the finding that there was a positive selection for a tyrosine at position 481 in 
non B-cell passaged virus, and this is apparent in isolates passaged through several 
different cell lines (Woelk et al., 2001). The authors suggest that this is the result of 
a natural selection for the MCP receptor, rather than an artefact of Vero passaging. 
The same study also showed that there was a strong selection for a serine residue at 
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546 only in virus passaged through Vero cell lines, and as already indicated this 
change can confer MCP receptor usage. These data show that there are several non-
random amino acid changes that are dependant upon the cell line used for 
propagation, and more work needs to be carried out to determine the most realistic 
strain of measles. The physiological relevance of MCP as the measles receptor was 
indeed recently demonstrated (Manchester et al., 2000). There are however 
precedents for this type of host range switching, for example certain picornaviruses, 
which have a positive (+) sense RNA genome, appear to be able to switch host range. 
This occurs not only when passaging the virus through cell lines from different 
species, but also after passaging through different cell lines from the natural host. 
It therefore seems possible, that the ability of different isolates of measles to utilise 
different receptors could just be an artefact of virus propagation in unnatural cells. 
On the other hand, it also seems feasible that measles virus could use both receptors 
at different times during an infection, since the available evidence supporting each 
receptor acting alone is less than compelling. 
1.1.8. The immunosuppressive effect during a measles virus infection 
One of the most important consequences of a measles infection is the profound 
suppressive effect it has on the immune system. This was first noticed by von 
Pirquet, when he noticed the disappearance of the delayed-type hypersensitivity skin 
test to tuberculin, and an exacerbation of tuberculosis in measles patients (von 
Pirquet, 1908). The suppression of the immune system allows the opportunistic 
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infections, which cause most of the mortality associated with measles, to take hold 
(Beckford et al., 1985). This immune suppression occurs through a number of 
different routes. Measles virus causes a decrease in the effectiveness with which 
antigens are recalled, a suppression of lymphoproliferative responses (Ward et al., 
1991), and abnormal lymphokine production (Atabani et al., 2001). It is interesting 
to note that these immunosuppressive effects occur at the time the immune response 
to the virus is at its strongest. 
Monocytes, which are infected by measles virus, are responsible for the production 
of accessory factors (e.g. IL-1 and TNF-a). The level of IL-1 produced by infected 
monocytes is usually slightly raised, whereas the levels of TNF-a produced are 
reduced. TNF-a is a proinflamatory cytokine that is known to play an important role 
in the inflammatory response, and the lymphoproliferative effect. This decrease in 
TNF-a production caused by monocyte infection may be partially responsible for the 
decrease in lymphoproliferation that is associated with measles virus infections. It is 
thought that this reduction in TNF-a may reduce the efficacy of the immune 
response to new infections. 
1.2. Membrane Cofactor Protein 
1.2.1. Preliminary remarks 
Membrane cofactor protein is a member of the regulators of complement activation 
(RCA) gene family and is expressed on the surface of all human cells examined so 
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far, with the exception of red blood cells (Johnstone et al., 1993a). It inhibits the 
complement system by acting as a cofactor for factor 1-mediated cleavage of C3b and 
C4b, and is also involved in some cell signalling pathways. Since MCP is a 
complement inhibitor that protects host cells from complement-mediated lysis, it has 
recently become of interest in the field of xenotransplantation (Begum et al., 2000; 
Diamond et al., 2001; Loveland et al., 1993; Shinkel et al., 1998; Thorley et al., 
1997). In addition to its natural role as a complement regulator, MCP has been found 
to be the cellular receptor for several important human pathogens in addition to 
measles virus. 
1.2.2. The domain structure of MCP 
Membrane cofactor protein is a single-chain membrane-bound glycoprotein. It 
contains an extracellular region, a single pass membrane-spanning segment, and a 
short cytoplasmic region (although a soluble form is also present in low 
concentrations in blood plasma, tears and semen) (Hara et al., 1992). The 
extracellular portion of the protein consists of four complement control protein 
(CCP) modules (also known as short consensus repeats, or sushi domains), a region 
rich in serine, threonine and proline residues (the STP region), and a region of 
unknown function. Following the extracellular region is a single, hydrophobic, 
transmembrane helix, and a short cytoplasmic sequence that is rich in arginine, 
lysine, and threonine residues (Liszewski et al., 1991). A schematic representation 
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Figure 1.5 Schematic representation the structure of MCP, showing the four 
common isoforms (adapted from Liszewski et al., 1996). 
1.2.3. Structure of MCPI2 
The publication of the crystal structure of MCPI2 shows a number of interesting 
features (Casasnovas et al., 1999). A hexamer was found in the unit cell and so six 
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independent structures were solved, and a representative monomer is shown in 
Figure 1.6. The structures of these six monomers differed in their intermodular 
angles by —15 0  implying that the modules may be joined by a flexible linker. The 
presence of a Ca2  ion at the intermodular interface and crystal packing forces may 
further act to reduce the flexibility of this junction. Furthermore, the hexameric 
structure and the presence of a Ca 2  ion at the interface between modules, are not 
supported by physiological evidence, implying that these features may be crystal 
artefacts. Given the potential for physiologicaly relevent flexibility in the 
intermodular junction, elucidation of the solution structure and dynarnis of this pair 
of modules should yield further information regarding its fuction. 
The crystal structure provides interesting information concerning the structural basis 
for the functionally important glycans on module 2. The glycans of module 2 are 
located on the opposite side of MCP 12 to the viral binding site. The regions 
involved in measles virus binding, therefore appear to form an extended glycan free 
binding site. Moreover, hydrophobic contacts were observed between the glycans 
and residues Y87 1104 of the polypeptide chain in each of the six independent copies 
of the protein. Together these data provide further evidence that measles virus does 
not merely bind to the glycans, and that instead interactions between the glycans and 







Figure 1.6 Crystal structure of a representative MCPI2 monomer, with the N-
terminus uppermost. The figure shows the Winked glycans and Ca 2-  ion. 
Cysteines involved in disulphide bonds are shown in yellow. 
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1.2.4. Post-transcriptional modifications of MCP 
Alternative splicing of MCP mRNA generates four common isoforms, although 
some rarer isoforms also exist. There are two common STP regions (B and C) and 
two distinct common cytoplasmic regions (1 and 2); the four CCP modules are 
present in all of the isoforms identified to date. The C version of the STP region is 
present in all of the major isoforins, and so the presence or absence of the B form of 
the STP region is responsible for some of the variation; the cytoplasmic sequence is 
either 1 or 2 in the common isoforms. The prominent isoforms are therefore Cl, C2, 
BC  and BC2. The exact reasons for the occurrence of different isoforms are not yet 
fully understood. Most cells appear to express broadly similar levels of each isoform 
while notable exceptions include sperm, brain, kidney, and the salivary gland 
(Johnstone et al., 1993b). 
1.2.5. Post-translational modifications of MCP 
There are three N-glycosylation sites in MCP, one in each of CCP modules 1, 2 and 
4. In addition to its N-glycosylation, MCP is also heavily 0-glycosylated in the STP 
region. The 0-glycosylation may help to protect the protein from proteolysis and 
there are precedents for this in other membrane proteins (Reddy et al., 1989). Both 
the 0-glycosylation, and the N-glycan, on CCP modules 2 and 4 are required for 
MCP's complement regulatory activity (Liszewski et al., 1998) . Of particular 
interest though is the glycan on CCP module 2, since it is necessary for both the 
natural complement regulation activity, and for function as the measles virus receptor 
(Maisner et al., 1996; Maisner et al., 1994), implying that it could be performing 
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some structural role. Interestingly it was demonstrated that the exact nature of the N-
glycans on module 2 of MCP are unimportant for measles receptor function (Maisner 
et al., 1995). There is also growing suspicion that the cytoplasmic region can be 
phosphorylated, and it has been implicated in certain cell signalling pathways (Wang 
et al., 2000; Wong et al., 1997). 
1.2.6. The CCP module 
The RCA protein structure is based upon the complement control protein structural 
motif, which, as its name implies, is present in many of the complement control 
proteins. The RCAs contain at least three CCP modules connected by short linker 
sequences (Barlow et al., 1991). CCP modules usually occur in elongated head-to-
tail arrays with a functional site that typically involves at least two modules and their 
associated junctions. It is for this reason that the intermodular orientation is 
considered to be of particular importance. The genes encoding the complement 
control proteins are very closely related. CCP modules, as are identified by the 
presence of a consensus sequence containing a pattern of cysteine residues, and a 
tryptophan residue, spanning some 60 residues. This consensus sequence occurs 
numerous times in a wide range of proteins. Although the CCP module was first 
identified as a structural motif in complement control proteins, it has been found in 
an increasing number of apparently unrelated proteins, from clotting proteins to 
neurotransmitter receptors. CCP modules are also found in a wide variety of 
different organisms, from C. elegans and various viruses through to man. 
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1.2.7. The CCP module structure 
A CCP module consists of approximately sixty amino acids including four cysteines 
which form disulphide bonds in a 1-3, 2-4 pattern as illustrated by the first structure 
of the 16th  CCP module of complement factor H (Norman et al., 1991). Give the 
structural significance of the disulphide bonds it is perhaps unsurprising that the 
disulphide bonds were shown to be essential for MCP to serve as a measles virus 
receptor (Maisner et al., 1994). A sequence alignment of several CCP modules along 
with the consensus sequence is shown in Figure 1.7. The majority of the structure is 
composed of small anti-parallel n-sheets, which form a tightly packed barrel-like 
structure around a compact hydrophobic core that contains a consensus tryptophan 
side chain (very rarely replaced by a phenylalanine). The modules generally occur in 
a head-to-tail or 'beads on a string' arrangement; and both well-defined (Wiles et al., 
1997) and flexible (Smith et al., 2002) intermodular junctions have been described. 
Whilst sequence and length variations between CCP modules are considerable, 
modelling by homology the structures of individual CCP modules is at least feasible. 
Reliable methods for predicting the relative arrangement of neighbouring modules 
are, however, as yet a long way from being available. Until such methods are 
developed, the intermodular arrangement will necessarily require elucidation by 
empirical methods. It is suspected that in certain circumstances a flexible linker may 
be critical to biological function. Given the likelihood that crystal packing forces 
could artefactually rigidify the junction, the use of high field NMR spectroscopy to 
provide solution structures of CCP module is particularly appropriate. 
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Name SS 	Pi 	 P2 NV-loop 	P3 	P4 OS P6 P7 pe 
VCP_1 LS: TI P SRPIN)F JS 	TAMNyNZ DrIEYL LP YRXQ:PIYAX T TWT LFNQ IKR 
NCP_1 SDk EE PP TFEANEL I KPKP 	YYEI -ERVDYX KK - YFYIPPL.ATHTI 0 RNHTVLP VSDDA YRE 
CR1_15 L H QA P DKFLFAKL KTQTNAS DFPITSLKYER?E TY RPFSIT,LON LVWS SPKDV KRK 
CR11 WGQ NA P EWL.PFARP TNLTDEF EFFI :TYLNYE RP YS - RPFSI I LEN SVWT AK!DR RRK 
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Figure 1.7 Alignment of several CCP modules, showing the consensus 
sequence. Sequence numbers refer to the sequence of DAF; Prolines (green), 
cysteines (red), glycines (purple) and tryptophan (blue) are colour-coded; Beneath 
each block of sequence alignments: the use of the one-letter code indicates a 
specific residue that is conserved across all sequences shown; a + sign indicates a 
residue that is conserved or conservatively replaced in all the sequences shown; 
whereas a? indicates a residue-type that is not completely conserved (taken from 
Kirkitadze et al., 2001). 
1.2.8. RCA proteins can act as receptors for pathogens 
Like MCP, many of the other RCA proteins serve as the receptors for important 
human pathogens, and every RCA protein has been implicated in interactions with at 
least one important pathogen. Erythrocyte-borne complement receptor type I (CR1, 
CD35) is important in the rosetting process associated with severe cases of malaria, 
and has been shown to bind to the P. .falciparum VAR-i adhesin proteins on the 
surfaces of infected erythrocytes (Krych-Goldberg et al., 2002). CCP modules 1-2 of 
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complement receptor 2 (CR2, CD21) bind the Epstein-Barr virus (EBV) gp350/220 
protein conferring on CR2 the ability to act as the receptor for EBV (Molina et al., 
1991). Decay accelerating factor (DAF, CD55) acts as the receptor for many of the 
picornaviruses, for example echoviruses and coxsackieviruses. In addition DAF has 
been shown to bind the Dr antigen of certain strains of E. coli (Lindahl et al., 2000). 
Complement factor H has been shown to bind to Streptococcus pyogenes (through 
binding the M protein), Borellia burgdorferi (through the surface protein OspE) 
(Hellwage et al., 2001), Onchocerca volvulus microfilariae (Meri et al., 2002) and 
Neisseria gonorrhoeae (Ram et al., 1998). The discovery that factor H retains its 
complement regulatory activity when bound to the S. pyogenes M protein may 
illustrate one reason why the complement control proteins are such a 'popular 
choice' for a pathogenic receptor. C4b binding protein (C4bp) is also recognised by 
several important human pathogens including S. Pyogenes (Blom et al., 2000), 
Bordetellapertussis (Berggard et al., 200 1) and N gonorrhoeae (Ram et al., 2001). 
MCP is, therefore, not unique in its ability to act as a receptor for pathogens. 
Pathogens that use MCP as a receptor include: measles virus (MV); human herpes 
virus-6 (HHV-6) (Santoro et al., 1999); pathogenic Neisseria (Kallstrom et al., 1997) 
and S. Pyogenes (Giannakis et al., 2002; Okada et al., 1995). The attachment sites 
for N gonorrhoeae have recently been identified as CCP module-3 and the STP rich 
region (Kalistrom et al., 2001). HHV-6 is implicated in the progression of HP! to 
AIDS. Like the measles virus, HHV-6 has an immunosuppressive effect. This could 
be connected in some way to their both utilising MCP as their receptor. 
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1.2.9. The importance of MCP as a receptor for measles virus 
As has already been discussed, MCP can serve as the receptor for at least some 
strains of measles. A considerable body of data exists for the structural requirements 
of the interaction between MCP and the measles H protein. The H protein's binding 
site on MCP was localised to the first two CCP modules (Manchester et al., 1997) 
using a combination of deletions and chimeric proteins between MCP and the related 
protein, decay accelerating factor (DAF) that cannot serve as a measles receptor. 
The binding site was shown to be distinct from the C3b/C4b/factor I interaction sites, 
which have been located to CCP modules 2/3/4 (Adams et al., 1991; Iwata et al., 
1995; Liszewski et al., 2000). The binding of haemagglutinin to MCP appears to 
require the protein to have structural integrity, since the interaction requires the 
disulphide bonds to be intact and N-glycan on module two to be present (Maisner et 
al., 1996; Maisner et al., 1994). It is interesting to note that the exact nature of the 
glycan on module two seem to be relatively unimportant (Maisner et al., 1995), 
implying that the glycan serves some structural role rather than acting as an 
additional attachment site for haemagglutinin. This idea was further supported with 
the publication of the crystal structure of the first two CCP modules of MCP 
(Casasnovas et al., 1999). There have been several studies to identify the MCP 
residues that are required for haemagglutinin binding. These include peptide 
inhibition studies, site directed mutagenesis changing selected residues to serine (Hsu 
et al., 1999), and alanine scanning mutagenesis. These results are summarised in 
Figure 1.8. The residues identified from the above studies were shown to be surface-
exposed in the crystal structure, and appear to form an extended binding site that is 
free from carbohydrates. 
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DA EEPPTFEAME LIGKPKPYTEGE PVDYK KKGYFYIPPLATHTI DRNHTWLPVSDDA YRET 
P :PLNGQAVPANGTYEFGYQMHF1 NEGYYLIGEEILY ELKGSVAIWSGKPPI EK 
Figure 1.8 Summary of the residues of MCPI2 that have been implicated in 
measles virus binding. The consensus cysteines and tryptophans are shown in 
yellow, and bold respectively. The glycosylated asparagine residues are shown in 
bold italics. Residues implicated as important on the basis of mutagenesis to 
alanine and serine are shown as underlined, or red respectively. Residues 
implicated by peptide inhibition are shown in blue 
1.2.10. 	The function of MCP in cell signalling 
The biological role of the intracellular domain of MCP has remained largely a 
mystery. It is not required for the natural complement function of MCP, as a version 
of MCP with a GPI anchor rather than the normal transmembrane and cytoplasmic 
regions still serves to protect cells from complement attack (Shinkel et al., 1998). 
Purified pili from pathogenic Neisseria cause a calcium flux that can be blocked by 
anti-MCP antibodies (Kallstrom et al., 1998); partial deletion of the cytoplasmic 
domain of MCP reduced the effectiveness of a N. gonorrhoeae infection (Kallstrom 
et al., 2001); binding to haemagglutinin or anti-MCP antibodies causes down 
regulation of IL-12 (Karp et al., 1996): and GST fusions with the intracellular 
regions of MCP associate with kinases in macrophages (Wong et al., 1997). All of 
these results suggest a possible role for the intracellular region of MCP in cell 
signalling pathways. Further evidence of a cell signalling role for MCP came when 
it was discovered that a tyrosine in the cyt-2 cytoplasmic domain of MCP is 
phosphorylated by the Lck kinase from the src kinase system (Wang et al., 2000). 
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Precisely why MCP should posses a cell signalling role still remains moot, although 
it is not impossible that it may be to provide a link between the cellular immune 
system and the complement system 
1.2.11. 	The possible importance for MCP in xenotransplantation 
It is generally accepted that the scarcity of donor organs is one of the chief limiting 
factors governing the number of transplant operations that can be performed. 
Moreover, when human organs are used for transplantation, there exists a small but 
significant risk that the implanted organs will carry an infection. For these reasons 
researchers have started to examine the possibility of using alternatives to donated 
human organs. To date two options are generally considered to have reasonable 
potential. One option, based on organ engineering and embryonic stem cell research, 
would involve growing new organs in the laboratory using cloned human embryonic 
stem cells with the potential recipient acting as the donor of genetic material for their 
own organs. This approach, the favoured option from a therapeutic standpoint, still 
requires numerous serious technical problems to be overcome, although encouraging 
results have been obtained with skin and trachea. In addition to the technical 
difficulties are the associated moral and ethical problems that still plague any work 
related to the field of human cloning. The other technique generally referred to as 
xenotransplantation, involves the use of non-human organs for transplantation. In 
this case the donor animals of choice appear to be pigs since their organs are of 
similar size to human organs. In addition there is less public opposition to the 
experimental use of pigs than there is to the use of primates. Pigs are also assumed 
30 
Introduction 
to suffer from fewer diseases that could potentially be transmitted to humans. There 
are though major problems that stand in the way of xenotransplantation: of 
uppermost concern is that of hyperaccute rejection (HAR). HAR is a process that 
involves antibody initiated complement activation (Kadner et al., 2001), and results 
in rapid degradation of the target. It is thought that using pigs transgenic for human 
complement regulators, MCP and DAF in particular, could be a potentially important 
tool in the prevention of HAR, and this approach has indeed delivered some success 
for ex vivo perfusion experiments using transgenic mice (Mulder et al., 1995; Mulder 
et al., 1996), and in xenotransplantation experiments in baboons (Kadner et al., 
2001). In the case of MCP, however, modification of the protein has been 
undertaken, aiming to produce MCP that retains the ability to regulate complement, 
whilst losing the ability to act as a receptor for measles virus (Begum et al., 2000). 
Other approaches that have been proposed, include pigs that are transgenic for 
several complement regulators simultaneously e.g. DAF and MCP since these two 
complement regulators appear to act synergistically (Brodbeck et al., 2000). One 
method that has provided some ex vivo success, is the direct addition of a soluble 
MCP-DAF chimera (named complement activation b!ocker-2 CAB-2), to human 
blood that was perfusing a porcine heart (Kroshus et al., 2000). The inclusion of 
CAB-2 prolonged the survival of the heart. It still remains unclear, however, as to 
how this approach could be migrated to a human therapy. 
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1.2.12. 	The importance of MCP in reproduction 
Pregnancy and reproduction in general present the human immune system with an 
intriguing problem. The foetus is just another piece of foreign tissue as far as the 
immune system is concerned. It is clear therefore that there must be ways to protect 
the foetus whilst still retaining the ability to fight infection. It appears that this is 
achieved, at least in part, through the action of the complement regulatory proteins 
MCP and DAF. It was shown that mice that were deficient in the murine 
complement regulator Crry (an analogous protein to MCP and DAF) were unviable, 
and the foetuses abort (Xu et al., 2000). This was demonstrated to be due to their 
inability to prevent the activation of complement at the feto-maternal interface. 
In addition to protecting the foetus MCP appear to play other roles in reproduction. 
A soluble form of MCP, lacking the transmembrane domain and cytoplasmic tail, 
was found in semen at 10-fold greater concentrations than those found in plasma 
(Seya et al., 1993), and this has been linked to the prevention of sperm rejection. 
MCP may also play another, seemingly unrelated, role in reproduction since it has 
been associated with the sperm egg interaction, and certain types of sterility have 
been associated with abnormal seminal MCP expression (Kitamura et al., 1997). 
It therefore remains an important goal of current research to understand all the 
complement regulators as fully as possible. It is hoped that a fuller knowledge of 
these proteins could potentially provide highly significant therapeutic benefits in 
such diverse fields as transplantation, autoimmune diseases, and in the treatment of a 
diverse number of important human pathogens. 
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1.3. The complement system 
1.3.1. Preliminary remarks 
As already indicated MCP is a complement control protein whose natural biological 
function is to help prevent the complement system from attacking host cells. The 
complement system is one of the major components of the human immune system, 
and serves to clear foreign matter from the host. It was originally identified as a heat 
labile component of blood serum that could 'complement' the ability of antibodies to 
cause bacterial lysis. It is now known to consist of over thirty proteins, both soluble 
and membrane bound (Law et al., 1995). Activation of the complement system can 
occur by one of three mechanisms - the classical, lectin and alternative pathways) - 
all of which are of necessity tightly regulated. The essence of the complement 
system is a cascade of proteolytic activations of zymogens, which results in the 
various effector functions associated with the complement system. Despite, or 
perhaps because of, the central role of the complement system in the immune system, 
certain pathogens have evolved methods to hijack the complement system and use it 
to facilitate an infection. The complement system, when poorly regulated, has also 
been associated with a number of autoimmune diseases. 
1.3.2. Nomenclature of complement proteins 
The nomenclature used for the complement system is complex, and reflects by-and-
large the chronological order of protein discovery rather than their order of 
participation in a complement cascade. The proteins of the classical pathway are 
generally termed 'components' and are given a C followed by a number (e.g. C2). 
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Many of these proteins are zymogens so require proteolytic activation, and therefore 
the active enzyme is illustrated by the addition of a bar above the name (e.g. Cir). 
Following the proteolytic activation, the cleavage products are differentiated from 
each other and the parent protein by the addition of a lowercase letter (e.g. C2, C2a 
& C2b). Usually the small fragment is termed 'a' and the larger active fragment 'b', 
although an exception is 'C2', where 'C2a' is the larger active fragment and 'C2b' is 
the smaller one. Other complement proteins are generally termed 'factors', and are 
named with a capital letter (e.g. factor B), this can be abbreviated to FB or even 
dropped altogether leaving just B. The complement regulatory proteins are usually 
given an abbreviation (e.g. MCP), or are referred to by their cluster of differentiation 
(CD) number (e.g. CD46). 
1.3.3. Activation of the complement system 
As has already been stated, activation of the complement system occurs either via the 
classical pathway, the lectin pathway, or the alternative pathway. The classical 
pathway is activated by antibodies from the adaptive immune system, and results in 
complement activation which is part of the innate immune system. The classical 
pathway therefore acts as a critical link between the adaptive and innate immune 
systems. Very closely related to the classical pathway is the lectin pathway, which is 
activated by the binding of certain lectins to foreign sugar groups (in particular the 
terminal mannose residues often found in yeast glycoproteins and bacteria). The 
lectin pathway differs from the classical pathway only in the way that complement 
component C4 is activated The final method of activation of the complement system 
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is known as the alternative pathway that provides a 'tick-over' activation, which can 
rapidly amplify when needed. A schematic representation of the whole complement 
system is given in Figure 1.9. 
1.3.3.1. Complement activation via the classical pathway 
Central to the classical pathway is proteolysis of C4 eventually resulting in the 
formation of the classical pathway C3 and C5 convertases - C4b2a and C4b2a3b 
respectively. The initial step in the classical activation of complement is the 
activation of Cl. Cl is a calcium dependant, soluble serum protein complex 
consisting of a molecule of Clq, two Cir molecules and two Cis molecules. Clq 
has no intrinsic enzymatic activity, but is involved in interactions with immune 
complexes (Reid, 1983), whereas Cir and Cis are zymogens that provide the 
catalytic activity. Clq has an unusual "bunch of tulips-like" structure, consisting of 
six copies of a subunit that has a collagen-like region with a globular head. Clq 
interacts with the F c region of antibodies with several simultaneous interactions 
being required for stable binding. The result is that Clq binds strongly to the F 
domains of aggregated IgG molecules (as found in immune complexes), but not to 
the uncomplexed IgG present in normal serum. The binding of immune complexes 
to Cl causes a conformational change in Clq resulting in the auto-activation of Cir. 
Activated Clr then activates C is and further Cl r resulting in the active form of Cl 
(Clq(r 2 s2 )).Activated Clq(r 2 s2 ) then acts on the classical pathway complement 
component C4 to yield the two components C4a (a weak anaphylatoxin) and 
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the classical pathway complement component C4 to yield the two components C4a 
(a weak anaphylatoxin) and activated C4b that contains an exposed thioester. 
Activated C4b is highly unstable and is rapidly attacked by any surrounding 
nucleophilic groups (mostly from water molecules) to yield inactive C4b (iC4b). A 
small fraction of the activated C4b molecules bind covalently to hydroxyl groups on 
proximal cell surfaces, resulting in the presence of surface-bound C4b. The surface-
bound C4b generated in this manner can then bind to complement component C2, 
yielding C4b2. The C2 component of the newly formed C4b2 is now able to act as a 
substrate for activated Cis, yielding C2b and the classical pathway C3 convertase 
C4b2a. The classical pathway C3 convertase acts on C3 to form C3b and the 
anaphylatoxin C3a. The creation of C3b exposes a thioester, and like C4b reacts 
rapidly with free hydroxyl groups on the cell surface, in a process known as 
opsonisation. In addition C3b can bind to the classical C3 convertase (C4b2a) to 
form the classical pathway C5 convertase (C4b3b2a). This C5 convertase cleaves C5 
to generate anaphylotoxic C5a, and C5b. The newly exposed thioester in C5b 
promotes binding to the surface of the cell under attack by antibody, and the surface-
bound C5b then initiates the formation of the membrane attack complex (MAC), 
which ultimately results in cell lysis. 
1.3.3.2. Complement activation via the lectin pathway 
As already stated the difference between activation of complement through the 
classical pathway and lectin pathway lies only in the mechanism of formation of 
C4b. Activation of the lectin pathway involves mannan-binding protein (MBP) - a 
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calcium-dependent lectin in the collectin family instead of the Cl complex. 
Activation occurs when MBP binds sugar residues on foreign oligosaccharides 
(typically the terminal mannose residues), allowing it to interact with a MBP 
associated serine protease (MASP) (Holmskov et al., 1994). There are two types of 
MASP; MASP1 and MASP2 which are homologous in structure to Cir and Cis. 
MASP activation occurs in a similar fashion to Cir and Cis. The activated MBP- 
MASP complex can then act on C4 in the same way as Clq(r 2 s2 ) to initiate the 
formation of the classical pathway 0 convertase C4b2a. 
1.3.3.3. Complement activation via the alternative pathway 
Activation of complement via the alternative pathway occurs without any specific 
initiating event. Instead there is a continuous 'tick-over' mechanism of activation. 
In host tissue this is kept in check, but it is rapidly amplified in the absence of the 
necessary control mechanisms. There is an internal thioester bond in C3 that can be 
hydrolysed by water (Law, 1983). This yields a form of C3 (C3i) that can bind to 
factor B giving C3iB. Factor D is then able to cleave the factor B potion of C3iB 
resulting in C3iBb and Ba. The C3iBb produced in this way acts as a fluid phase 
alternative pathway C3 convertase that cleaves C3 into C3b (and the anaphylatoxin 
C3a) in a similar way to the classical pathway C3 convertase. The unstable C3b that 
is generated is quickly degraded unless it attaches to foreign material. When C3b is 
deposited on a foreign surface, it can also interact with factor B which is 
subsequently cleaved by factor D. When activated in this manner, the result is the 
active surface-bound alternative pathway C3 convertase - C3bBb, and a positive 
Introduction 
feedback loop is initiated. It is clear therefore that both the classical pathway and the 
alternative pathway can cause activation of the alternative pathway's positive 
feedback loop. The C3bBb generated by either pathway is then able to bind to 
further C3b to form the alternative pathway C5 convertase - C3bBb3b. 
1.3.4. Formation of the membrane attack complex 
The final direct effect of the complement cascade is the formation of the membrane 
attack complex (MAC). This stage is initiated by the proteolytic cleavage of C5 by 
either the classical or the alternative C5 convertase. For C5 to act as a substrate for 
the C5 convertases it needs to be bound to C3b and to a surface. Following cleavage 
of C5 into C5a (an anaphylatoxin that dissociates) and C5b, the formation of the 
MAC occurs through the sequential binding of the complement components C6-C9 
in a non-enzymatic process to the C5b on the foreign surface. After the addition of 
C7, the nascent MAC becomes hydrophobic and preferentially inserts into the lipid 
bilayer of the cell surface. Component C8 then binds followed by up to 14 
monomers of C9, to form a pore that can lead to cell lysis. Formation of the MAC in 
the fluid phase is largely prevented by proteins such as vitronectin, which serve to 
inactivate C5b67 before it can attach to host surfaces. Interestingly a small amount 
of MAC formation is important for the activation of certain cells of the immune 
system. The membrane containing a portion of MAC is endocytosed, and can 
stimulate the cell to produce and metabolise arachidonic acid, and other factors 
which can serve to stimulate the inflammatory response. 
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1.3.5. Regulation of the complement system 
It is clear that a system such as complement that has positive feedback loops and a 
"tick over" mechanism of activation requires rigorous regulation. Complement has 
been called a triggered amplification cascade because a small initial cause leads to an 
effect that has been greatly amplified. Improper or disproportionate action of 
complement results in inflammation and, potentially, severe tissue damage. Indeed, 
inappropriate complement activation is responsible for the debilitating symptoms 
associated with numerous diseases, although minute amounts of complement 
activation on host cells actually appears to be beneficial. The extreme destructive 
power of complement requires that at every stage there are checks and balances to 
prevent its activation on host cells. This is particularly true for the stages that lead to 
the generation of the critical C3 and C5 convertases that amplify the system so 
effectively. 
1.3.5.1. 	Regulation of classical pathway activation 
Regulation of the classical pathway occurs primarily at two distinct points in the 
cascade: the activation of C4 by Cl, and the formation and persistence of the C3/C5 
convertases. 
The first step of regulation in the classical pathway occurs by controlling the 
activation of Cl. Activation of Cl is controlled by the Cl inhibitor (C1-Inh); a 
serine protease inhibitor (SERPIN) that binds to and inactivates activated Cir and 
Cl s. The (Cl -Jnh)-C 1 r-C 1 s-(C 1 -Inh) formed in this way dissociates from Cl q, thus 
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preventing further activation of classical pathway. The free Cl q thus generated is 
then able to interact with the Cl q receptor and perform several effector functions 
including inhibition of IL-1 production. 
The second and possibly more important points of regulation are at the formation of 
the classical pathway C3 convertase (C4b2a) and C5 convertase (CO20b). These 
stages are efficiently regulated through two important and distinct mechanisms: by 
increasing the rate of dissociation of C2a from C4b in C4b2a; and by promoting the 
factor I mediated degradation of C4b. Dissociation of the separate components 
C4b2a takes place spontaneously relatively rapidly (-4-5 mm) even in the absence 
of other proteins and this acts as a natural break. Given the activity of C4b2a, 
however, efficient regulation requires this rate of dissociation to be further increased, 
should the cascade need to be halted altogether, as in the case with host cells. The 
process of increasing the rate of dissociation of C2a from C4b in C4b2a is known as 
decay acceleration. Decay acceleration activity is mediated by the interaction of 
C4b2a with some of the host complement control proteins that can promote the 
dissociation. The decay accelerating proteins on the cell surface are decay 
acceleration factor (DAY) and complement receptor type 1 (CR1), and in the fluid 
phase this role is carried out by C4 binding protein (C4-bp). 
Regulation of the C3/C5 convertases through the degradation of C4b is achieved 
through the action of factor I, and is also mediated through the action of some of the 
host complement control proteins. Factor I is a highly specific serine protease that 
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cleaves C4b at two points in its alpha chain, yielding the inactive fragments C4c and 
C4d whose further functions (if any) are unknown. The activity of factor I alone is 
relatively low, however it becomes greatly increased when the relevant complement 
control protein act as cofactors. This process is achieved on the cell surface by MCP 
and CR!, and in the fluid phase by C4-bp, acting as co-factors for factor I. The 
actions of C4-bp CR1 and MCP therefore serve to increase the rate of factor I 
mediated degradation of C4b, and so inhibit the action of the classical pathway C3 
convertase. 
To summarise the mechanism of classical pathway C3 convertase regulation: on a 
self surface MCP and CR1 can act as cofactors for factor I, whilst DAF and CR1 
promote the dissociation of C2a from C4b in C4b2a. These two mechanisms work 
in concert and are complemented by the equivalent action of C4bp in the fluid phase. 
On a non-self surface however, the absence of these regulators fails to inactivate 
complement, and lysis of the organism ensues. It can be seen that both C4bp and 
CR1 possess both decay acceleration and cofactor activities. A summary of the 
action of all the complement control proteins of both the classical and alternative 
pathways is shown in Table 1.1 
Table 1.1 Summary of the mechanism of action of the complement control 
proteins (adapted from Weisman et al. 1990) 
Protein Fluid phase or 
membrane bound 
Decay Acceleration Factor I cofactor Activity 
Classical Alternative Classical pathway 
cleavage of C4b 
Alternative pathway 
cleavage of C3b 
C4bp Fluid Yes No Yes No 
Factor H Fluid No Yes No Yes 
DAF Membrane Yes Yes No No 
MCP Membrane No No Yes Yes 
CR1 Membrane Yes Yes Yes Yes 
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1.3.5.2. Regulation of alternative pathway activation 
The alternative pathway is regulated, like the classical pathway, through the action of 
the complement control proteins and their capacity to accelerate decay and act as co-
factors. 
Decay acceleration in the alternative pathway is achieved in the fluid phase through 
the action of the complement control protein factor H promoting dissociation of Bb 
from activated C3 (C3i and C3b). This is analogous to the decay acceleration 
activity of C4-bp in the classical pathway. DAF and CR1 also act on the cell surface 
in the alternative pathway to promote the dissociation of Bb from C3 in an analogous 
fashion to their activities in the classical pathway. 
Factor I is also able to function as part of the alternative pathway to catabolise C3b 
into C3c and C3dg. The destruction of C3b is promoted in the fluid phase by the 
cofactor activity of factor H, and on the cell surface by the cofactor activities of MCP 
and CR!. Factor H is known to bind heparin and other polyanions such as the sialic 
acid groups often found on many mammalian cell surface glycoproteins. Factor H 
appears to be able to distinguish between self and non-self cells through its 
interaction with these polyanions, and its affinity for C3b increases by approximately 
10-fold in the presence of polyanions (Meri et al., 1994; Pangbum, 2000; Pangburn, 
2002). This increased affinity in the presence of polyanions has been shown to 
correlate with the protection of host cells, presumably through both cofactor and 
decay acceleration activities. 
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To summarise the mechanism of alternative pathway C3 convertase regulation: on a 
self surface MCP and CR1 can act as cofactors for factor I, whilst DAF and CR1 
promote the dissociation of Bb from C3b in C3bBb. On a non-self surface however, 
the absence of these regulators fails to inactivate complement, and lysis of the 
organism ensues. These two mechanisms also work in concert on the cell surface, 
and are complemented by the powerful selective activity of factor H. Factor H is 
able to distinguish self from non-self in many cases through the presence or absence 
of polyanions such as sialic acid on the cell surface. A summary of the action of all 
the complement control proteins of both the classical and alternative pathways is 
shown in Table 1.1 
1.3.5.3. Regulation of the membrane attack complex 
As with the other areas of the complement system, the MAC is also tightly regulated 
to prevent autologous cell lysis. One way in which MAC formation is regulated is 
through the action of the S-protein (vitronectin). It appears that when MAC starts to 
form in the fluid phase, vitronectin binds irreversibly to the C5b67 complex 
abrogating the membrane binding properties of the MAC. Another such MAC 
regulatory protein is CD59 (also known a protectin, H11.1720, MACiF, MIRL, or 
MEM-43-Ag), which seems to function to prevent the polymerisation of C9 on the 
C5b-8 complex in the final stages of pore formation (Lachmann, 1991). The 
presence of these proteins on a self-surface prevents excessive MAC deposition on 
autologous tissue, protecting it from complement attack. 
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1.3.6. Effects of complement activation 
The principal biological effects of the complement system are: the enhancement of 
killing of microbes; the processing and clearing of immune complexes; and the 
enhancement of the antibody response. 
1.3.6.1. The action of complement to enhance the killing of microbes 
Complement can enhance the killing of microbes in three ways, simultaneously. The 
first method is by the direct lysis of a cell by MAC formation. Second, activation of 
the complement system generates large amounts of the anaphylatoxins C3a and C5a, 
which act to enhance the inflammatory response. C5a acts as a potent chemotactic 
agent, activates neutrophils and monocytes, degranulates mast cells, and increases 
the expression of cell adhesion molecules. This results in: increases blood flow to 
the area, a respiratory burst (increases the production of oxygen free radicals), and 
increased production of IL-1, 1L6 and histamine. As would be expected the half-life 
of C5a is very short since carboxypeptidase N rapidly removes its terminal arginine, 
resulting in C5a-des-Arg, which is considerably less potent. C3a acts in a similar 
fashion to C5a, but is less potent and has little or no chemotactic activity. 
The third method by which the complement system acts to enhance microbial killing 
is through opsonisation. This process is the result of the coating of the cell surface 
with the opsonins C3b and C4b. These act as ligands for cell surface receptors on 
phagocytes, and stimulate phagocytosis. In addition the binding of the opsonised 
complex to macrophages activates theses cells and results in increased production of 
proteases, and oxygen free radicals. Finally the opsonised material is recognised by 
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erythrocyte-bome complement receptor type 1 (the immune adherence receptor) and 
cleared from the blood stream (see below). 
1.3.6.2. The role of complement in clearing immune complexes 
It was noted relatively early on that classical pathway complement activation inhibits 
the formation of precipitating immune complexes, and that in a similar manner 
alternative pathway complement activation can solubilise precipitated immune 
complexes. Precipitation of immune complexes is due to the formation of a 'lattice' 
effect between antibody and antigen, where the antibodies bind multiple different 
antigen molecules. Since it was found that C3-deficient serum was unable to 
perform these tasks it was inferred that it was the C3 component of complement that 
is important. The covalent binding of activated C3 (C3b or C3i) has important 
effects on immune complexes. Binding of C3 reduces the overall size of an immune 
complex, possibly by disrupting the binding of antibody to antigen. The presence of 
C3 allows the immune complex to bind to erythrocytes, by attaching to the 
complement receptor type 1 (CR1 or CD35), allowing the complex to be transported 
through the blood to the liver and spleen, and eventually cleared through the action 
of macrophages. 
1.3.6.3. The role of complement in enhancing the antibody response 
Whilst the complement system is not solely responsible for the antibody response it 
does play an important assisting role. Complement enhances the antibody response 
by assisting in the delivery of immune complexes to antigen presenting cells, and 
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also in the promotion of B-cell activation (Carroll, 2000). It has also recently been 
suggested that the complement system plays a role in preserving long-term 
immunological memory. Complement receptors have been found to be important in 
localising antigen and C3 to follicular dendritic cells (FDC), which is important in 
the maintenance of long-term immunity (Barrington et al., 2001; Carroll, 2000). 
1.3.7. Human disorders associated with complement abnormalities 
Given the central role of complement in the immune system, it is unsurprising that 
numerous human disorders are associated with complement abnormalities. There are 
two major categories of complement abnormalities: those associated with 
deficiencies, and those arising from the complement mediated damage to self 
resulting from an overactive or poorly regulated complement system. 
1.3.7.1. Human disorders associated with complement deficiencies 
Just about every important component of the complement system has a disorder 
associated with its deficiency, and a detailed discussion of all the known complement 
associated disorders is beyond the scope of this thesis. A summary of some of the 
more interesting ones will follow. 
Disorders associated with classical pathway components include systemic lupus 
erythematosus (SLE), glomerulonephritis and immune complex diseases. Those 
associated with alternative pathway deficiencies include severe meningitis, and 
recurrent upper respiratory infection. Abnormalities in components involved with 
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MAC formation include recurrent Neisserial infections. 	Abnormalities in 
complement control proteins include haemolytic uraemic syndrome (HUS), and 
angioedema. 
1.3.7.2. Haemolytic Uremic Syndrome 
Familial haemolytic uremic syndrome is an inherited disorder that is associated with 
haemolytic anaemia, acute renal failure, and thrombocytopenia. This disorder has 
been associated with a number of mutations in complement factor H (fH). The 
majority of these mutations appear to be clustered at the C-terminus, and most reside 
in domain 20 (Perkins et al., 2002). The majority of these mutations therefore, occur 
within the region of fH that is able to bind C3d, and to one of the regions of fH that is 
able to bind heparin (modules 19-20). This would suggest that HUS is either caused 
or exacerbated by the inability of tEl to bind to either C3d or polyanions. It is known 
that HUS is associated with endothelial cell activation, in a complement associated 
manner, and so it is possible (albeit not proven) that the HUS associated with fH 
mutations is due to the inability of ff1 to regulate the alternative pathway due to 
disrupted polyanion binding. It remains to be seen, however, whether this is indeed 
the case. 
1.3.7.3. Human disorders associated with over active complement systems 
There are several ways in which an over active complement system can lead to 
health problems and one such class is autoimmune disorders. In this case the 
immune system acts on host tissues and organs causing severe damage and possible 
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loss of organ function. Within this area are such important human disorders as 
arthritis and diabetes. It is not yet clear exactly how these disorders are initially 
triggered, however, what is known is that the patient suffers severe complement 
mediated tissue damage. 
1.3.8. Microbial strategies to evade or exploit the complement system 
It seems reasonable to suspect that there has been considerable interplay between the 
evolution of pathogens and the immune systems they are trying to evade. It should 
come as no surprise therefore that there are several known methods used by 
pathogens to evade complement attack. It is known that certain Gram-negative 
bacteria possess long 0-linked polysaccharide chains, which are very efficient at 
activating the complement system. The problem from the host point of view is that 
this results in MAC formation at points distal from the cell membrane, and therefore 
the bacteria escape the eventual cell lysis. Other bacteria use a capsule that is rich in 
sialic acid, which appears to confer resistance to alternative pathway activation. It 
appears that possession of a capsule rich in sialic acid promotes the preferential 
binding of factor H rather than factor B to the tick-over C3b formed, resulting in the 
inhibition of alternative pathway activation (Jarvis, 1995). One of the most 
interesting methods of evading the complement system is found in organisms such as 
trypanosomes and certain viruses. These organisms have gained the ability to 
express proteins similar to the host's complement control proteins. For example, 
trypanosomes express variant surface glycoprotein (VSG) (Davitz et al., 1987), and 
Vaccinia virus expresses VCP which is a highly efficient soluble complement 
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inhibitor (Isaacs et al., 1992), the crystal structure of which has recently been solved 
(Murthy et al., 2001). This structure, shows several discrepancies when compared to 
the NMR structures of VCP34 (Wiles et al., 1997) and VCP 23 (Henderson et al., 
2001). It is seems likely from the NIMIR structures that the intermodular arrangement 
between modules 2 and 3 is flexible, whereas in the crystal structure, this junction 
appears rigid. Further investigation is therefore needed into the nature of this 
junction to determine unequivocally, whether it is indeed flexible as suggested by the 
NMR structure. 
As already stated, certain pathogens use components of the complement system as 
their receptors, however this is not the only method that pathogens use to exploit the 
complement system. Certain flavoviruses appear to actually use complement 
activation to facilitate their infections. An example of this is Dengue virus, which 
appears to utilise antibody and C3b attached to the virus to enter macrophages via 
their Fc receptors (Casali et al., 1983). 
1.4. Protein glycosylation 
1.4.1. Preliminary remarks 
One of the most common protein modifications in eukaryotes is glycosylation, yet 
this near ubiquitous phenomenon is only poorly understood. The majority of 
extracellular eukaryotic proteins are glycosylated, often with the sugars making up 
the largest portion of the protein mass. The glycans on glycoproteins appear not to 
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be limited to a single function, instead there are examples where glycans or glycan 
recognition have been associated with protein folding (Ronnett et al., 1984; Slieker et 
al., 1986), sorting (Hauri et al., 2000), quality control (Hammond et al., 1994), 
structural integrity (Casasnovas et al., 1999; Wyss et al., 1995), the immune system 
(Rudd et al., 1998), signal transduction (Wells et al., 2001), prion pathogenesis 
(Rudd et al., 1999; Rudd et al., 2002) and, potentially, information storage (Lehrman, 
2001). One of the reasons that sugars perform such a large number of tasks is 
possibly due to the extreme chemical variability that can occur in oligosaccharides, 
which vastly out weighs that of both proteins and nucleic acids. Unlike proteins and 
nucleic acids the sources of variation in the structures of oligosaccharides arises from 
their ability to branch, and to vary the linkage type and positioning combination with 
the large number of different monosaccharide units. It is precisely this variability 
and structural heterogeneity that often results in some of the major difficulties that 
are associated with studying glycoproteins. It appears that, even on the same protein 
expressed in the same cell there may be several distinct glycan moieties attached to a 
particular glycosylation site, referred to as the glycoforms. The function of these 
individual glycoforms is not understood, and our ignorance will not be improved 
until purifying and studying individual glycoforms is made routine. However, given 
the number of important functions that glycans possibly serve, surely it remains one 
of structural biology's most important goals to fully understand the structural effects 
of protein glycosylation. 
Glycans may form associations with proteins in a number of different forms, such as 
proteoglycans, and GPI anchors, which are beyond the scope of this thesis. Instead I 
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shall provide a summary of the most important aspects of protein N-linked 
glycosylation, with only a cursory description of the many other kinds. 
1.4.2. Winked and other types of protein glycosylation 
There are two major types of protein glycosylation; 0-linked glycosylation and N-
linked glycosylation, although there is increasing evidence for a third type, so called 
C-glycosylation (Hofsteenge et al., 1994). C-glycosylation occurs through the direct 
covalent attachment of a glycan to a carbon atom on a tryptophan residue. 0-linked 
glycosylation involves the addition of sugar residues to the hydroxyl groups of 
certain serine and threonine residues through a condensation reaction. The reason 
why some serine/threonine residues become 0-glycosylated is very poorly 
understood, although it can be predicted with dificulty and only limited success using 
comparisons with known 0-glycosylated proteins. N-linked glycosylation on the 
other hand is the attachment of glycans to the side chain nitrogen of asparagine 
residues in the consensus N-X-S/T where X is any amino acid with the exception of 
proline. Whilst the presence of this sequon, does not guarantee that N-linked 
glycosylation will occur at this site, it can only occur at this sequon. 
1.4.3. N-Linked glycosylation 
The vast majority of secreted proteins receive N-linked glycans during their 
synthesis, whereas the majority of cytosolic proteins remain non-glycosylated. This 
phenomenon is largely because the core glycans are synthesised such that they face 
the lumen of the ER. In itself, this is hardly surprising given that N-linked glycans 
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are involved in a large number of extracellular recognition events, and enable the 
host to quickly alter the recognition properties of a protein. As already stated, 
protein N-linked glycosylation only occurs at the specific sequon N-X-S/T. The 
initial step in N-linked glycosylation is the synthesis of a specific core saccharide 
unit that is common to the N-linked glycans found in all organisms, with the sole 
exception of trypanosomatids. Next comes the attachment of these core sugars to the 
asparagine residue in the endoplasmic reticulum, in a process that occurs co-
translationally (Chen et al., 1999). The factor(s) that govern which of the sequons 
that are glycosylated are not yet fully understood, however it appears that translation-
speed (Ujvari et al., 2001), distance from the C-terminus (Nilsson et al., 2000) and 
steric effects may all be important. The next phase in N-glycosylation is the initial 
trimming of the core sugars in the ER with the concomitant association of the 
nascent protein with chaperones and helper proteins to facilitate disulphide bond 
formation and correct folding. The final stage of N-linked glycosylation is the 
further processing of the glycan moiety in the Golgi apparatus until the maturation of 
the glycoprotein is complete, and the protein is translocated to its final destination. 
Given the central nature of the glycosylation machinery to protein folding and 
recognition, it is not surprising that there are a number of diseases and disorders that 
are associated with aberrant glycosylation including muscular dystrophy (Muntoni et 
al., 2002). Each of the steps involved in protein N-glycosylation will be described in 
greater detail in the following sections. 
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1.4.4. Synthesis of the core sugars 
The 'core sugars' are a 14-saccharide unit that is synthesised as a membrane bound 
dolicholpyrophosphate precursor (G1c3Man 9GlcNAc2-PP-dol) partly in the cytosol 
and partly in the lumen of the ER. This synthesis is a multistep process and requires 
the activity of enzymes that are located on either side of the ER membrane. 
The underlying principals behind the synthesis of the core sugars and the early events 
in N-glycosylation have been known for some time, and will be summarised here 
(for a review see Burda et al., 1999). The initial stage in the synthesis of the core 
sugars is the synthesis of Man 5-GIcNAc2-PP-dol, which occurs in the cytoplasmic 
side of the ER membrane. This stage occurs in two major steps (steps 1 & 2 in the 
schematic shown in Figure 1.10), the first of which is the synthesis of GlcNAc 2-PP-
dol, and the second of which is the synthesis of Man5GlcNAc 2-PP-dol. During the 
first step two moieties of UDP-G1cNAc are sequentially transferred to P-dol to give 
G1cNAc2-PP-dol. Following this five moieties of GDP-Man are sequentially 
transferred to the GlcNAc 2-PP-dol produced in the previous phase. This yields a 
Man5GlcNAc2-PP-dol, which is also located on the cytoplasmic side of the ER 
membrane. This species is subsequently acted on by flippase (step 3 in the schematic 
shown in Figure 1.10), an enzyme with no synthetic activity, but which simply 
transfers the species to the lumenal side of the ER. All of the subsequent steps 
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Figure 1.10 Schematic illustration of the steps involved in the synthesis of the 
core glycans of N-linked glycosylation. Step 1: transfer of two GIcNAc residues 
from UDP-GIcNAc to Dol-P yielding GIcNAc2-PP-dol. Step 2: transfer of 5 mannose 
residues from GDP-Man to GIcNAc 2-PP-dol yielding Man 5GlcNAc2-PP-dol. Step 3: 
flipping of the glycans from the cytoplasmic to lumenal side of the ER membrane. 
Step 4: transfer of 4 mannose residues from dol-P-Man to Man 5GlcNAc2-PP-dol 
yielding Man9GlcNAc2-PP-dol. Step 5: transfer of 3 glucose residues from dol-P-Glc 
to Man9GlcNAc2-PP-dol yielding the fully formed Glc 3Man9GlcNAc2-PP-dol. 
The next stage in the synthesis of the core sugars, involves the transfer of four 
moieties of dol-P-Man onto the Man5GlcNAc2-PP-dol to yield Man9G1cNAc 2-PP-
dol (step 4 in Figure 1.10). Following this, three moieties of dol-P-Glc are 
subsequently sequentially transferred to Man9GIcNAc 2-PP-dol yielding the final core 
species of Glc3Man9GlcNAc 2-PP-dol. Interestingly these do]-P-Man and dol-P-Glc 
moieties are also synthesised on the cytoplasmic side of the ER membrane, and 
subsequently'flipped' onto the lumenal side. The steps involved in the synthesis of 
the core sugars is summarised in the schematic illustration shown in Figure 1.10. It 
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should be noted that this scheme of core glycan synthesis is highly conserved, and is 
the case for wild type fungi, plants, and mammalian cells, however, exceptions are 
known to exist. In the case of trypanosomatid cells, the core sugars are synthesised 
unglucosylated as Man9GlcNAc2-PP-dol, Man7GlcNAc2-PP-dol or Man6GlcNAc2 -
PP-dol depending on the species. This case will not be discussed further, as none of 
the organisms connected to this study exhibit this type of glycosylation 
1.4.5. Attachment of the core sugars to the nascent polypeptide chain 
Attachment of the core sugars to the polypeptide chain takes place cotranslationally 
with synthesis of the nascent polypeptide chain (for a review see Parodi, 2000). The 
transfer occurs through the action of the enzyme oligosaccharyltransferase (OST) 
The reaction releases dol-PP with the concomitant covalent attachment of the 
remainder of the precursor onto the consensus Asn residue of the N-X-S/T sequon 
through a condensation reaction. OST, a highly complex enzyme, consists of eight 
subunits and is located in the ER membrane. Moreover, it has been demonstrated 
that in yeast cells OST can transfer the standard triglucosylated core sugars to the 
protein species 20 fold faster than it can transfer unglucosylated species (Ballou et 
al., 1986). It is thought that this difference in transfer efficiency is important for 
ensuring that the only fully glucosylated core sugars are transferred to the protein. 
This is thought to be an important point as the subsequent trimming of the glucose 
residues from the glycans on a nascent glycoprotein are directly involved in the 
folding process (see section 1.4.6 for a fuller description of the role of glycan 
processing during glycoprotein folding). 
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1.4.6. Initial processing of the core sugars and the role in protein 
folding 
The initial steps in N-glycan processing appear to be reasonably well conserved 
between many diverse species. Indeed it has been demonstrated that there are few 
differences between these processes between mammalian cells and S. cerevisiae 
This observation is probably largely due to the effects that these processes exhibit 
during the protein folding process. It is thought that the initial processing of the N-
glycans follows the basic scheme: partial deglucosylation, full deglucosylation 
followed by demannosylation. The deglycosylation steps are highly important for 
recruitment of appropriate chaperones, whereas the initial demannosylation step 
seems to acts like an indicator that folding is complete. The initial step of partial 
deglucosylation is thought to be due to the action of glucosidase I, removing the 
outermost glucose residue, followed by the action of glucosidase II removing the 
next glucose residue (see Figure 1.11 for clarification) from the N-glycans of the 
nascent glycoprotein. This may not always be the case, however, and it may be that 
the glycans are fully deglucosylated (either by glucosidases I and II, or by 
glucosidase II alone), followed by partial reglucosylation yielding the 
monoglucosylated glycan. The exact nature of this deglucosylation process is largely 
unimportant, however, as the important factor is that the glycans achieve a 
monoglucosylated state. This monoglucosylated form of the glycan facilitates the 
recognition of the nascent glycoprotein by the ER resident lectins calreticulin (CRT) 
and calnexin (CNX), which have been shown to play an important role in the folding 
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of many proteins (Peterson et al., 1995). Moreover, it appear that it is not simply the 
monoglucosylated glycan that is recognised by CRT and CNX, but instead it appears 
that recognition by these lectins requires interactions between the lectin and both 
glycan and protein moieties. 
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Figure 1.11 Schematic representation of the core glycans attached to the 
consensus Asn residue of a protein. The diagram shows the sites involved in the 
initial trimming of the glycans during protein folding. 
The binding of either CNX or CRT to the monoglucosylated nascent glycoprotein 
fhcilitates the binding of Erp57. Erp57 is a cellular folding factor that possesses thiol 
oxidoreductase activity, and is able to bind both either CNX or CRT. The 
association of the nascent monoglucosylated protein with CNX or CRT and Erp57 
facilitates the folding and the formation of any necessary disulphide bonds through 
dkulphide hond shuffling. The glycans of the nascent glycoprotein are subsequently 
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deglucosylated and the nascent glycoprotein dissociates from Erp57 and CNX or 
CRT. Following this primary folding step the fate of the protein and the glycans are 
significantly linked. The glycans may be reglucosylated, facilitating the 
reassociation with CNX or CRT and Erp57, with concomitant refolding and retention 
in the ER, or this reglucosylation may not occur resulting in the glycoprotein being 
'released' and passing through the remainder of the secretory pathway The enzymes 
involved in the attachment and removal of the terminal glucose residue to/from the 
glycans are glucosidase II, and UDP-glucose: glycoprotein glucosyl transferase (GT). 
It important to note that GT appears to be able to differentiate between properly 
folded and improperly folded glycoproteins, and only appears to reglucosylate the 
glycans attached to improperly folded glycoproteins. In this way GT appears to act 
as a folding sensor allowing correctly folded glycoproteins to pass through the 
secretory pathway, whilst improperly folded proteins are retained in the ER for 
further folding attempts until such time as they become correctly folded, or are 
subsequently targeted for proteosomal degradation. It can be seen therefore that the 
early events in N-linked glycosylation are intimately linked with disulphide bond 
formation and proper folding of nascent glycoproteins. 
1.4.7. Further processing of the glycans in the Golgi apparatus 
Following the initial processing of the N-linked glycans in the ER, and the 
concomitant folding of the nascent protein, these glycans may be further processed in 
the Golgi apparatus to yield the mature glycoform of the protein. At this point the 
glycosylation profiles observed tend to differ between higher and lower eukaryotes. 
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There are three major classes of N-glycans: high mannose, hybrid, and complex, and 
a schematic representation of some of the more common types of N-glycans in these 
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Figure 1.12 Schematic illustration of different types of N-glycan structure, the 
enzymes involved in their processing, and associated diseases and disorders 
(adapted from Chui et al 2001). 
High mannose-type glycans are in effect little more than the core sugars. They 
consist solely of GlcNac and Man residues and exist commonly as Man89GlcNac2 
structures, although they may become trimmed down. This type of glycosylation 
pattern is the typical of the types produced by many types of lower eukaryotes, 
particularly yeasts, and is the one that is most commonly produced by P. pastoris. In 
the case of some heterologous proteins produced by P. pastoris, however, the 
phenomenon of hyperglycosylation may be observed. During this process the arms 
of the glycan are significantly extended by the addition of further mannose residues 
(Cereghino et al.. 2000). For hyperglycosylation in P. pastoris it is known that these 
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glycans are comprised entirely of GlcNac and mannose residues, although it has 
been demonstrated that in some cases at least, these glycans are only partially 
sensitive to a-mannosidase. It was subsequently discovered that there are phosphate 
groups between some of these mannose residues that were not sensitive to alkaline 
phosphatases (Martinet et al., 1997). Hyperglycosylation of proteins may reduce the 
activity of some enzymes, and may result in the protein being highly antigenic 
(Cereghino et al., 2000) The hyperglycosylation of recombinant proteins therefore 
becomes an interesting problem, that will need to be addressed before their full 
therapeutic use can be realised 
Complex glycans can exhibit great diversity that is dependant on a number of factors, 
including: organism, cell type, position in the developmental cycle etc. There are 
however a number of generalisations that differentiate complex glycans from high 
mannose type glycans. Complex glycans are fucosylated on the GlcNac residue 
attached to the asparagine residue. In addition to the fucosylation, the Man residues 
get trimmed until three remain. These are then elongated through the addition of 
other types of sugars: initially GlcNac, then Gal, and finally the terminal branches 
are often ended with sialic acid. Hybrid glycans, as the name suggests, lie between 
the extremes of high mannose and complex glycans, and have no sialic acid or fucose 
residues. Hybrid glycans usually have only one or two elongations to the central 
mannose sugars. 
The terminal sialic acids found in complex glycans, can have important 
consequences in the context of the immune system, since there is evidence that these 
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allow self from non-self discrimination in the complement system (Meri et al., 1990; 
Meri et al., 1994; Pangburn, 2000). It is also interesting to note that mutation in the 
a-mannosidase II gene induces a systemic autoimmune disease similar to systemic 
lupus erythematosus (Chui et al., 2001). a-mannosidase II is one of the enzymes 
involved in the hybrid to complex transition, and therefore one would expect a good 
number of cell surface glycoproteins to have fewer than the normal number of sialic 
acid residues. If this were the case, it is not inconceivable that the ensuing 
autoimmune disease is due, at least in part to a failure of the complement system 
alternative pathway to discriminate self from non-self. 
1.4.8. Effects of the Winked glycans on glycoproteins 
The precise function of the N-linked glycans in many glycoproteins is often poorly 
understood. Although, as previously described, much of the importance associated 
with N-linked glycosylation lies with the links between the initial steps in N-
glycosylation and protein folding, there are, cases where the glycans themselves play 
a functional role. 
The role of glycans are many, and protein glycan interactions may be involved in 
several important ways, including recognition, immunological processes, and 
structural phenomena. Glycans can mask important regions in a protein that would 
otherwise be exposed, including the sites of protease sensitivity, or antigenic sites. 
Examples include HIV, which, uses glycosylation to mask potential antigenic sites 
(Reitter et al., 1998). The interaction between a protein and a N-glycan can take a 
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number of forms, and cases exist where the protein affects the structure of the 
glycan, and where the glycan affects the structure of the protein. Cases where the 
protein affects the glycan include that of CD2, where contacts between the protein 
and the first two GlcNac residues reduce the mobility of the core sugar residues 
resulting in the glycan 'lying' parallel to the peptide (Wyss et al., 1995). An 
example of a case where the glycans are affecting the peptide is that of the cc-subunit 
of human chorionic gonadotropin (hCG), where the glycans have a significant effect 
on the mobility of the protein (De Beer et al., 1996; van Zuylen et al., 1997), without 
having a drastic effect on the overall conformation of the protein. It is further 
interesting to note that contacts between the glycan and protein are only observed in 
the free a-subunit rather than in the intact heterodimer. 
1.5. Signalling Lymphocyte Activation Molecule 
1.5.1. Preliminary remarks 
Signalling lymphocyte activation molecule, also referred to as SLAM, or IPO-3, is a 
co-stimulatory protein on B lymphocytes, and dendritic cells. SLAM was initially 
identified using a monoclonal antibody that bound to an unidentified antigen, and 
activated 1-cells (Cocks et al., 1995). SLAM facilitates the proliferation of activated 
B cells, upon binding to its ligands. This proliferation of activated B cells is 
associated with increased immunoglobulin production. SLAM, therefore is a 
receptor for co-stimulatory molecules, rather than a co-stimulatory molecule in its 
own right. Signalling through SLAM is also associated with increased levels of 
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interferon-gamma production. SLAM is expressed on thymocytes, B lymphocytes, 
dendritic cells, endothelial cells and certain subpopulations of I lymphocytes. 
Following activation, the expression of SLAM is up regulated. 
1.5.2. Domain structure of SLAM 
SLAM is a member of the immunoglobulin superfamily, and is within the CD2 
subset. SLAM is a type I membrane protein, and exist as one of three isoforms - the 
result of alternative splicing. The full length protein has a Mr of 70 kDa. Of the 
remaining isoforms, one is a secreted form lacking the transmembrane domain, and 
the other has C-terminal truncation, yielding a cytoplasmic domain that is 36 amino 
acids shorter than that of the full length version. 
The transmembrane region of SLAM is predicted to be comprised of between 21 and 
27 amino acids and is followed by an intracellular domain comprising the C-terminal 
77 amino acids. This region contains four tyrosine phosphorylation sites, three of 
which are predicted to form SH2 binding domains and which are thought to be 





Figure 1.13 Model of the extracellular Ig domains of SLAM. The model is based 
on the structure of the CD2-CD58 heterodimeric complex, and has the glycans 
shown in random orientations (taken from Mavaddat et al., 2000). 
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The extracellular region of SLAM is comprised of two immunoglobulin domains. 
The N-terminal domain is of the Ig V type, and the membrane proximal domain is of 
the Ig C2 type. The V type domain contains five potential N-linked glycosylation 
sites, and two Cys residues which are predicted to be disulphide bonded. The C2 
type domain, contains four potential N-linked glycosylation sites, and four Cys 
residues, which are predicted to form disulphide bonds in a 1-4, 2-3 pattern. From 
the sequence data it appears that SLAM would be expected to be highly 
glycosylated, although information concerning which of the glycosylation sites are 
recognised is as yet unavailable. 
A model of the extracellular immunoglobulin domains of SLAM based on its 
homology to CD2 and CD 58 is shown in Figure 1.13, and is shown with the 
potential N-linked glycans in a random arrangement (Mavaddat et al., 2000). The 
model shows SLAM as a homodimer, because it is predicted to be homophilic, and 
have the ability to act as a self ligand (see section 1.5.4). 
1.5.3. Receptors for SLAM 
As SLAM is involved in cell signalling events, it is clear that SLAM must form 
interactions on both sides of the cell membrane. As yet the only extracellular 
receptor for SLAM that has been identified is SLAM itself, however, this does not 
rule out the possibility that as yet undiscovered binding partners exist. There are two 
important intracellular receptors for SLAM that have been discovered to date. One - 
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EAT-2 is expressed in B-cells, and is responsible for SLAM's B-cell signalling; the 
other - SLAM associated protein - SAP (also referred to as SH2131A) is expressed in 
T-cells and is responsible for SLAM's T-cell signalling activity. 
There are interesting differences between SLAM's two main intracellular partners, 
concerning their ability to interact with SLAM in different phosphorylation states. 
EAT-2 is able to interact with SLAM only when both Tyr307 and Tyr327 of SLAM 
are phosphorylated, whereas SAP is able to interact with SLAM in both its 
phosphorylated, and dephosphorylated states (Mona et al., 2001). It seems likely 
that this could explain the differences between the effects of SLAM activation in B-
cells as compared to T-cells. 
1.5.4. SLAM may be able to perform bidirectional signalling 
As indicated the only known extracellular receptor for SLAM is itself, and that 
SLAM - SLAM interactions allow bidirectional signalling between B-cells and T-
cells, i.e. SLAM has the ability to act as a self-ligand. It had been proposed that the 
self affinity for SLAM is very high, lying somewhere in the low nM range 
(Punnonen et al., 1997). Subsequent experiments using SPR technology, however, 
imply that the self-affinity is rather weak, with an affinity in the region of 200 tM 
(Mavaddat et al., 2000). This would be a lower affinity that that usually found with 
interactions on the leukocyte cell surface, which usually have dissociation constants 
in the range of 0.3 - 20 M (Davis et al., 1998). The difference in the affinity data 
between the two reports is quite hard to reconcile, and it was suggested by 
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(Mavaddat et al., 2000) that the apparent extremely high affinity could be due to 
protein aggregation occurring during the course of the experiments, although this 
appears to be speculation. It would seem illogical however for a protein involved in 
signalling events, to act in what would be essentially an irreversible manner. On the 
other hand, the low affinity suggested may rule out the possibility that SLAM self-
association has any physiological relevance. It is clear, however, that this question 
needs to be resolved before any firm conclusions can be drawn. 
1.5.5. SLAM is associated with X-linked lymphoproliferative disease 
In addition to the afore mentioned action of SLAM as a receptor for measles virus, 
SLAM is associated with another clinical condition, namely X-linked proliferative 
disease (XLP). XLP was identified as a distinct clinical disorder in 1969, when 
Purtilo recorded the deaths of six out of 18 male members of the Duncan family, 
(reported as Purtilo et al., 1975). The patients were all between the ages of 2 and 19 
years of age, and all died of a lymphoproliferative disease, which was initially 
termed Duncan's disease. The disease is characterised by dysgammaglobulinaemia, 
atypical lymphocytosis and lymphadenopathy, and a significant number of the 
affected boys presented with infectious mononucleosis, towards the latter stages of 
the disease. Initially it was thought that EBV infection was required for a patient to 
develop XLP, however subsequent studies have indicated that this is not necessarily 
the case. The gene associated with XLP was subsequently identified as SAP - 
SLAM's intracellular T-cell partner (Sayos et al., 1998). It is hoped that a more 
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thorough understanding of SLAM signalling and its interaction with SAP could lead 
to potential therapeutic agents to treat XLP. 
1.6. Summary and project aims 
Measles virus is able to use two different proteins for its cellular receptor - MCP and 
SLAM. MCP possesses an N-linked glycan on its second module that is essential for 
functionality in a manner that implies it is structuraly significant. This thesis 
describes the investigations performed on the measles binding regions of its receptors 
MCP and SLAM. 
The expression and characterisation of both the MCP12 module pair and MCP2 
single module are described. Particular attention was payed to understanding the 
underlying mechanisms by which the functionally essential glycans on the second 
module of MCP exert their effects through the use of biophysical techniques. These 
investigations form part of an ongoing effort aimed towards a complete elucidation 
of the mechanisms behind both the effects the module 2 glycans have on MCP and 
the interaction between MCP and the measles virus. 
The expression of the measles interacting region of the second measles receptor are 
also described, with the eventual goal of understanding the reasons why measles 
virus is able to utilise two different receptors from different protein families. 
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2. Materials and Methods 
All aqueous buffers were made up in Milli-Q grade water. The buffer components 
were of the highest available grade and were typically purchased from Fischer or 
Sigma-Aldrich. Centrifugation of volumes greater than 1.5 ml was carried out either 
in a Sorvall RC SC plus, a Sorvall 26 plus or a Sorvall legend RT centrifuge. 
Centrifugation of volumes less than 1.5 ml was carried out in a Hereus Biofuge Pico. 
Concentration of large volumes of protein (>300 ml) was achieved using hollow 
fibre prep scale 'TFT' cartridges (Millipore), 5 kDa molecular weight cut off. 
Concentration of protein volumes 10-300 ml was performed using a high-pressure 
stirred cell with ultrafiltration membranes (Amicon) with a molecular weight cut off 
as described. Concentration of protein volumes of less than 10 ml was performed 
using centrifugal concentrators (Viva-science) with molecular weight cut off 
membranes as described. UV/Vis spectroscopy was carried out in an 8543 UV/\Tis 
spectrophotometer (Hewlet Packard) using either quartz (2. <290 nm) or disposable 
cuvettes (2. > 290 run). 
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2.1. General DNA Methods 
2.1.1. Polymerase Chain Reaction (PCR) 
DNA fragments were amplified using the PCR in a Techne CyclogeneTM, a 
Stratagene Robocyclefrm or Eppendorf 'Master CyclerTM Personal' thermal cycler. 
Reactions carried out in the Techne Cyclogene thermal cycler were overlaid with 50 
j.tl of mineral oil. This step was unnecessary for reactions carried out in the other 
two thermal cyclers. The high fidelity DNA polymerases 'Deep Vent' (New 
England Biolabs, NEB) 'Herculase' or 'Herculase Hot Start' (Stratagene) were used 
for gene amplification. The reactions were assembled on ice in sterile 0.5 ml 
(Cyclogene thermal cycler) or 0.2 ml (other thermal cyclers) thin walled PCR tubes. 
The thermal cycler was preheated to 96 °C before the tubes were inserted. Reactions 
were carried out on a 50 tl scale, and were typically set up as follows: 
Component Quantity Final concentration 
10 X reaction buffer 5 	.il 1 X concentration 
dNTP mix (10 mM each) 1 	tl 200 j.tM 
Template DNA (10 ngj.t1') 1 	tl 200 pg.pi' 
Primers (100 ngj.il 1 ) 1 il each 2 ng.pi' 
DMSO 2.5 p.l 5% 
Polymerase (5 U.t1') 0.5 p.1 0.05 U.j.tl' 
d.H20 40 p.1 
Total reaction volume 38 p.1 
2.1.2. Agarose gel electrophoresis 
Agarose gels were made using molecular biology grade agarose (Bio-Rad) in TAE 
buffer (see Appendix A) using the gel percentages given containing 0.2 p.g.mr' 
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ethidium bromide, and were run in a minielectrophoreisis gel tank (Anachem) at a 
constant current of 80 mA. The DNA bands were visualised using long wavelength 
UV radiation. 
2.1.3. DNA extraction from Agarose gels 
Following electrophoresis the relevant DNA bands were excised form the agarose 
and purified using the Qiagen gel extraction kit, which is based on (Vogeistein et al., 
1979), according to the manufacturer's instructions. The DNA was eluted from the 
spin columns in autoclaved deionised H 20, and the concentration estimated by A 260 
measurement. 
2.1.4. Ethanol precipitation of DNA 
DNA was precipitated using ethanol. Sodium acetate, pH 5.2, was added to the 
DNA to a final concentration of 300 mM, followed by the addition of two volumes 
of 95 % (vlv) ethanol (-20 °C). The mixture was then incubated at 0 °C for 30 
minutes, centrifuged at 13,000 g for 30 minutes, and the supernatant poured off. The 
pellet was then washed twice with 1 ml of 70 % ethanol and centrifuged at 13,000 g 
for 5 minutes between each wash. The pellet was dried at 37 °C, and redissolved in 
autoclaved milli-Q water for 30 minutes at room temperature before storage at —20 
°C until required. 
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2.1.5. Restriction Digests 
Restriction enzymes were typically purchased from NEB. Restriction digests were 
carried out on a 20 i.l scale unless otherwise stated. Digests were carried out for 2 
hours at 37 °C unless otherwise stated. As excessive concentrations of glycerol can 
inhibit the action of some restriction enzymes, the total amount of enzyme added to 
any reaction was less than or equal to 5 %, to keep the final glycerol concentration 
less than 2.5 %. 
2.1.6. DNA Ligation 
DNA ligation was conducted according to (Sambrook et al., 1989) at 16 °C for 16 
hours using T4 DNA ligase (NEB). Alternatively ligation was performed using the 
Roche 'rapid ligation' kit for 5 minutes at room temperature according to the 
manufacturer's instructions. The ligation reactions were carried out using the vector: 
insert ratios described; and were typically performed on a 10 tl scale with 1 Weiss 
unit of T4 DNA ligase per reaction unless otherwise stated. 
2.1.7. E. coil Transformation 
E. coli (strains as described) was transformed with circular plasmid DNA using the 
calcium chloride method (Sambrook et al., 1989), or by using 'One Shot' chemically 
competent cells (Invitrogen), according to the manufacturer's instructions. The cells 
were transformed with 5 j.d of a ligation reaction unless otherwise stated. Following 
the transformation procedure the cells were plated onto LB (see Appendix A) 
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containing the appropriate antibiotic —25 jig.mr' Zeocin for pPICZa, or 100 ,ig.mr 1 
Ampicillin for pPIC9, pGEM-T, PetlSb, and Pet32. In the case of LB Zeocin plates 
the LB contained only 5 g.1' of NaCl instead of the usual 10 g.F', to prevent 
inactivation of the zeocin. Following transformation the plates were incubated at 37 
°C for 16 hours after which time colonies could be picked for "miniprep". In the 
case of pGEM-T, the plates were then refrigerated for a further 8 hours to allow the 
blue colour to develop in negative transformants, without the formation of satellite 
colonies. 
2.1.8. Plasmid minipreps, midipreps and maxipreps 
Plasmids were recovered from E. coli using the Qiagen "Qiaprep Spin Miniprep" kit 
(12 tg); the Promega "Wizard Plus Midiprep", or Sigma ."GeneElute Plasmid 
Maxiprep" kits (250 pjg), according to the manufacturer's instructions. Each kit uses 
a modified version of the alkaline lysis method followed by high salt-mediated 
adsorption of DNA onto a silica matrix. In all cases cultures were inoculated with a 
single colony from a freshly incubated selective plate. Cultures for miniprep were 
grown in 5 ml LB (plus appropriate antibiotic) and typically incubated for 5-6 hours 
at 37 °C with shaking at 250 rpm. Cultures for midiprep and maxiprep were grown 
in 100 ml, and were incubated overnight at 37 °C with shaking at 250 rpm. The 
DNA produced by each kit was finally eluted with autoclaved deionised water. The 
DNA concentration was determined using A260 measurements after the purity of the 
plasmid DNA had been established by confirming that the A260/A2 80 ratio was 1.7-1.8 
(Sambrook et al., 2000). 
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2.1.9. DNA sequencing 
Fluorescent automated DNA sequencing was performed using a modification of the 
dideoxy method (Sanger et al., 1977), using either 'Big-Dye' or dRhodamine dye 
terminators, according to the manufacturer's instructions (Applied Biosystems). The 
sequencing gels were run by the Automated DNA Sequencing Service (Institute of 
Cell and Molecular Biology - University of Edinburgh) and were run on an ABI 377 
XL sequencer. 
2.1.10. 	Transformation of P. pastoris by electroporation 
Expression of the proteins in P. pastoris was done in one of three strains: KM71, 
KM71-His, or X33. The yeast was transformed by electroporation in a 0.2 cm 
electroporation cuvette in a Bio-Rad Gene Pulser (1.5 kV, 200 1, 25 pF). All the 
steps in the electroporation process were carried out at 0 °C except where stated. A 
single colony of P. pastoris was taken from a freshly streaked plate and used to 
inoculate 5 ml of YPD (see Appendix A). The culture was incubated overnight (30 
°C, 200 rpm). An aliquot containing 1.0 ml of this culture was used to inoculate a 
further 100 ml of YPD, and was incubated (30 °C, 250 rpm) until an A0 of 1.3-1.5 
was achieved. The cells were harvested by centrifugation under sterile conditions 
(1500 g, 5 minutes at 4 C) and resuspended in 100 ml of autoclaved Milli-Q water. 
The cells were then harvested again under the same conditions and resuspended in 50 
ml of water followed by harvesting and resuspension in 4 ml of 1 M sorbitol. The 
cells were then harvested for a final time and resuspended in 200 jil of 1 M sorbitol. 
The cells (80 [tl) were then incubated on ice for 5 minutes with 10 tg of linearised 
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plasmid (1 tg.tF'), and pulsed (1500 V, 25 p.F and 200 Q). Immediately after 
pulsing 1 ml of ice-cold 1 M sorbitol was added to the cuvette, and the contents 
transferred to a 15 ml sterile centrifuge tube. The mixture was then incubated at 30 
°C with no shaking for 2 hours. Transformants were selected on YPDS (yeast 
extract peptone dextrose sorbitol - see Appendix A) + 100 jtg.mI' Zeocin 
(pPICZa,), or MD plates (pPIC9). 
2.2. General protein methods 
2.2.1. Trichloroacetic acid (TCA) precipitation of proteins 
A half-sample volume of TCA (30 % w/v) was added to each sample. The samples 
were then incubated on ice for 30 minutes, and the resulting precipitate was collected 
by centrifugation at 13,000 g for 20 minutes at room temperature. The supernatant 
was then poured off, and the pellet washed twice through the addition of 1 ml 
aliquots of a mixture of ethanol and diethyl ether (1:1 v/v) followed by centrifugation 
at 13,000 x g for 2 minutes at room temperature. The pellet was then dried by 
incubation at 37 °C for 10 minutes prior to sodium dodecyl sulphate (SDS)-
polyacrylamide gel electrophoresis (PAGE). 
2.2.2. SDS-PAGE 
SDS-PAGE was carried out according to the method of (Laemmli, 1970) either on a 
Bio-Rad Mini-protean-3 mini SDS-PAGE system using 10-20 % acrylamide gradient 
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Tris-HC1 'Ready-Gels', or on a Bio-Rad Criterion SDS-PAGE system using 10-20 % 
acrylamide gradient Tris-HC1 Criterion gels. SDS-PAGE gels were run at a constant 
voltage of 200 V for 50 minutes (Ready-Gels) or 80 minutes (Criterion gels). 
2.2.3. Immuno-blotting 
The protein was subjected to SDS-PAGE (as above) and transferred to nitrocellulose 
membrane in 'Towbin Buffer' (see Appendix A) at a constant current of 150 mA for 
2 hour in a Bio-Rad western blotting system. Following transfer the membrane was 
blocked by incubation for 2 hours at room temperature in PBS (see Appendix A) 
supplemented with 5 % non-fat dried milk (blocking buffer) on a bottle-rolling 
platform. The membrane was then incubated overnight with the primary antibody 
diluted in blocking buffer (dilutions and identity as given). Following extensive 
washing in PBS supplemented with 0.05 % (w/v) TWEEN20. The membrane was 
then incubated for 2 hours with the secondary antibody diluted in blocking buffer 
(dilutions and identity as given) at room temperature on a rolling bottle platform. 
Following extensive washing in PBS (peroxidase conjugated secondary) or TBS 
(phosphatase conjugated secondary) the membrane was stained with 3,3 '- 
Diaminobenzidine (DAB) (peroxidase conjugated secondary) or 5-Bromo-4-chloro-
3-indolyl phosphate/Nitro blue tetrazolium (BCIP/NBT) (phosphatase conjugated 
secondary). 
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2.2.4. Test inductions of recombinant P. pastoris clones 
Single colonies were purified by streaking on the appropriate solid media, and a 
single colony used to inoculate 10 ml of buffered minimal glycerol medium (BMG - 
see Appendix A) in a 50 ml sterile disposable centrifuge tube. The culture was 
incubated for 24 hours at 30 °C with agitation at 225 rpm, and the cells harvested by 
centrifugation at 2000 g for 5 minutes; the supernatant decanted; and the pellet 
resuspended in 5 ml of buffered minimal methanol medium (BMM - see Appendix 
A). The culture was incubated as before for 4 days, and was fed daily to 0.5 % (v/v) 
with methanol. Aliquots of 1 ml were taken and tested for expression using SDS-
PAGE. 
2.2.5. Large scale growth and induction of recombinant P. pastoris 
KM71/KM7IH clones 
A single colony was picked from a freshly streaked plate of the clone of interest, and 
used to inoculate 10 ml of BMG. YPD + 100 tg.mr' Zeocin were used for clones 
containing pPICZa, and minimal dextrose medium (MD - see Appendix A) plates 
used for clones containing pPIC9. The culture was incubated overnight at 30 °C 
with shaking at 250 rpm. This culture (5 ml) was used to inoculate 100 ml of fresh 
BMG, and the resulting culture was incubated overnight at 30 °C with shaking at 250 
rpm. Four two litre conical flasks each containing 500 ml of BM were inoculated 
with 20 ml of the previous culture and incubated overnight at 30 °C with shaking at 
250 rpm. The cells were then harvested by centrifugation at 1000 g for 5 minutes at 
4 °C, in sterile centrifuge pots, and resuspended in 11 of BMM. The resuspended 
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culture was then split equally between four two litre conical flasks and incubated at 
29 °C with shaking at 250 rpm for the optimal induction time. The cultures were fed 
daily to a final concentration of 1 % (v/v) with methanol to replace methanol that had 
been used by the yeast or had been lost by evaporation. Following induction the 
culture was harvested by centrifugation at 3000 g for 10 minutes at 4 °C, and the 
supernatant retained. 
2.2.6. Chromatography 
All chromatographic steps with the exception of ConA affinity chromatography were 
carried out on a Waters 650E FPLC system fitted with a 996 photodiode array 
detector, or on a BioCad 700E protein purification system (Applied Biosystems). 
2.2.7. Protein deglycosylation 
Protein samples were deglycosylated using the endoglycosidase EndoHf (NEB). 
EndoHf is a fusion protein between the EndoH gene from Streptomyces plicatus 
(Robbins et al., 1984) and the maltose binding protein affinity tag. Protein samples 
were deglycosylated with 1,000 U of EndoHf for each glycosylation site per 
milligram of recombinant protein (1 NEB unit is equivalent to 1 hUB milliunit) in 50 
mM sodium phosphate, pH 5.5, with 1 mM Phenylmethylsulfonyl fluoride (PMSF) 
and 5 mM EDTA for 4 hours at 37 °C typically in a total volume of 5 ml. 
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2.2.8. Protein N-terminal sequencing 
N-terminal sequencing was performed by Edman degradation on an ABI 477A 
automated sequencer at the Welmet protein characterisation facility, University of 
Edinburgh. Purified protein samples were run on SDS-PAGE and transferred to 
'ProBlot' polyvinylidene difluoride (PVDF) membrane, in Towbin buffer (see 
Appendix A) at a constant current of 150 mA for 2 hours. Protein bands were 
stained using 0.1 % Coomassie Blue G-250 in methanol, and destained with 10 % 
(v/v) acetic acid, 50 % (v/v) methanol. Following de-stain, the membrane was dried 
and the band excised. 
2.2.9. Mass spectrometry (MS) 
Mass spectrometry was performed using positive ionisation atmospheric pressure 
electrospray and was carried out on a Platform II single quadrupole mass 
spectrometer (Micromass). Purified samples were desalted using reverse phase 
chromatography on a C4 column and the fractions containing protein were freeze-
dried and redissolved in acetonitrile/H 20 (1:1, v/v) containing 0.5 % formic acid. 
Cone voltages were ramped to give the optimum signal-to-noise ratio over a wide 
mlz range. 
2.2.10. 	Carboxymethylation of MCP2 to determine the number of 
disulphide bonds 
MCP2 was deglycosylated with PNGaseF (NEB) by incubating MCP2 with 1000 U 
of PNGaseF per mg of MCP2, in 50 mM potassium phosphate, pH 7.5, at 37 'C for 4 
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hours. Three samples of the PNGaseF-deglycosylated MCP2 in 100 mM This, pH 
8.5, were prepared (100 .t1 of 100 ig..tF'). One sample was subjected to liquid 
chromatography-mass spectrometry (LC-MS) untreated; another was incubated in 
the presence of 40 mM neutralised iodoacetate at room temperature for 30 minutes, 
and was then subjected to LC-MS. The third was denatured and reduced by 
incubating for 1 hour at 37 °C in the presence of 10 mM DTT, 8 M Urea, and 100 
mM Tris, pH 8.5. Neutralised iodoacetate was subsequently added to a final 
concentration of 40 mM, and the reaction incubated at room temperature for 30 
minutes. This sample was then also subjected to LC-MS. 
2.2.11. 	Removal of glycoproteins and cleaved sugars 
The oligosaccharides cleaved during deglycosylation, and any protein that remained 
glycosylated following deglycosylation, were removed from the sample using "ConA 
Sepharose" (Amersham-Pharmacia Biotech). ConA is a lectin isolated from the jack 
bean Canabalia ensformis,  and binds to the terminal a-D-mannose and a-D-glucose 
residues of certain oligosaccharides, along with sterically related residues with 
available C-3, C-4 or C-5 hydroxyl groups (Reeke et at., 1975). Following 
enzymatic deglycosylation of proteins, the sample pH was increased to 7.5 using 1 M 
Trizma base (Sigma) and 4 M sodium chloride was added to a final concentration of 
0.5 M. Removal of the sugars was typically achieved using 5 ml of ConA sepharose 
per litre of BMM P. pastoris induction medium. The sample was applied to a gravity 
fed, 5 ml, ConA sepharose column that had previously been equilibrated with 
binding buffer (20 mM Iris, pH 7.5, 0.5 M NaCl), and the flow-through collected in 
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2 ml fractions. A280 was recorded for each fraction and when the A280 reading had 
returned to near baseline, elution buffer (20 mM Tris pH 7.5, 0.5 M NaCl, 1 M 
methyl-a-D-glucopyranoside) was added. Again 2 ml fractions were collected and 
A280 readings taken. 
2.3. Expression, purification and characterisation of MCPI2 
2.3.1. Cloning of MCPI2 into pPlC9 
The fragment corresponding to the N-terminal two modules of MCP (MCP12) was 
amplified by PCR using MCP cDNA as a template (BC2isoform cloned into pSG5, 
kindly supplied by Dr. J. Atkinson from the Washington University School of 
Medicine, St. Louis). The PCR reaction was set up as described in section 2.1. 1,  and 
was cycled according to the following parameters: 
Temperature Time No. Cycles 
95°C 2 min 1 
95°C 30 Sec 
35 
1mm  
55 °C 45 Sec 
74°C 
74°C 10 m in 1 
4 °C Hold  
The sequences of the primers were: 
MCP1 5' 
5' GGGGAATTCTCCGATGCCTGTGAGGAGCCACCAAC 3' 
MCP2 3' 
5' GCGGCGCCCGCCTATCACAAAACCTTTTCACATATTGG 3' 
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The restriction sites EcoRl and Notl were incorporated into the 5' and 3' primers 
respectively to facilitate directional cloning. Stop codons were incorporated into the 
3' primer to allow expression of the protein without the extra residues that would 
otherwise be incorporated from the vector. 
The fragment obtained from PCR was subjected to agarose gel electrophoresis (1.4% 
gel), and was subsequently purified from the gel using the Qiagen gel extraction kit 
according to the manufacturer's instructions. The fragment was then precipitated 
with ethanol according to section 2.1.4, and was redissolved in 20 .tl of autoclaved 
milli-Q water. The fragment was then digested with EcoRl and Notl, for 2 hours at 
37 °C in the reaction described below: 
Ethanol-precipitated MCP12 PCR product 17 	tI 
10 X reaction buffer 2 p1 
EcoR! (NEB) 20 ujir' 0.5 p1 
Not! (NEB) 20 ur' 0.5 p1 
Following the restriction digest, the reaction was heat-inactivated by incubating for 
20 minutes at 65 ° C. The digested DNA was then precipitated according to section 
2.1.4, and redissolved in 10 itl of autoclaved milli-Q water. The purified digested 
fragment was then ligated into pPIC9 previously cut with EcoRl and Notl using a 
1:1 molar ratio of insert to vector. The resulting construct was used to transform 
chemically competent E. co/i Top 10 (Invitrogen) according to the calcium chloride 
method (Sambrook et al., 1989). Positive transformants were selected on LB agar 
plates containing 100 jig.m1' ampicillin. Ten colonies were picked, and each used to 
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inoculate 5 ml of LB containing 100 jig.m1 1 ampicillin. The cultures were incubated 
overnight at 37 °C with shaking at 250 rpm. They were then "miniprepped", and 0.5 
Vg of each plasmid was digested with EcoRl and Not!; and run on an agarose gel 
(1.4 %) to confirm the presence of the insert. Plasmids containing the insert were 
sequenced (dRhodamine) to confirm the identity and accuracy of the insert. 
2.3.1.1. Transformation of P. pastoris KM71 with MCP12 pPIC9 
The MCP12 pPIC9 clone was subjected to midiprep using the Promega "Wizard Plus 
Midiprep" kit according to the manufacturer's instructions, and 35 pg of the product 
was linearised with BglH (100 NEB units), in a total volume of 300 p1 at 37 °C for 3 
hours. Complete digestion was confirmed using agarose gel electrophoresis (1.2 %). 
The enzyme BglII cuts pPIC9 in two places, so the region containing the insert was 
purified away from the other fragment using agarose gel electrophoresis followed by 
gel extraction. The purified, linearised plasmid fragment containing the insert was 
precipitated using ethanol and redissolved to a final concentration of 1 tg.jil' in 
autoclaved, deionised water. The P. pastoris KM7 1 cells were transformed with 5 
tg of this linear plasmid fragment by electroporation, and transformants were 
selected on MD (minimal dextrose - see Appendix A) plates. The colonies were 
then screened using membrane immuno-screening to identify which clones were 
most likely to express the highest levels of recombinant protein. Twelve 
transformants that appeared to express at reasonable levels were purified by streaking 
on MD plates and these were then used for test inductions to estimate which one 
expressed the protein at the highest level. The identity of the expressed protein was 
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verified by immunoblot. N-terminal sequencing and mass spectrometry confirmed 
the integrity of the protein sequence. 
2.3.1.2. Membrane immunoscreening of MCP12 pPIC9 KM71 clones 
The following procedure was carried out in a laminar flow hood to reduce the 
chances of contamination. Once the colonies from a P. pastoris transformation were 
of sufficient size to be manipulated (approx 2-4 mm in diameter) each clone was 
tested for protein expression using an immuno-screening procedure. A "Hybond-C 
Extra" membrane disk (Amersham-Pharmacia Biotech) was overlaid on each plate. 
A standard plate spreader was then used to apply sufficient pressure to the reverse of 
the membrane to allow a small amount of each colony to be transferred onto the 
membrane. The membrane and master plate were then marked with a sterile 
hypodermic needle, in such a way that unambiguous alignment of the membrane and 
master plate was possible. The membrane was then removed from the master plate 
and applied reverse side down to a MG (minimal glycerol - see Appendix A) plate, 
ensuring that the membrane was in contact with the plate across its entire area. The 
plate and membrane were then incubated at 30 °C for 24 hours after which time 
protein expression was induced by transfering the membrane to a MM (minimal 
methanol - see Appendix A) again ensuring that the membrane's entire surface was 
in contact with the plate. The plate was incubated at 30 °C for 48 hours, and was fed 
daily by adding 0.5 ml of methanol to the lid of the plate. 
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2.3.1.3. Time Course optimisation of MCP12 Expression 
A single colony was picked from a freshly streaked MD plate of MCP 12 pPIC9 
KM7 1 and used to inoculate 10 ml of BMG in a 50 ml sterile cell culture centrifuge 
tube. The culture was incubated overnight at 30 °C with shaking at 250 rpm. This 
culture was subsequently used to inoculate a further 100 ml of BMG in a 500 ml 
baffled conical flask, closed with a foam stopper. This culture was incubated for 2 
days at 30 °C with shaking at 250 rpm, and was subsequently harvested by 
centrifugation at 1500 g, at room temperature using aseptic technique. The pellet 
was then resuspended in 50 ml of BMM, and incubated at 29 °C with shaking at 250 
rpm for a total of 6 days. The culture was 'fed' daily with methanol by the addition 
of 1 % of the culture volume of HPLC grade methanol. Starting on day 2, 1.5 ml 
samples of the culture were taken, and the supernatant harvested by centrifugation at 
12,000 x g, and subsequently stored at -20 °C until the end of the sixth day of 
induction. Once all five samples had been collected, the 1 ml aliquots of the 
supernatants were deglycosylated by the addition of 2000 U of EndoHf (NEB), and 
incubating at 37 °C for four hours. The samples were then precipitated using TCA 
(see section 2.2.1), and subjected to SDS -PAGE 
2.3.2. Purification of recombinant MCPI2 
2.3.2.1. 	Initial purification of MCP12 on a Resource Iso column 
Large scale growths of MCP12 were performed as described in section 2.2.5. The 
culture was harvested after induction by centrifugation (2500 x g, 10 mins at 4 'C). 
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Proteases inhibitors were added - PMSF (0.5 mM final concentration) and EDTA (5 
mM final concentration), and microbial growth was inhibited with NaN 3 (0.05 % 
final concentration). The culture supernatant was concentrated using ultrafiltration, 
down to a final volume of 20 ml per litre of induced culture supernatant. 
After it was concentrated the protein was exchanged into 100 mM Tris buffer, pH 
8.3, on a gravity-fed PD1O gel filtration column (Amersham-Pharmacia Biotech), 
and an equal volume of 4 M (NH4)2SO4 was added and the pH readjusted to 8.3, 
giving the final sample conditions of 50 mM Tris, 2 M (NH 4)2SO4 , pH 8.3. This 
was then applied in 4 ml aliquots to a "Resource Iso" hydrophobic interaction 
chromatography column (Amersham-Pharmacia Biotech) that had been pre-
equilibrated with 2 M (NH 4)2SO4, 50 mM Tris, pH 8.3, with a flow rate of 2 ml.min - 
1 . Unbound protein was washed from the column with five column volumes of 
starting buffer. The bound MCP12 was then eluted with a linear gradient from 2M 
(NEL1)2SO4 to 0 M (NH42SO 4 (both containing 50 mM Tris pH 8.3) over 20 column 
volumes. Samples of the fractions containing protein were exchanged into 50 mM 
sodium phosphate, pH 5.5, using 500 tl centrifugal concentrators with a molecular 
weight cut off of 5 kDa. These samples were then deglycosylated by the addition of 
2 .il of EndoHf, TCA-precipitated and subjected to SDS-PAGE. Fractions 
containing MCP12 (as judged by SDS-PAGE) were pooled, concentrated to a final 
volume of 5 ml using a 20 ml centrifugal concentrator with a 5 kDa molecular weight 
cut-off membrane and exchanged into 50 mM sodium phosphate, pH 5.5. PMSF was 
added to a final concentration of 1 mM and EDTA to a final concentration of 5 mM. 
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2.3.2.2. Purification of EndoHf deglycosylated MCP12 
The protein obtained as described in section 2.3.2.1 was then deglycosylated with 
EndoHf, as described in section 2.2.7. The deglycosylated MCP12 was subsequently 
purified using a ConA sepharose column (5 ml) to remove the cleaved sugars and 
any remaining glycoprotein as described in section 2.2.11. The protein was then 
exchanged into 0.1 M Tris, pH 8.5, using a PD1O column. The resulting partially 
purified MCP 12 in 0.1 M Tris, pH 8.5, was then applied in 1 ml aliquots to a MonoQ 
HR5/5 column (Amersham-Pharmacia Biotech) that had been pre-equilibrated with 
the same buffer using a flow rate of 1 ml.min', and the unbound protein was washed 
away with five column volumes of starting buffer. MCP12 was eluted using a linear 
gradient of 0 M to 1 M NaCl, in 0.1 M Tris pH 8.5 over 15 column volumes. 
2.3.2.3. 	Purification of glycosylated MCP12 
The MCP12 purified on the "Resource Iso" column described in section 2.3.2.1 was 
applied in 0.5 ml aliquots to a C4 reverse phase column, that had previously been 
equilibrated with 95 % (v/v) acetonitrile; 0.05 % (v/v) trifluoroacetic acid (TFA) in 
water with a flow rate of 1 ml.min'. Unbound salts and contaminants were washed 
away with 10 column volumes of the starting buffer. Bound glycosylated MCP12 
was eluted with a linear gradient from 95 % acetonitrile, 0.05 % (v/v) TFA to 5 % 
acetonitrile, 0.05 % v/v TFA. Fractions containing glycosylated MCP12 (as judged 
by SDS-PAGE) were lyophilised and subsequently redissolved in 20 mM potassium 
phosphate pH 6.0. 
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2.4. Recombinant MCP2 from P. pastoris 
2.4.1. Cloning MCP2 into pPICZaA 
The region corresponding to module 2 of MCP (MCP2) was amplified by PCR using 
the same template DNA as that for MCPI2 (MCP-BC2-pSG5). The PCR reaction 
was set up as described in section 2.1.1, and was cycled according to the following 
parameters: 
Temperature Time No. Cycles 
95°C 1 min 1 
95 °C 30 Sec 
35 
30 Sec  
55°C 30 Sec 
74 °C 
74°C 10 min 1 
4 °C Hold  
The sequences of the primers were: 
MCP2 5' &oR 
5' CCGGAAIflFCTATAGAGAAACATGTCC 3' 
MCP2 3' NoUI 
5' GCGGCGGCCGCCTATCACAAAACCTTTTCACATATTGG 3' 
Two stop codons were incorporated to allow expression of the protein without the 
tags present in the vector. The restriction sites EcoRI and NotI were incorporated 
into the 5' and 3' primers respectively to facilitate directional cloning. The fragment 
obtained from PCR was subjected to agarose gel electrophoresis (1.4% gel), and was 
subsequently purified from the gel using the Qiagen gel extraction kit according to 
the manufacturer's instructions. The fragment was then precipitated with ethanol 
according to section 2.1.4, and was redissolved in 20 ptl of autoclaved milli-Q water. 
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The fragment was then digested with EcoRl and Notl, for 2 hours at 37 °C in the 
reaction described below: 
Ethanol precipitated MCP2 PCR product 17 il 
10 x  reaction buffer 2 	tl 
EcoRl (NEB) 20 U.,ir' 0.5 111 
Not! (NEB) 20 U.jtY 1 0.5 	.tl 
Following the restriction digest the reaction was heat-inactivated by incubating for 
20 minutes at 65 T. The digested DNA was then precipitated according to section 
2.1.4, and redissolved in 10 itl of autoclaved milli-Q water. The purified digested 
fragment was then ligated into pPICZaA previously cut with EcoRl and Notl using 
a 1:1 molar ratio of insert to vector. The result was used to transform chemically 
competent OneShot E. coli Top 10 cells according to the manufacturer's instructions. 
Positive transformants were selected on plates of low salt LB agar + 25 .ig.mF 1 
Zeocin. Ten colonies were picked, and each used to inoculate 5 ml of low salt LB 
containing 25 tg.mr 1 Zeocin for selection. The cultures were incubated overnight at 
37 °C with shaking at 250 rpm. They were then subjected to miniprep, and 0.5 tg of 
each plasmid was digested with EcoRl and Notl; and run on an agarose gel (1.4 %) 
to confirm the presence of the insert. Plasmids containing an insert of the predicted 
size for MCP2 were sequenced (Big Dye) to confirm the identity and accuracy of the 
insert. 
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2.4.1.1. Transformation of P. pastoris KM7IHis with MCP2 pPICZa 
The MCP2 pPICZaA clone was obtained by maxiprep using the Sigma Genelute 
Maxiprep kit according to the manufacturer's instructions, and 50 jig of the product 
was linearised with Sad (200 NEB units), in a total volume of 300 j.tl at 37 °C for 3 
hours. Complete digestion was confirmed using agarose gel electrophoresis (1.2 %). 
The purified linearised plasmid fragment containing the insert was phenol: 
chloroform extracted, and then precipitated with ethanol. The resulting pellet was 
redissolved in 10 jil of autoclaved deionised water. The P. pastoris KM71H cells 
were transformed using 5 jig of this linearised plasmid by electroporation (1.5 kV, 
200 Q, 25 j.tF) using a Bio-Rad Gene pulser. Transformants were selected on YPDS 
agar + 100 p.g.ji1 1 zeocin plates. Five colonies from the initial transformation plate 
were purified by streaking on YPD agar + 100 jig. jir' zeocin plates and these were 
then used for test inductions to estimate which expressed MCP2 at the highest level. 
N-terminal sequencing and mass spectrometry were used to confirm the integrity of 
the sequence. 
2.4.1.2. Test inductions of recombinant MCP2 P. pastoris clones 
Single MCP2 KM71H colonies were purified by streaking on YPD agar plates 
containing 100 j.tg . j.tF' zeocin, and a single colony used to inoculate 10 ml of BMG 
in a 50 ml sterile tissue culture centrifuge tube. The culture was incubated for 24 
hours at 30 °C with agitation at 225 rpm, and the cells harvested by centrifugation at 
2000 g for 5 minutes; the supernatant decanted and discarded; and the pellet 
resuspended in 5 ml of BMM. The culture was then incubated as before for 4 days, 
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and was fed daily by the addition of HPLC grade methanol (0.5 % of culture 
volume). Aliquots of 1 ml were taken from each clone, deglycosylated with 1000 U 
of EndoH f and tested for expression of MCP2 using SDS-PAGE. 
2.4.2. Purification of recombinant MCP2 
2.4.2.1. Initial purification of MCP2 on a Resource Iso column 
Large scale growths of MCP2 were performed as described in section 2.2.5. The 
culture was harvested after induction by centrifugation (2500 g, 10 mins at 4 °C). 
Proteases inhibitors were added - PMSF (0.5 mM final concentration) and EDTA (5 
mlvi final concentration), and microbial growth was inhibited with NaN 3 (0.05 % 
final concentration). The culture supernatant was concentrated using ultrafiltration, 
down to a final volume of 20 ml per litre of induced culture supernatant. 
After it was concentrated the protein was exchanged into 100 mM Tris buffer, pH 
8.3, on a gravity-fed PD10 gel filtration column (Amersham-Pharmacia Biotech), 
and an equal volume of 4 M (NH4)2SO4 was added and the pH readjusted to 8.0, 
giving the final sample conditions of 50 mM Tris, 2 M (NH4)2SO4, pH 8.0. This 
was then applied in 4 ml aliquots to a Resource Iso hydrophobic interaction 
chromatography column that had been pre-equilibrated with 2 M (NH4 2SO4,50 mM 
Tris, pH 8.0, with a flow rate of 2 ml.min 1 . Unbound protein was washed from the 
column with five column volumes of starting buffer. The bound MCP12 was then 
eluted with a linear gradient from 2 M (NH 4)2 SO4 to 0 M (NH4)2SO4 (both 
containing 50 mM Tris pH 8.0) over 20 column volumes. Samples of the fractions 
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containing protein were exchanged into 50 mM sodium phosphate, pH 5.5, using 500 
tl centrifugal concentrators with a molecular weight cut off of 5 kDa. These 
samples were then deglycosylated by the addition of 2 pJ of EfldOHf, TCA-
precipitated and subjected to SDS-PAGE. Fractions containing MCP2 (as judged by 
SDS-PAGE) were pooled, concentrated to a final volume of 5 ml and exchanged into 
50 mlvi sodium phosphate, pH 5.5, using a 20 ml centrifugal concentrator with a 5 
kDa molecular weight cut off membrane. PMSF and EDTA were added to final 
concentrations of 0.5 mlvi and 5 mlvi respectively. 
2.4.2.2. Purification of EfldOHf deglycosylated MCP2 
The protein obtained as described in section 2.4.2.1 was then deglycosylated with 
EndoHf, as described in section 2.2.7. The deglycosylated MCP2 was subsequently 
purified using a ConA sepharose column (5 ml) to remove the cleaved sugars and 
any remaining glycoprotein as described in section 2.2.11. The protein was then 
exchanged into 0.1 M Tris, pH 8.5, using a PD 10 column. The resulting partially 
purified MCP12 in 0.1 M Tris pH 8.5 was then applied in 1 ml aliquots to a 
Poros20Q column (Applied Biosystems) that had been pre-equilibrated with the 
same buffer using a flow rate of 5 ml.min', and the unbound protein was washed 
away with five column volumes of starting buffer. MCP 12 was eluted using a linear 
gradient of 0 M to 1 M NaCl in 0.1 M Tris, pH 8.5, over 20 column volumes. 
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2.4.2.3. Purification of glycosylated MCP2 
The MCP2 purified on the Resource Iso column described in section 2.4.2.1 was 
applied in 0.5 ml aliquots to a C4 reverse phase column that had previously been 
equilibrated with 95 % acetonitrile, 0.05 % v/v trifluoroacetic acid (TFA) solution in 
water with a flow rate of 1 ml.min'. Unbound salts and contaminants were washed 
away with 10 column volumes of the starting buffer. Bound glycosylated MCP 12 
was eluted with a linear gradient from 95 % acetonitrile, 0.05 % v/v TFA to 5 % 
acetonitrile, 0.05 % v/v TFA. Fractions containing glycosylated MCP2 (as judged by 
SDS-PAGE) were lyophilised and subsequently redissolved in 20 mM potassium 
phosphate pH 6.0. 
2.5. Recombinant MCP2 from organisms other than P. pastoris 
2.5.1. Cloning and expression of MCP2 in E. coli 
2.5.1.1. Cloning MCP2 into pET15b 
The region of DNA representing module 2 of MCP was amplified by PCR (annealing 
temp 55 °C; elongation time 30 seconds), using the same template as that for MCP 12 
(MCP-BC2-pSG5). 
The sequences of the primers were: 
MCP2 5' Ndelll 
5' GGGAATTCCATATGTATAGAGACATGTCC 3' 
MCP2 3' Xholl 
5' CCGCTCGAGCGGCTATCACAWCCTTTTCA 3' 
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The restriction sites Nde I and Xho 1 were incorporated into the 5' and 3' primers 
respectively to facilitate directional cloning. Stop codons were incorporated in the 3' 
primer to truncate the protein so that the minimum of cloning artefacts were 
expressed. The band of the predicted size for MCP2 was purified using agarose gel 
electrophoresis (1.4 %), followed by gel extraction. The band was then digested with 
Ndel and )Thol, and was then repurified by agarose gel electrophoresis, followed by 
gel extraction. The digested fragment was then ligated into pET-15b using the 
'Rapid Ligation Kit' (Roche), and used to transform chemically competent One Shot 
Top 10 E. coli cells. The transformants were selected on LB Ampicillin plates. 
Colonies were taken for miniprep and the plasmids digested with Ndel and X7o1 to 
confirm the presence of an insert of the correct size. Plasmids containing an insert of 
the predicted size for MCP2 were sequenced (Big Dye) to confirm the identity and 
sequence of the insert. 
2.5.1.2. Cloning MCP2 into pET32 
MCP2-pET 1 5b was digested with Nco 1 and Xho 1, and the result run on agarose gel 
electrophoresis (1.2 %). The smaller fragment corresponding to the region of interest 
was purified form the gel, precipitated (see section 2.1.4) and the pellet redissolved 
in 10 j.tl of autoclaved Milli-Q water. This fragment was then ligated into pET32a 
(previously cut with Ncol and .A7o1) using the Roche Rapid Ligation kit according 
to the manufacturer's instructions, and the result used to transform chemically 
competent OneShot ToplO E. coli cells. Transformants were selected on LB 
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Ampicillin plates. Positive clones were selected and the plasmid retrieved by 
maxiprep using the Sigma Gene Elute Maxiprep kit according to the manufacturer's 
instructions. This plasmid DNA was subsequently further purified using phenol: 
chloroform extraction and ethanol precipitation. 
2.5.2. Cloning and Expression of MCP2 in Drosophila S2 Cells 
2.5.3. Growth and Maintenance of S2 Cells 
2.5.3.1. General maintenance 
Drosophila S2 cells were cultured in Invitrogen's Complete Drosophila Expression 
Medium (DES)TM  containing 10 % heat inactivated fctal bovine serum; or in 
Ultimate InsectTM  serum free medium. The cells were resuspended before seeding a 
fresh culture. The S2 cells were grown in adherent culture and flasks were seeded to 
a density of 2 x 106 cells ml-1 in 10 ml of fresh medium in new T75 flasks with vent 
closures. The cells were incubated at 28 °C until a cell density of 1 x  107 cells ml-1 
was achieved, at which point the cells were split to a density of 2 x 106 cells ml -1  
with fresh media, and T75 plates. The general health of the culture was followed 
using microscopic examination, and trypan blue cell viability assay. 
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2.5.4. Cloning of MC132 into pMTIBiPN5-His-A 
The MCP2 gene fragment containing a N-terminal His tag and thrombin cleavage 
sequence previously cut from the MCP2 pETl5b construct using Ncol and .X7iol (see 
section 2.5.1.2). The insert was ligated into pMTfBiP/V5-His-A previously cut with 
Ncol and Xhol, using the Roche Rapid Ligation Kit according to the manufacturer's 
instructions. The result was used to transform chemically competent OneShot Top 10 
E. coli cells according to the manufacturer's instructions and positive transformants 
selected on LB agar plates containing 100 jtg.m1' ampicillin. 
2.5.4.1. Transfection of S2 cells with pMTIBiP/V5-His-A-MCP2 
Plates (35 mm) were seeded with 3 x 106 S2 cells in 3 ml of complete DES. The 
cells were incubated for 16 hours at 28 °C, in a humidified plate incubator, by which 
time the cells had reached a cell density of 3.4 x 106. The cells were transfected 
using calcium phosphate DNA precipitation with calcium chloride and Hepes-
buffered saline. Transfection by this method is thought to be mediated by 
endocytosis of the DNA/calcium phosphate precipitate. The DNA used for 
transfection was a 20:1 mixture of pMT/BiP/V5-His-A-MCP2, and the selection 
vector was pCoHygro. The cells were incubated in the presence of the calcium 
phosphate - DNA solution for 16 hours, after which time the cells were washed 
twice with complete DES, and incubated for a further 2 days at 28 C in the same 
plate. The cells were then resupended in complete DES containing 300 j.tg.mr' 
hygromycin, and the cells incubated for 3 weeks until resistant cells started to grow 
out. 
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2.5.4.2. Induction of expression of MCP2 in S2 cells 
Once a stable cell line had been established, protein expression was induced by the 
addition of copper sulphate to a final concentration of 500 p.M to the growth 
medium. The stable cell line was adapted to use serum free medium, by passaging 
twice through serum free medium, in T25 flasks. Following adaptation to serum free 
medium, a T25 flask was seeded with 2 x 106 cells. The cells were incubated for 16 
hours at 28 °C, followed by the addition of 100 mM copper sulphate to a final 
concentration of 500 p.M. The cells were then incubated for a further 24 hours 
before assaying the culture medium for the presence of MCP2. 
2.6. Cloning and Expression of SLAM 
2.6.1. Cloning of SLAM into pGEM-T 
The cDNA of SLAM (CDw150) was amplified using a modification of touchdown 
PCR using 2.5 U of 'Herculase HotStart' DNA polymerase (Stratagene). The Quick-
Clone universal human cDNA library (Clontech) was used as a template (8 ng); 100 
ng of each primer; a final concentration of 0.2 mM of each dNTP; and 5% (v/v) 
DMSO. 
The sequences of the primers were: 
5' primer 
5' CTTTTGGGGCAAGCTACGGAACAGGTG 3' 
3' primer 
5' CACTAGCATAGACTGTGATGGAATTTGTTTC 3' 
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Neither primer had a restriction sites built in to reduce the possibility of forming 
unwanted side products. 
The reaction was cycled as follows 
Temp Time No. Cycles 








l min 3Os  




l min 50s  
52 °C 30s 
74°C 
74 °C 10 min 1 Cycle 
4 0C hold 
The PCR product was purified using agarose gel electrophoresis (1.4 %) followed by 
gel extraction. They were A-tailed and ligated into pGEM-T (Promega) according to 
the manufacturer's instructions. Transformants were selected on LB-amp containing 
X-gal, and white colonies that potentially contain the SLAM gene were subjected to 
miniprep, and digested with Ncol and Ndel that are present in the flanking 
sequences of the vector. Plasmids containing an insert of the predicted length for 
SLAM were sequenced (Big-Dye) to confirm both the identity and sequence of the 
insert. 
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2.6.2. Cloning of SLAMI into pPICZaA 
The N-terminal domain of SLAM was amplified by PCR using SLAM-pGEM-T as a 
template (annealing temperature 60 °C; and extension time 45 seconds). 
The sequences of the primers were: 
5' primer: 
5' CCGGAAT]TCGCAAGCTACGGAAC 3' 
3' primer: 
5' TTTTCCTTTTGCGGCCGCCTACTGGGTCTTG 3' 
The restriction sites EcoRl and Notl were incorporated into the 5' and 3' ends of the 
PCR product respectively, to facilitate directional cloning. A stop codon was 
incorporated at the 3' end of the gene to allow expression of the N-terminal domain 
without the purification tags present on the expression vector. Following 
amplification the PCR product was purified using agarose gel electrophoresis and gel 
extraction. The purified PCR product (0.5 [tg) was digested using EcoRl (10 NEB 
units) and Notl (5 NEB units), and was then repurified using agarose gel 
electrophoresis followed by gel extraction. The digested PCR product (50 ng) was 
ligated using the rapid ligation kit (Roche), into pPICZaA (25 ng) pre-cut with 
EcoRl and Not!. The reaction was used to transform One Shot ToplO E. coli and 
transformants selected on LB-Zeocin plates. Ten colonies were subjected to 
miniprep and the plasmid digested with EcoRl and Notl to test for the presence of 
the insert. Plasmids containing an insert, of the predicted size for the N-terminal 
domain of SLAM, were sequenced (Big Dye) to confirm the identity and sequence of 
the insert. 
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2.6.3. Transformation of P. pastoris X33 with SLAMI pPICZaA 
The SLAM! pPICZaA clone was "maxipreped" using the GenElute Maxiprep kit 
(Sigma) according to the manufacturer's instructions, and 15 tg of this was 
linearised with Sad (100 NEB units), in a total volume of 300 jil at 37 °C for 3 
hours. Complete linearisation was checked using agarose gel electrophoresis (1.2 
%). The linearised plasmid was purified using phenol: chloroform extraction 
followed by ethanol precipitation. The X33 cells were transformed with 5 tg of 
linearised plasmid by electroporation and transformants were selected on YPDS 
Zeocin plates. Twelve transformants were purified by streaking on YPD Zeocin 
plates and these were then used for test inductions to estimate which one expressed 
the protein at the highest level. 
2.6.4. Optimising the expression conditions for SLAMI 
The SLAM1 X33 clone that appeared to express the highest levels of protein was 
used for expression optimisation. A single colony was picked from a freshly 
streaked YPIDZ plate and used to inoculate 10 ml of BMG. This culture was 
incubated over night at 30 °C with shaking at 250 RPM and used to inoculate 50 ml 
of BMG. This culture was incubated over night as before and used to inoculate 500 
ml of BMG. This culture was incubated overnight as before until it reached 0D 600 of 
21. The cells were harvested by centrifugation at 1500 g for 5 minutes at room 
temperature and resuspended in 1 litre of BMM (0.5 % (v/v) methanol). The culture 
was then split into 4 x 250 ml, each had an 0D 600 of 13. The cultures were fed with 
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methanol daily to 0.5 %; 1 %; 2 % or 4 %. The absorbance at 600 nm was recorded 
each day at the time of feeding, and a sample was taken for analysis of protein 
expression. Each sample was deglycosylated with 100 NEB units of EfldOHf prior to 
SDS-PAGE. 
The identity of the expressed protein was confirmed using immunoblotting, 
employing a goat polyclonal IgG raised against amino acid residues 33-51 of human 
SLAM (sc-1334 - Autogen-Bioclear) as the primary (1:500 dilution). A rabbit anti-
goat IgG peroxidase conjugate (A-5420 Sigma) was used as a secondary antibody 
(1:5000 dilution). The membrane was stained for 5 minutes with the precipitating 
peroxidase substrate DAB with nickel enhancer (Sigma). 
The expressed protein was tested for the presence of N-glycans using a band shift 
type assay. Two 1 ml samples of culture supernatant were taken following induction, 
and one was deglycosylated with 1000 NEB units of EndoHf at 37 °C for 2 hours, 
whilst the other was simply incubated at 37 °C for 2 hours. The samples were then 
precipitated with TCA and subjected to SDS-PAGE, and stained with a colloidal 
coomassie blue stain (Sigma). 
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3. Expression, Purification, and characterisation of MCPI2 
3.1. Preliminary remarks 
The importance of the first two modules of MCP (MCP 12) as a receptor for measles 
virus, and potentially other pathogens, has been demonstrated, and to date the whole 
of this protein has been characterised in reasonable detail. A greater understanding 
of MCP 12 may prove useful for fully determining its interaction with measles virus 
and other potentially pathogens. We were therefore interested in characterising this 
region in greater detail, with the intention of understanding the mechanism by which 
these pathogens use MCP to gain entry into cells. 
Since this region of the protein is only a fragment of the whole it cannot be obtained 
by purification from a natural source, instead some form of artificial method will be 
required to produce this fragment. Limited proteolysis can be used to produce 
domain fragments; however, this approach has problems with consistency and purity. 
Another possible method for producing domain fragments is chemical synthesis, and 
there has been some success using this method for producing some relatively small 
proteins (Bersch et al., 1998), but the yield rapidly falls off above 50 - 60 amino 
acids. This technique is further hampered by the requirement to artificially fold the 
protein following synthesis. An additional disadvantage is the expense of isotopic 
labelling. A promising technique based on inteins for splicing together smaller 
fragments is still not widely proven (Muir et al., 1998; Xu et al., 1999). At the 
present time, the most successful means of producing the quantities of larger or more 
complex proteins required for structural and biophysical characterisation is to 
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employ a heterologous gene expression system. The work described in the following 
section describes the successful expression and purification of the MCP12 fragment 
in the methylotrophic yeast P. pastoris. 
3.2. Cloning and Expression of MCPI2 
The ease with which the expression of foreign genes in E. coli can be achieved has 
markedly increased over the last decade, and E. coli is now the expression host of 
choice for producing a wide variety of foreign genes from a number of different 
organisms. Amongst the major advantages of using E. coli as an expression host are: 
the general level of understanding of E. coil genetics; the ease of performing genetic 
manipulations; the high levels expression that are often achieved; and the speed with 
which initial protein samples can be obtained (Baneyx, 1999). There are, however, a 
number of serious limitations associated with using E. coli as an expression host. 
Being a prokaryote, E. coil has notably different cellular machinery to higher 
eukaryotes, with the result that E. co/i is unable to perform many of the processes 
involved in the folding of multi-modular proteins (Georgiou et al., 1996), although 
efforts have been made to address this issue by genetically modifying E. co/i with 
various chaperones etc (Thomas et al., 1997). In addition to this E. coil is unable to 
perform many of the necessary post-translational modifications that are common in 
eukaryotic proteins. In the case of MCP the most important of these are disulphide 
bond formation and N-glycosylation, both of which have been shown to be necessary 
for MCP to be fully active (Liszewski et al., 1998; Maisner et al., 1994). The use of 
E. coil in this case would therefore probably require the use of a refolding protocol, 
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and any N-linked glycans would need to be added chemically at a later stage. 
Instead it would seem a natural choice to use one of the eukaryotic expression 
systems as a starting point for expressing fragments of MCP. 
There are several available eukaryotic expression systems, each with its own 
advantages and disadvantages. They are generally divided into two main classes, 
namely higher eukaryotic and lower eukaryotic expression systems. The former 
typically employ the culture of immortalised cell lines from various higher 
eukaryotes including mammals, and examples of such cell lines include Chinese 
hamster ovary (CHO) cells. In mammalian expression systems, the gene to be 
expressed is transferred to the cell line of interest using such methods as viral 
infection (e.g. adenovirus or lentivirus), electroporation (Shigekawa et al., 1988) 
lipid mediated transfection (Feigner et al., 1989) or calcium phosphate transfection 
(Chen et al., 1987). Since mammalian systems are derived from higher eukaryotes 
and are the closest available expression host to man, they are able to produce 
correctly folded and glycosylated proteins. Although even with mammalian 
expression systems, the glycosylation profile of the recombinant protein may not 
fully reflect its natural state. These expression systems have, therefore, been 
particularly useful for the expression of proteins such as membrane proteins that 
proved difficult to express in other systems. 
There are, however, several limitations of the mammalian expression systems. The 
most important of these are: low yields of protein; the complex media required for 
growth and maintenance of the cells; and the large period of time required between 
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cloning the gene and obtaining the initial protein samples. Biophysical and structural 
studies usually require tens of milligrams of highly purified and homogeneous 
protein. Therefore, the tens of micrograms per litre yields that are often associated 
with mammalian expression systems would prove unsuitable. As such these 
expression systems are of primary use in such cases, only once it has been 
established that the protein cannot be obtained using another system. The complex 
media requirements of mammalian cell culture makes the isotopic enrichment 
required by one of the most powerful biophysical techniques, high field NMR 
spectroscopy, unattractive from a cost point of view ('-j £2,000 per litre for ' 5N CHO 
cell growth medium, at the time of writing). Bearing these points in mind it seems 
logical to initially attempt to use a non-mammalian eukaryotic expression system for 
the expression of MCP fragments. 
Insect cells provide another route to higher eukaryotic expression of proteins. These 
expression systems employ similar cell culture techniques to the mammalian 
expression systems already discussed. The cell lines are derived from species such 
as Spodoptera frugiperda (Sf9, and Sf21 cells) Trichoplusia ni (High FiveTM) and 
Drosophila melanogaster (S2 cells). The insect expression systems have similar 
capabilities to their mammalian counterparts as far as post-translational 
modifications are concerned. The major difference in protein processing between the 
two expression systems lies in the glycosylation profiles of the resultant 
glycoproteins. Insect cells are generally unable to produce the complex glycans that 
are observed in proteins expressed in mammalian systems (Altmann et al., 1999). 
Insect expression systems do, however, have a number of advantages over 
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mammalian expression systems. These advantages include: less stringent media 
requirements and the ability to easily adapt to growth on serum-free medium; 
generally higher expression levels - 8-10 tg.mr 1 for human melantoransferrin 
(Hegedus et al., 1999); and reduced equipment requirements - generally a CO2 
incubator is not required. 
Of the other available eukaryotic expression systems in common use, yeast has many 
advantages when it comes to expressini complex proteins for biophysical studies. 
There are two yeast expression systems currently in common usage - Saccharomyces 
cerevisiae and Pichia pastoris. Both of which are able to form multimodular and 
disulphide bonded proteins (White et al., 1994), and they can perform rudimentary 
glycosylation, (high mannose-type glycosylation patterns rather than the complex or 
hybrid patterns often found in higher eukaryotes). One potential advantage of using 
P. pastoris over S. cerevisiae for the expression of MCP 12 is due to the phenomenon 
of hyperglycosylation. Hyperglycosylation is the result of the organism adding 
excessive numbers of mannose residues to the core sugars during glycan maturation 
in the Golgi apparatus. This phenomenon is frequently observed in proteins 
expressed in S. cerevisiae; however its occurrence in P. pastoris is considerably less 
common (Lundblad, 1999). Expression in S. cerevisiae, of CCP module pairs and 
individual CCP modules from factor H, for NIMR structural studies, has been 
reported although the yields are typically quite low. In the case of factor H module 
16 the yield of purified protein was only around 0.1 mgI 1 (Barlow et al., 1991). The 
other commonly used yeast expression system - P. pastoris is particularly powerful 
(for a review see Cereghino et al., 2000). In addition to its ability to produce 
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properly processed complex proteins, the levels of foreign protein that have been 
achieved are often very high, and levels of over 2.5 g.i' of secreted protein have 
been reported (Paifer et al., 1994). These expression levels combined with P. 
pastoris's ability to grow on minimal medium, permits isotopic labelling of 
recombinant proteins without the prohibitive costs associated with the higher 
eukaryotic systems. Moreover, P. pastoris previously has been used successfully to 
express and isotopically label several different complement control protein fragments 
for biophysical and structural investigations (Guthridge et al., 2001; Henderson et al., 
2001; Smith et al., 2002; Wiles et al., 1997). It is logical therefore to employ P. 
pastoris as the initial expression system for the production of the N-terminal 
fragments of MCP in the current study. The following section describes the 
successful cloning and expression of the two N-terminal modules of MCP (MCP12) 
in P. pastoris. 
3.2.1. Cloning and expression of MCPI2 in P. pastoris 
The P. pastoris expression vector pPIC9 was chosen for the initial expression of 
MCP12, because it is an inducible expression vector that targets the recombinant 
protein to the secretory pathway, and subsequently into the culture medium. 
Secretion of recombinant proteins offers several advantages over intracellular 
expression. Secretion of proteins facilitates both disulphide bond formation and N-
linked glycosylation, both of which are known to be important in this instance. In 
addition, secretion is generally associated with less troublesome purification 
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protocols. This is especially true in the case of P. pastoris which is known to 
naturally secrete only very low levels of protein (Higgins, 1998). The pPIC9 vector 
(see Figure 3:1 for pPIC9 plasmid map) is a shuttle vector that uses ampicillin 
resistance for selection in E. co/i, and the histidine auxotrophic marker for selection 
in P. pastoris. The gene of interest is cloned behind the powerful inducible promoter 
from the native P. pastoris alcohol oxidase gene AOX1, and induction of protein 
expression is subsequently achieved by switching the carbon source from the 
glycerol used during the growth phase to methanol. The protein was targeted for 
secretion by cloning the gene of interest behind the secretion signal from the cc-
mating factor from S. cerevisiae. The a-factor secretion signal was chosen in over 
the native P. pastoris PHO 1 secretion signal, since generally more success has been 
achieved using the cc-factor secretion signal (Laroche et al., 1994). This secretion 
signal contains the KEX2 cleavage, followed by two EA repeats. Cleavage of the 
secretion signal is a two step process (Achstetter, 1989); the initial cleavage is by the 
KEX2 gene product; which cleaves on the carboxyl side of R in the secretion signal 
sequence EKR'EAEA. The second step is cleavage by the STE13 gene product of 
the two EA repeats. STE1 3 is a membrane bound dipeptidase that cleaves on the 
carboxyl side of A in the sequence NH-XA (Julius et al., 1983). 
This type of cloning strategy inevitably leaves a number of extra amino acid residues 
on the expressed protein as a result of cloning artefacts. In this case efficient 
cleavage of the secretion signal by both KEX2 and STE13 is predicted to leave extra 
YVE residues on the protein's N-terminus. This would therefore result in the 
predicted sequence of the N-terminus of the protein, before the first cysteine of the 
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consensus CCP module sequence, being YVEFSDA. However is has been reported 
that STE 13 processing of the secretion signal does not always occur efficiently for 
heterologous proteins in P. pastoris (Goda et al., 2000); in which cases the protein is 
secreted with extra residues on its N-terminus (either EA or EAEA depending on the 
efficiency of STE 13 cleavage). 
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Figure 3:1 A plasmid map of pPIC9 showing the key features of the AOXI 
promoter, a-factor secretion signal, ampicillin resistance, and HIS4 gene to 
provide the histidine auxotrophic marker for selection in P. pastoris (taken 
from Invitrogen, 2002a). 
The transformation of P. pastoris involves the integration of linearised recombinant 
vector into the host genome by the process of homologous recombination. The 
vector is linearised in a region that contains homologous sequences to ones found in 
the host genome (Cregg et al., 1985). The presence of several homologous regions in 
the vector permits a choice of methods by which the recombinant plasmid is 
integrated into the host genome. This has important implications for the eventual 
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phenotype of the recombinant P. pastoris, which is dependant on both the region in 
which the plasmid is linearised and the genotype of the original host strain. Aside 
from the His phenotype used to select recombinants, there is another important 
phenotype to consider when generating recombinant P. pastoris. P. pastoris has two 
alcohol oxidase genes, AOX1 and AOX2, and of these the AOX1 gene contributes 
the majority of the alcohol oxidase activity in the cell (Cregg et al., 1989). This 
occurs despite the 97% sequence identity between the AOX1 and AOX2 genes. 
Yeasts that contain wild type AOX1 and AOX2 have wild type methanol utilisation 
(Mut4 ), and those that have a disrupted AOX1 gene exhibit slow methanol utilisation 
(MutS) .  In this way, disruption of the AOX1 gene leaves the yeast with a working 
copy of the AOX2 gene only, which results in poor growth characteristics on 
methanol, whilst the growth rate on other carbon sources remains unaffected. The 
different ways in which the recombinant plasmid can integrate into the host genome 
are illustrated in Figure 3:2 
Figure 3:2 - Following page. The generation of recombinant P. pastoris 
clones using pPIC9. A: Linearisation of the plasmid in the HIS4 region causes 
insertion at the His4 locus of the host chromosome, and results in a His phenotype 
for all strains and a Mut phenotype that depends on the host strain (Mut GS1 15 and 
Muts KM71). B: linearisation of the plasmid in the AOX1 region (either 5'AOX1, 
3'AOX1 or AOX1 transcription termination regions), causes insertion in the 
corresponding AOXI region of the host chromosome. This results in a similar 
phenotype to that for insertion at His4 - His all strains, and Mut GSII5 and Muts 
KM71. C: linearisation of the plasmid in both 5' and 3' AOX1 regions causes gene 
replacement of the entire AOXI coding region. This results in a His M uts 
phenotype and should only be performed in the GSI 15 strain (taken from Invitrogen, 
2002a). 
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Polymerase chain reaction (PCR) was used to amplify the region of MCP encoding 
the N-terminal two modules (MCP12) and asymmetric restriction sites were 
incorporated into the primers (5' EcoRl and 3' Not!) so that directional cloning was 
possible. In this way any positive transformants should contain the inserted gene 
fragment in the correct orientation. The multicloning region of pPIC9 is shown 
alongside the final construct in Figure 3:3. The PCR product, shown in Figure 3:4, 
gave a single band of approximately 500 bp which is slightly larger than one would 
expect for MCP12. This DNA fragment was then ligated into pPIC9 and used to 
transform E. coli lop 10 cells. The transformation yielded a large number of 
transformants, ten of which were worked up by 'miniprep' and tested by restriction 
digest (EcoRl and Noti) for the presence of the required DNA fragment. Clones 
containing inserts of the correct size for MCP12 were then sequenced to confirm 
their identity. A clone containing an insert of the predicted sequence for MCP 12 was 
subsequently employed to prepare the DNA used to transform the P. pastoris strain 
KM7 1. This P. pastoris strain was transformed by gene insertion in the AOX1 
region, and was achieved by linearising the plasmid with Pme 1, which cuts the 
plasmid in the 3' AOX1 region. This strategy should yield P. pastoris clones with a 
His MutS  phenotype. 
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a-Factor(949-1215) 
ATCAAAAAAC AACTAATTAT TCGAAGGATC CAAACG ATG AGA TTT CCT TCA PITT TTT ACT CCA 
Met Arg Phe Pro Ser lie the Thr Ala 
GTT TIA TTC GCA GCA TCC TCC GCA TTA GCT GCT CCA GTC MC ACT ACA ACA GM CAT 
Val Leu the Ala Ala Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp 
GAA ACG GCA CAP. ATT CCG GCT GAP. GCT GTC ATC GGT TAC TCA CAT TTA GAA GGG CAT 
Glu Thr Ala Gin lie Pro Ala Glu Ala Val lie Gly Tyr Ser Asp Leo Glu dy Asp 
TIC GAT GTT GCT GTT TTG CCA TTT TCC MC AGC ACA AAT AAC GGG TTA TTC TTT ATA 
the Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu the lie 
a-Far Primer S1te(152.1172) 	 XhoI 
PIAT ACT ACT ATT GCC AGC PITT GCT GCT AAA GAA GM CCC GTA TCT CTC GAG MA AGA 
Asn Thr Thr lie Ala Ser lie Ala Ala Lys Glu Glu Gly Val Ser Leu Glu Lys Arg 
gn cvag* (1W4) 	SnaB I ER I 	Mdl 	No I 
V 	 I 	I I I 
GAG GCT GM GCT TAC GTA GM TTC CCT AGG GCG GCC GCG MT TM TTCGCCTLAg  
Glu Ala Glu Ala Tyr Val Glu Phe Pro Arg Ala Ala Ala Asn 
B 	EKREAEAYVE FSDAC.... 
Figure 3:3 A: The cloning region of pPIC9 showing: the a-factor secretion signal 
with the KEX2 and STE13 cleavage sites, and the EcoRl and Noti restriction sites 
used for inserting the MCP12 gene fragment. B: The pPIC9-MCPI2 construct in 
the region of the secretion signal showing: the KEX2 and STE1 3 cleavage sites 
(red); the artefactual cloning residues (purple) and the start of the MCP12 sequence 
(blue). 
Figure 3:4 PCR amplification of the MCPI2 fragment. The gel shows a single 
band that appeared to be slightly larger than the predicted size for MCP12 
containing the EcoRl and Noti restriction sites, stop codon, and extra bases added 
to facilitate efficient restriction digests. 
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3.2.2. Immuno-screening of recombinant P. pastoris clones 
The transformation yielded a large number of transformants, and since there is often 
significant clonal variation amongst recombinant P. pastoris clones, expression 
levels between individual colonies may vary significantly. Moreover, some clones 
may produce unusually high expression levels, and these are often associated with 
multi-copy integration events (Clare et al., 1991). These multi copy clones, 
sometimes referred to as 'jackpot clones', occur spontaneously but are relatively rare, 
accounting for only 1% of the total number of His transformants. It is therefore 
desirable to screen a large number of colonies for expression following a P. pastoris. 
One way of doing this is to carry out a large number of 'test inductions', and test 
each one for protein expression. It is often impractical, however, to perform such an 
analysis on each of the hundreds of clones generated by a typical P. pastoris 
transformation. This is particularly true for proteins such as MCP 12 that cannot 
easily be assayed. It is therefore useful to find another method of screening. 
Antibodies to the protein of interest can prove useful in this respect. In this case the 
recombinant protein should be secreted, therefore if the clones are induced whilst 
growing on a membrane with a high protein-binding capacity, the protein should 
become immobilised on the membrane. It should then be a relatively straightforward 
task to detect the immobilised protein using standard immunostaining techniques. 
A colony lift was performed from the initial selective minimal dextrose (MID) plates 
from the transformation using a membrane with high protein binding capacity. 
These membranes were transferred to minimal glycerol (MG) plates and incubated 
for 24 hours at 30 T. The membranes were subsequently transferred to minimal 
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methanol (MM) plates, and incubated for a further 48 hours at 30 T. Following the 
first 24 hours, the membrane colonies were fed' by adding 500 .tl of methanol onto 
the lid of the MM plates. The membranes were subsequently stained as described in 
section 2.3.1.2. The results of these membrane screens are shown in Figure 3:5 and 
appear to show, that certain colonies express greater levels of MCPI2 than others; 
the clone indicated in Figure 3:5 was used for further analysis. These results need to 
be interpreted with caution however, since it is difficult to correct for the size of the 
colony. They do provide several important pieces of information however, not least 
of which is that this method of colony screening provides a reasonable assurance that 
the protein that is subsequently observed is MCP 12, since antibodies against the N-
terminus of MCP were used for detection. 
L r P"j 
Figure 3:5 lmmuno-screening of the MCPI2 pPIC9 KM7I membranes. The 
membrane shows that most clones express at only a relatively low level and 
colonies are hard to distinguish from the background. There are a few clones, 
however that appear to give much stronger signals. The clone marked by the arrow 
was the one chosen for further analysis. 
It had previously been discovered that the N-terminal module of MCP (MCPI) 
became hyperglycosylated when expressed in P. pastoris (O'Leary, 2000), and that 
these glycans were sensitive to EndoH f. EndoHf is an endoglycosidase that cleaves 
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high mannose type N-glycans between the first and second G1cNAc residues 
(Robbins et al., 1984). That the glycans of MCP1 were sensitive to EfldOHf, should 
come as no surprise given that the glycosylation patterns found in P. pastoris are 
reported to be of the high mannose type (see schematic in Figure 1.12), and this type 
of glycans are amenable to cleavage using EndoH (Miele et al., 1997). In order to 
determine whether the MCP12 expressed by P. pastoris was also hyperglycosylated; 
the clone indicated in Figure 3:5, was grown on a test scale (10 ml) and 1 ml samples 
subjected to SDS-PAGE, both before and after treatment with EfldOHf. This SDS-
PAGE result, shown in Figure 3:6, shows a smear for the untreated sample that is 
considerably larger than what would be expected for MCP12 - 28-35 kDa rather than 
the predicted 16 kDa for non-glycosylated MCP12. Moreover, following enzymatic 
deglycosylation with EndoHf the smear was replaced by a single band of the 
expected molecular weight for MCP 12. These data are similar to those obtained with 
MCP1 (O'Leary, 2000), and provide compelling evidence that the MCP12 species 
expressed by P. pastoris is subject to hyperglycosylation, and that the attached 
glycans are of the high mannose type. This hyperglycosylation may potentially 
cause problems with subsequent experiments, by virtue of the extreme heterogeneity 
of the glycoforms of the protein, and also in the increased size molecular weight of 
the species. 
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Figure 3:6 SOS-PAGE showing the effect of EndoH 1 treatment on the MCPI2 
fragment expressed by P. pastoris. The EndoH f treated sample (dg MCP12) 
shows a discrete band of around 16 kDa, which is close to what would be expected. 
The untreated sample (gMCP12), on the other hand, shows a smear centred at 
approximately 30kDa. 
3.2.3. Optimisation of Expression of MCPI2 
There are several conditions to optimise with any new recombinant P. pastoris 
expression attempt, including cell density at induction, aeration, p1-I, and 
temperature. The majority of these factors merely contribute to maintaining the 
culture in its optimal growth conditions. These factors are therefore typically strain 
specific rather than protein specific. There is, however, one main parameter that is 
worth optimising for each protein construct, namely length of induction. The aim of 
adjusting the induction time is to find the optimum balance between the amount of 
protein produced and modification or degradation. To address this issue, SDS-PAGE 
was performed on deglycosylated I ml samples taken from a culture of MCPI2 at 
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days 2 - 6 post, and this is shown in Figure 3:7. The gel shows that yield increases 
with increasing induction time, but by days five and six, degradation appears to 
become significant. It is slightly difficult to interpret such a gel, however, since the 
method requires that the protein is deglycosylated before running the SDS PAGE. 
Since the deglycosylation reaction takes place at 37*C over a period of four hours, it 
is feasible that the observed degradation occurs during the deglycosylation reaction, 
despite the addition of both PMSF and EDTA as protease inhibitors. Nevertheless, 
the optimal yield to degradation ratio appears to occur on day five, and therefore for 
subsequent larger scale growths the culture was induced for five days. 
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Figure 3:7 Induction time optimisation of MCPI2. The SIDS PAGE of 
deglycosylated imi samples shows a gradual increase in MCP12 production (band 
near 16.5 kDa marker) over the six days. By day six however degradation appears 
to become more of a problem. The band between the 83 kDa and 62 kDa markers 
is around the predicted size for EndoH f . 
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Despite the use of antibodies, that had been raised against synthetic peptide 
corresponding to residues in the N-terminal domain of MCP12, for the membrane 
screens. Further confirmation was sought that the species observed on the gel was 
indeed MCP12. This was subsequently achieved through the use of N-terminal 
protein sequencing. The sequence of the N-terminal ten residues was thus 
determined to be: YVEFSDACIEE, which correspond exactly to the expected 
sequence for MCP 12 preceded by the predicted cloning artefacts. Furthermore, these 
N-terminal sequencing data indicate both that there was complete processing of the 
a-factor secretion signal, and that there was no significant proteolytic degradation at 
the N-terminal end of the protein. 
3.3. Purification of MCPI2 
3.3.1. Initial purification of MCPI 2 
The purification of glycoproteins can often be problematic due to the heterogeneity 
of the species to be purified. One solution to this problem is to enzymatically cleave 
the N-linked glycans; however too can prove problematic. The deglycosylation 
reaction requires prolonged incubation at 37 °C, which as discussed potentially 
allows any proteases present to degrade the sample. This can be alleviated to some 
extent by the inclusion of protease inhibitors in the sample; however protease 
inhibitors are rarely completely effective. In this case is seems logical to try an 
initial purification step to remove most of the contaminants present in the crude 
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all MCP12 preparations was the same, regardless of the glycosylation state required 
for the final sample. The initial purification was achieved using hydrophobic 
interaction chromatography (HIC) on a Resource iso column (Amersham Pharmacia 
Biotech). 
HIC Purification of MCPI2 on a Resource iso Column 
Figure 3:8 Result of HIC purification of crude glycosylated MCPI2 on a 
Resource iso column. All the fractions that stuck to the column appear to contain 
MCP12 but with differing glycosylation profiles. These fractions should theoretically 
all behave equally after deglycosylation. Only the protein from fraction 9 was pooled 
for further analysis since it is possible that the different behaviour of the 
neighbouring fractions on HIC may be indicative of unfolded protein. 
The chromatogram, shown in Figure 3:8 shows a rather broad main peak that is due 
to differences in hydrophobicity between the different glycoforms. Examination of 
SDS-PAGE performed on column fractions both before and after deglycosylation is 
shown in Figure 3:9 and Figure 3:10 respectively. These SDS-PAGE results, when 
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to separate MCP12 from most of the major contaminants, including the abundant 
species that causes the crude concentrated culture supernatant to appear deep green 
in colour. Even though the main peak is very broad, it appears that most of the 
constituents are MCP12 with different glycoforms, and a band of the correct size for 
deglycosylated MCPI2, is the major species in each of these fractions following 
treatment with EndoHf. It is possible, that the broadness of the peak arises in part 
from the presence of unfolded species with different hydrophobicity properties. For 
this reason only those fractions that made up the central part of the peak were taken 
for further analysis. Furthermore it can be seen that the flow-through fractions also 
contain MCPI2 albeit in relatively small amounts; this appears to arise 
predominantly from a small proportion of very heavily glycosylated protein. 
2 	3 	 7 	8 	9 	10 
Figure 3:9 SDS-PAGE showing the purification of MCPI2 on resource iso. The 
glycoprotein samples were concentrated and exchanged into water before being 
subjected to SDS-PAGE. The rather broad hump apparent in the chromatogram 
appears to be due to the partial separation of the different glycoforms. This is 
apparent by observing that the size of the major species in each lane grows 
progressively smaller with increasing fraction number. 
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Figure 3:10 SDS PAGE of deglycosylated MCPI2 purified on a Resource iso 
column. A band of around 70kDa is visible in each lane, and corresponds to the 
expected size for endoH f. The same amount of protein that was applied to the 
glycosylated gel (Figure 3:9) was deglycosylated with endoHf and loaded in the 
same way and despite this there appears to be a much larger amount of protein on 
this gel compared to the gel in Figure 3:9. This effect is due to the protein being 
concentrated into a single band following deglycosylation, rather than the diffuse 
smear that is observed in Figure 3:9. The deglycosylation reaction appears not to 
have gone to completion, as indicated by the remnants of the higher molecular 
weight bands that are visible in Figure 3:9. Degradation can also be observed, but it 
is hard to know whether this degradation existed in the samples prior to 
deglycosylation or is an artefact of deglycosylation. 
3.3.2. Purification of EndoHf deglycosylated MCPI2 
The pooled fractions corresponding to the central portion of the main peak from the 
HIC chromatography were concentrated, and deglycosylated using EndoH f. EndoH 
cleavage of N-linked glycans results in a single N-acetylglucosamine (GIcNAc) 
residue attached to the asparagine residue of the glycosylation sequon, and this 
enzyme has been used successfully for the removal of high mannose type glycans 
from recombinant proteins subsequently used for biophysical studies (McAlister et 
al., 1998). In addition to the deglycosylated protein species, the deglycosylation 
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reaction should also yield the glycans that were cleaved off the protein, while a 
fraction of glycoprotein that remains glycosylated. These glycospecies are in 
addition to the unattached sugars that are naturally produced by P. pastoris. Such 
contaminants can be difficult to remove using conventional chromatography. The 
majority of these species are likely to contain the mannose residues typical of high 
mannose type glycans. The lectin Conconavalin A (ConA) from the jack bean 
Canavalia ensformis  binds selectively to the non-reducing terminal mannose; and to 
a much lesser extent to glucose residues of branched glycans (Hietanen et al., 1989). 
ConA is readily available pre-immobilised to a sepharose matrix. This may therefore 
represent an efficient way to remove the cleaved glycans along with the non-
deglycosylated protein. The fully deglycosylated protein should not adhere to the 
column, or should stick only very weakly due to its remaining N-acetylglucosamine 
residue, since ConA has only a low affinity for GlcNAc. The glycans and non-
deglycosylated protein on the other hand should bind tightly to the column. The 
chromatogram shown in Figure 3:11 shows that whilst most of the protein had been 
effectively deglycosylated, and passed straight through the column as predicted, 
there is still a proportion of protein that stuck to the column indicating incomplete 
deglycosylation. This method therefore proved to be a useful technique for removing 
the glycans, and non-deglycosylated protein from the deglycosylated MCP12. This 
purification method was also useful in removing the non-attached sugars that are 
present in the culture supernatant of P. pastoris cultures. 
124 
Results and Disucssion 











MC P12 / 







0 	 10 	 20 	 30 	 40 	 50 	 60 	 70 	 80 	 90 
Column volume lml 
Figure 3:11 ConA purification of deglycosylated MCPI2. Fully deglycosylated 
MCP12 flows straight through the column without retention, the sugars are eluted 
along with any remaining glycosylated MCPI2. 
Following EndoHf deglycosylation and ConA purification, the sample was subjected 
to anion exchange chromatography, on a MonoQ HR5/5 column (Amersham 
Pharmacia Biotech) or a Poros20Q column (Applied Biosystems). This step was 
designed to remove the EndoHf used for deglycosylation, any degraded MCP12 
along with any remaining contaminants. The chromatogram shown in Figure 3:12 
shows a single sharp peak, with only minor other impurities. Only the fractions 
comprising the main sharp peak were pooled and taken for further analysis. The 
fractions on either side were discarded, despite the presence of trace quantities of 
MCP12 in these samples (data not shown) to reduce the possibility of carrying 
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Figure 3:12 Anion exchange purification of deglycosylated MCPI2. The 
chromatogram gives a single peak with a slight tail both leading and following the 
peak. When the fractions were pooled for further analysis these regions of the 
chromatogram were excluded. 
Following the anion exchange purification step of the EndoH f deglycosylated 
MCP 12, this protein became purified to homogeneity as judged by SDS PAGE, as 
illustrated in Figure 3:13. The yield from this recombinant clone was typically in the 
region of 10 mg of purified deglycosylated MCP12 per litre of induction medium. 
This expression level was subsequently shown to be sufficient to allow isotopic 
labelling with 15N and further biophysical characterisation. 
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Figure 3:13 SOS PAGE of purified deglycosylated MCPI2. The gel shows that 
MCP12 has been purified to homogeneity, as judged by SIDS PAGE and runs at 
approximately the correct molecular weight for MCP12. 
3.3.3. Purification of glycosylated MCPI2 
The heterogeneity of glycoforms present in the glycosylated form of MCP12 causes 
various difficulties arise. The two most noticeable of these difficulties are the 
difficulties associated with purifying glycosylated MCPI2 away from other 
contaminating proteins, and those associated with purifying glycosylated MCPI2 
away from the non-attached sugars that are naturally produced by P. pastoris. The 
presence of large quantities of non-attached sugars that are present in the culture 
medium of P. pastoris means that the lectin affinity chromatography that was 
effectively used for the removal of contaminating sugars with deglycosylated 
MCPI2 cannot be used for this purpose for glycosylated MCPI2. Moreover, the 
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large quantities of covalently attached sugars, and their excessive heterogeneity, can 
cause it to behave unpredictably during subsequent chromatography. 
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Figure 3:14 Reverse phase purification of glycosylated MCPI2. The fractions 
from the central peak between 25 and 29 ml column volume contained purified 
glycosylated MCPI2 and were pooled for further analysis. Fractions either side 
contained the remaining impurities and trace quantities of MCP12. 
Reverse phase chromatography has been successfully used to remove the unattached 
P. pastoris sugars from recombinant protein samples. It was a logical choice 
therefore to choose reverse phase chromatography as the final purification step for 
glycosylated forms of MCP12. The chromatogram shown in Figure 3:14 shows that 
the majority of the glycosylated MCP12 is eluted form the C4 reverse phase column 
between 25 ml and 29 ml elution volume. The chromatogram as expected exhibits a 
relatively broad peak for MCP12, and effectively separates the glycosylated MCP12 
from the remaining protein impurities. It remains unclear whether all of the 
contaminating sugars have been removed from the sample, since there is no practical 
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method for assessing this. Due to the heterogeneity of this sample it is difficult to 
determine with any certainty the exact purity of this sample. All of the glycosylated 
protein is found within the expected region for glycosylated MCP12. Moreover 
following deglycosylation with EndoH f only two bands are observed. One of these is 
the correct size for deglycosylated MCP12, whilst the other is the correct size for 
EndoHf. 
The results in the preceding section demonstrate the successful purification of both 
glycosylated and enzymatically deglycosylated forms of MCP12. 
3.4. Biophysical Characterisation of MCPI2 
3.4.1. Preliminary remarks 
A full understanding of a protein requires biophysical methods of characterisation, 
which, offer ways to gain insights into everything from the chemical composition to 
the atomic resolution 3D structure. The results presented in the following section 
describe the characterisation of both the glycosylated and deglycosylated forms of 
MCP 12 using a number techniques. 
3.4.2. Mass spectrometry analysis of MCPI2 
To confirm that the protein species that had been purified was indeed MCP 12, and to 
establish the integrity of the MCP12 produced, electrospray ionisation mass 
spectrometry (ES-MS) was performed on a single quadrupole instrument. This type 
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of MS has a resolution of approximately 0.01 % (Siuzdak, 1996). It therefore has the 
ability to provide compelling evidence that the protein is the correct species, and to 
what extent it has been modified or degraded. In this case the ES-MS shown in 
Figure 3:15 of the intact unlabelled deglycosylated MCP12 gave a major species of 
15822 Da, this is 3 Da smaller than the predicted mass of 15825 Da for MCP12 with 
two G1cNAc residues and four disulphide bonds. This mass difference is difficult to 
interpret, and could potentially be explained by the hypothesis that only one of the 
glycosylation sites is recognised, and that the N-terminus has been incompletely 
processed (losing 203 Da from the loss of one GlcNac, but gaining 200 Da from the 
addition of EA). This idea would give a species of the correct mass, however it takes 
no account of the N-terminal sequencing results, which demonstrated complete 
processing of the secretion signal. It is also possible that three lysine residues have 
been converted to allysine, loosing 1 Da each. The discrepancy may also arise partly 
from amide formation at the C-terminus of the protein. The mass difference may 
also simply be due to a calibration error in the mass spectrometer. Regardless of 
which is true, it seems to be most likely that the species that was produced was 
MCP12 with two G1cNAc residues and four disulphide bonds. The species observed 
at 15859 Da is 37 Da larger than the main peak and probably represents a potassium 
adduct. The species observed at 15919 Da is 97 Da larger than the main peak and 
probably represents two potassium adducts and one sodium adduct. The presence of 
sodium and potassium adducts is an artefact of mass spectrometry, and should in no 
way alter the properties of the protein. 
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Figure 3:15 Mass spectrum of EndoH f deglycosylated MCPI2. The mass of the 
main peak is within 3 Da of the expected mass of EndoHf deglycosylated MCP12, 
with four disulphide bonds, and two GIcNAc residues. Other peaks discussed in the 
text. 
The small peak observed at 15560 Da is 262 Da smaller than the main peak and is 
consistent with the loss of the N-terminal YV residues. The small peak observed at 
15429 Da is 393 Da smaller than the main peak, which is close to the predicted mass 
for the loss of the N-terminal YVE residues - a predicted mass difference of 391.5 
Da. The ES-MS data are consistent with the expected data for EndoHf 
deglycosylated MCP12 with four disulphide bonds and two G1cNAc residues. These 
data, when combined with the N-terminal sequencing results indicate that both of the 
possible N-glycosylation sites in MCP12 have been glycosylated by P. pastoris, and 
that both sets of glycans were successfully removed. These data also indicate that 
the major portion of the protein is intact, and that only minor quantities of 
degradation are observed. Moreover, those small amounts of degradation that are 
observed all appear to involve removal of the cloning artefact amino acids, and 
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therefore would not be expected to have a detrimental effect on the protein's 
structure and function. 
A 1.71 e7 
mass 
Figure 3:16 Mass spectrum of EndoHf deglycosylated 15N labelled MCPI2. The 
spectrum shows a main peak that is consistent with > 90% incorporation of 15N into 
MCP1 2. 
In addition to its ability to confirming the identity and integrity of MCP12, ES-MS 
was also used to confirm the incorporation of 15N into MCP12 in a sample prepared 
for the purpose of heteronuclear NMR experiments. The mass spectrum shown in 
Figure 3:16 is of ' 5N labelled EndoHf deglycosylated MCP12. The sample of 15N 
labelled MCP 12 had been produced using exactly the same procedure as that for the 
unlabelled samples with the sole exception that the recombinant P. pastoris was 
cultured in medium that contained ' 5N ammonium sulphate (2 g1 1 ) as the sole 
nitrogen source (Wiles, 1996). The ES-MS spectrum shows a peak with a mass of 
15982 Da which is 157 Da larger than would be expected for unlabelled MCP12. 
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The incorporation of 15N at 100% of possible sites would result in an increase in 
molecular weight of 170 Da. These ES-MS data are consistent with approximately 
92% incorporation of 15N into MCP12. It is impossible use these ES-MS data to 
assess whether the incorporation of ' 5N nuclei into MCP12 is uniform; however a 
site preference for the incorporation of 15N labels has not been reported nor is 
expected. 
3.4.3. NMR spectroscopic analysis of MCPI2 
3.4.3.1. NMR analysis of deglycosylated MCP12 
Of all the biophysical techniques available for the study of proteins, high field NMR 
spectroscopy is perhaps the most powerful. The chief advantage that NMR 
spectroscopy has over other techniques is that it is the only biophysical solution 
technique that is residue specific. With multi-dimensional NMR spectroscopy one 
can observe the individual nuclei in a protein directly, non-destructively and in an 
aqueous environment. In favourable cases the optimum NMR conditions may even 
be near physiological with respect to temperature, salt concentration, and pH. Other 
solution techniques observe signals that are averaged over the whole protein, or that 
depend upon the presence of tryptophan or specifically inserted labels to give limited 
localised information. In addition, the majority of these techniques are either 
destructive or expose the protein to unnatural conditions. High field 
multidimensional NMR spectroscopy therefore provides a powerful method of 
probing a protein in great detail. 
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The dispersion of resonances over a wide range of -0.4 ppm to 11.2 ppm in the 1D 
'H spectrum shown in Figure 3:17 is indicative of a folded protein. The spectrum 
also shows relatively sharp peaks, indicating that self association was limited. Given 
the quality of this spectrum of MCP12, it made sense to produce a 15N labelled 
sample, to facilitate the acquisition of the multidimensional heteronuclear NIvIR 
experiments that permit more detailed analysis. A 15N sample was made which had 
>90% incorporation of' 5N (see Figure 3:16). 
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Figure 3:17 ID 1 H-NMR spectrum of EndoHf deglycosylated MPCI2. The 
sample was 0.9 mM in 20 mM potassium phosphate at pH 6.0. The spectrum was 
recorded at 37 °C at 600 MHz proton frequency with presaturation water 
suppression. 
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One of the most powerful NIvIIR experiments is the 2D 1 H- 1 N heteronuclear single 
quantum coherence spectrum ('H-' 5N HSQC). This experiment produces a single 
peak for each NH group in a protein. This therefore yields a resonance for each 
amino acid (with the exception of proline), along with a resonance for the NH group 
in the side chains of certain amino acids. This experiment therefore provides 
detailed residue specific information. The 'H- 15N HSQC spectrum shown in Figure 
3:18 is once again indicative of a folded protein. 
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Figure 3:18'H 15N HSQC spectrum of deglycosylated MCPI2. The sample was 
0.9 mM in 20mM potassium phosphate pH 6.0. 
Overall, the spectrum indicates that the protein is largely folded with a large number 
of resonances significantly shifted from random coil region in both the ' 5N and 'H 
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dimensions. There is however, a higher than expected degree of overlap in the centre 
of the spectrum. This region of overlap could be due to a number of factors which 
include: the presence of unfolded material; aggregation; the presence of 15N labelled 
impurities, or conformational exchange. Analysis of the number of resonances 
indicates than 107 resonances are reasonably well dispersed and countable, of these 7 
are probably side chain resonances. This results in the number of dispersed 
backbone NH resonances being approximately 100 and compares unfavourably with 
the predicted number of resonances. After accounting for the proline residues, the 
MCP12 species should yield 127 backbone NH resonances indicating too few 
resonances for both modules in MCP12 to be fully folded. There are however too 
many resonances to account for only one module being properly folded. Missing 
resonances can be due to excessive line broadening - a phenomenon that can be 
caused by a number of factors. Conformational exchange and amide exchange with 
water on an intermediate (ms) time scale can result in this line broadening, as can 
aggregation. Aggregation of proteins can be quite a common phenomenon at the 
concentrations required to give adequate signal to noise in NIMR experiments. 
To determine whether the presence of the overlapping region was due to a problem 
with one particular module, or was indicative of a more widespread problem, the 1 H-
15N HSQC of deglycosylated MCP12 was compared to a previously acquired 1 11- 15N 
HSQC spectrum of deglycosylated MCP1. The NMR data of MCP1 had been 
acquired on a deglycosylated sample of MCP1 previously expressed in P. pastoris 
(O'Leary, 2000). The spectra overlaid in Figure 3:19 indicate that both of the 
modules are folded - at least to some extent. This can be inferred because a large 
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number of resonances from the residues of MCP 1 can largely be correlated with 
similar resonances in the spectrum of MCP 12. In addition to the resonances that are 
similar to those from MCP 1; the HSQC spectrum of MCP 12 contains a good number 
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Figure 3:19 Overlay of 1 H 15N HSQC spectra of MCPI2 (green) and MCPI 
(purple). The overlay shows a large number of the resonances from MCPI have 
almost identical shifts to resonances in MCP12. In addition there are a large 
number of extra resonances in the MCP12 spectrum that presumably do not arise 
from MCP1. Taken together this indicates that both of the modules of MCP12 are to 
a large extent regularly folded. The central overlap present in the MCP12 spectrum, 
however appears to be absent from the MCP1 spectrum. 
In order to achieve the optimal conditions for NMR experiments on MCPI2, 'H-' 5N 
HSQC spectra were acquired under a number of different conditions. The conditions 






• 	 iyi 
0 , 
V 6 4M. 
Cb 
.,. 	 - 	 •••••••••••••••-. 	 . 	i - I__i , 












9 __  
10 
Results and Disucssion 
spectrum shown in Figure 3:18 represents HSQC spectrum of deglycosylated 
MCP12 with the greatest dispersion and least overlap in the random coil region that 
was recorded. TOCSY spectra were subsequently acquired on deglycosylated 
MCP 12 with a variety of different mixing times, in order to determine whether 
deglycosylated MCP 12 could be suitable for structural studies to be undertaken. 
OH 
Figure 3:20 TOCSY spectrum of MCPI2 with watergate water suppression. 
The spectrum was acquired at 37 °C; mixing time of 60 ms. The sample was 0.9 
mM in 20 mM potassium phosphate pH 6.0. 
The 2D 'H TOCSY spectrum shown in Figure 3:20 was acquired with a mixing time 
of 60 ms and shows a dearth of cross peaks. This is particularly true in the amide 
region of the spectrum; a phenomenon that is often associated with aggregating 
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proteins. Aggregating proteins generally have shorter T 2 values than do their 
monomeric counterparts and this results in a rapid 'fall off of the signal, with the 
result that the TOCSY transfer cannot extend far along the amino acid side chain. 
Interestingly however, the cross peaks that are present in this 'H TOCSY, also have a 
rather unusual shape, and appear distorted. It is unlikely that this phenomenon is due 
entirely to aggregation, and it is possible that conformational exchange may also be 
responsible. In order to determine whether the unfavourable behaviour of 
deglycosylated MCP12 was due to aggregation, 15N 12 values were measured, and 
these values were typically in the high 80's and low 90s' ms. 12 values in this range 
are slightly shorter than the ideal for a protein of this size and may suggest 
aggregation, however they are not too dissimilar to those obtained from CR1-'15-16 
('-90 ms). In addition, dilution of the sample had only a negligible effect on the 
measured ' 5N T2 values, indicating that either excessive aggregation was not 
occurring, or that aggregation was occurring to a similar extent over the range of 
concentrations tested. Taken together, the results described in this section indicate 
that deglycosylated MCP12 could be prone to aggregation under NMR conditions, 
that it is undergoing some form of conformational exchange process; or possibly a 
combination of both. In order to address these issues, a glycosylated sample of 
MCP12 was made and analysed, which is the subject of the following section. 
3.4.3.2. NMR analysis of glycosylated MCP12 
Given the functional and potentially structural importance of the N-glycan found on 
CCP module 2 of MCP, it is possible that the non-dispersed region of the HSQC 
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spectrum could be associated with the removal of the N-linked glycans. We 
therefore decided to produce a sample of MCP12 without removing the N-linked 
glycans added by P. pastoris. It would normally be expected that the presence 
carbohydrates on a protein would result in considerably broader NMR signals 
because of the extra mass they would add to the protein. This problem is especially 
pertinent in this case as the mass of carbohydrate that is attached to the N-
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Figure 3:21 1 1-11 - 15N HSQC spectrum of glycosylated MCPI2. The sample was 
0.9 mM in 20 mM potassium phosphate pH 6.0. 
The 'H-' 5N HSQC spectrum shown in Figure 3:21 once again shows a similar degree 
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spectrum appear to be sharper than those of the deglycosylated version. It is also 
clear that the overlap in the centre of the spectrum is significantly reduced compared 
to the deglycosylated form. When the 'H- 15N HSQC spectra from glycosylated and 
deglycosylated MCP12 are overlaid (illustrated in Figure 3:22) it becomes clear that 
there are some quite profound differences between the spectra from two forms of 
MCP12. 
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Figure 3:22 Overlay of the 1 H - 15N HSQC spectra from glycosylated and 
deglycosylated MCPI2. Both samples were 0.9 mM in 20 mM potassium 
phosphate pH 6.0. 
It can clearly be seen that the deglycosylated MCP 12 gives extra resonances that are 
not observed in the glycosylated sample. The glycosylated sample on the other hand 
appears not to have any resonances that are not found in both spectra. Given these 
profound differences between these two spectra, and the known biological 
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requirement for the glycans it would seem reasonable to think that the glycans may 
playing some structural role and that this gives rise to the differences between these 
spectra. It is possible however, that the glycans in the glycosylated sample are 
simply acting to make the protein more soluble and therefore less prone to 
aggregation. One would imagine, however that this 'solubility effect' would be 
compensated for by the increased molecular weight of the glycosylated sample. 
3.4.4. Gel filtration of deglycosylated MCPI2 
In order to determine whether the deglycosylated MCP12 contains dimers or higher 
order aggregates, the protein was applied to a Superdex 75TM  gel filtration column 
and the chromatogram of which is shown in Figure 3:23. This chromatogram shows 
a single sharp peak with no evidence of the presence of higher order aggregates. Gel 
filtration chromatography can also be used to estimate the molecular weight of a 
protein; however, the technique is shape dependant. It therefore makes sense in this 
case to calibrate the column using other CCP module constructs which one would 
expect to have a similar overall topology. Using single, double and triple CCP 
modules as a calibrant for this column, MCP12 elutes in the volume between the 
region where double and triple modules elute. This could possibly mean that it is 
present as a dimer that behaves as though it is smaller than it actually is. It is more 
likely, however given that MCP12 is of a larger molecular weight than that used to 
calibrate the column (VCP23 Mr 12.5 kDa, MCP12 Mr 15.5 kDa) that under these 
conditions deglycosylated MCP12 exists as a monomer. The glycosylated sample 
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was not applied to the Superdex 75TM  colunm since it was expected that the extreme 
heterogeneity of the sample would render the results meaningless. 
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Figure 3:23 Gel filtration of purified MCPI2 on a Superdex 75 column. The 
chromatogram shows a single sharp peak which eluting slightly earlier than would 
be expected for a protein of this size, when the Pharmacia gel filtration standards 
are used to calibrate the column. However, this has also been observed with 
several CCP module constructes, and when the column is calibrated using CCP 
module constructs, the protein elutes approximately where expected. 
Moreover, the observation that the gel filtration of MCP12 yielded a sharp peak 
indicates that the protein is not in an equilibrium between a monomeric and dimenc 
state, since in such cases broad peaks are often observed. The results presented thus 
far indicate that the glycans of MCP 12 result in different behaviour between the two 
forms, however whether this is due to a structural interaction, or intrinsic properties 
of the glycans themselves remains moot. 
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3.4.5. Differential Scanning Calorimetry of MCPI2 
In order to determine whether the glycans of glycosylated MCP12 provide it with 
increased thermal stability over deglycosylated MCP 12 differential scanning 
calorimetry was performed. Samples of both glycosylated and deglycosylated 
MCP 12 were prepared and subjected to analysis by differential scanning calorimetry 
(DSC). 
DSC is a method by which an insight can be gained into the thermal stability of a 
protein. The technique is based on the fact that there is an enthalpic difference 
between the folded and unfolded states of a protein, which arises due to the energy 
stored in the protein's structure. This difference can be measured upon thermal 
denaturation of the protein, and can therefore provide data about the thermal stability 
of the protein. Differential scanning calorimetry measures the thermal energy taken 
up by a sample upon heating or cooling. This is achieved by comparing the different 
thermal energy required to heat a sample and reference cell at the same rate. During 
the unfolding transition, the heat energy uptake (C r) in measured with respect to the 
reference cell and allows the transition temperature (T m) to be calculated. The T m is 
defined as the temperature at which 50% of the protein molecules are folded (Cooper 
et al., 2000). The data is then base line corrected, normalised to take account of the 
concentration, and fitted to an appropriate model of unfolding. For most proteins this 
is usually a simple 2-state unfolding model, although a multistate unfolding model 
may be appropriate for some proteins. DSC yields two independent measures of the 
enthalpy changed due to the thermal unfolding of a protein, namely the calorimetric 
enthalpy (AHcai) and Van't Hoff enthalpy (iHv). The calorimetric enthalpy is an 
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absolute, model free measure of the heat energy released upon unfolding, and is 
proportional to the amount of protein in the calorimeter cell. In effect AII cai is a 
measure of the area under the transition peak. The Van't Hoff enthalpy on the other 
hand is independent of the protein concentration, and is a measure of the degree of 
cooperativity of the unfolding process. The value of AH v is dependant on the shape 
of the transition curve, and assumes a two state reversible equilibrium. The sharper 
the transition curve, the greater the value for AH v (Plum et al., 1995). For an ideal 
protein, AHcai = AHVH , although there are several reasons why this may be not the 
case. 
The DSC data obtained for deglycosylated MCP12 are shown in Figure 3:24 and 
were best fitted to a model with two cooperative unfolding transitions, with T mS of 
58.5 °C and 68.5 T. It should be noted that in this case AH cai < AHVH and this is 
probably the result of using a multistep unfolding model. The T m values obtained for 
MPC12 can be compared to the value of 62 °C that had previously been obtained for 
EndoHf deglycosylated MCP1 (O'Leary, 2000). It is tempting to speculate that the 
value of 58.5 °C corresponds to the melting of MCP1, and that of 68.5 °C 
corresponds to that for MCP2, although this cannot be proven with these data. 
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Figure 3:24 Differential scanning calorimetry analysis of EndoHf 
deglycosylated MCPI2. These data fit best to a double melting model. This would 
indicate that the two modules melt independently, and that one module has a 
significantly higher melting temperature than the other. 
The DSC data for the glycosylated form of MCPI2 are shown in Figure 3:25, and 
were best fitted a simple two step unfolding model with a T m of 58.5 T. This would 
indicate that the presence of the N-linked glycans have destabilised one of the 
modules and that now both modules appear to share a common melting temperature. 
It is impossible, however to know from these data which if any module has had its 
thermal stability reduced by the presence of the N-linked glycans. It is therefore 
desirable to perform a similar analysis on the individual CCP module fragments. 
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Figure 3:25 Differential scanning calorimetry of glycosylated MCPI2. These 
data fit best to a two step unfolding model with a Tm of 58.5 C, indicating that both 
modules share a common melting temperature. 
The DSC data for both glycosylated and deglycosylated MCP 12, appear to suggest 
that the glycans have little effect on the thermal stability of one module in MCPI2, 
and that they may have a significant stabilising effect on the other. From the 
observations in the previous paragraph, it could be inferred that it is the second 
module that has undergone a lowering of T m upon deglycosylation, but this is 
speculative. It has therefore become desirable to perform similar experiments on the 
second module of MCP on its own, in order to delineate these effects, and these are 
the subject of subsequent chapters. In addition to recording similar data on the single 
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3.5. Functional Characterisation of MCPI2 
MCP12 appears to be behaving as though it contains some unstructured component. 
Thus far investigating whether this behaviour is the result of removing the N-linked 
glycans has proved difficult. It therefore seems useful to investigate the functional 
characteristics of both the glycosylated and deglycosylated forms of MCP12. This 
fragment of MCP is thought not to contain any complement activity; however it is 
thought to be the region that interacts with measles virus. This property, in principal 
at least, allows one to test MCP12 for activity. The N-linked glycans have been 
shown to be essential for this function, and the crystal structure of MCP 12, expressed 
in CHO cells, appears to suggest that this requirement for N-linked glycans has some 
structural basis. Thus far the minimum glycans necessary for function have not been 
determined, and it is possible that the presence of the GlcNAc following cleavage 
with EndoHf may be sufficient. In order to determine whether, the MCP12 fragment 
expressed by P. pastoris is active, and whether EndoH cleavage of the N-linked 
glycans renders it inactive, a modified version of the virus overlay protein blot assay 
(VOPBA) was performed (Ohtsuka et al., 1996). The VOPBA result shown in 
Figure 3:26, shows that hyperglycosylated protein as expressed by P. pastoris is able 
to bind measles virus. Removal of the N-linked glycans, however, results in a 
reduction of measles virus binding to a level below the detection threshold of this 
assay. This result also indicates that, as predicted neither deglycosylated MCP 1, nor 
the CR2 construct have the ability to bind detectable levels of measles virus. It 
would be possible to perform considerably more in-depth analysis on the ability of 
MCP12 to bind measles virus, and this should yield some interesting information. 
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Such a study, whilst interesting and informative could be a project in itself, and is not 
the subject of this thesis. The functional data presented here although preliminary in 
nature still demonstrate that the hyper-glycosylated protein expressed by P. pastoris 
is active, and therefore presumably is correctly folded, and that the deglycosylated 
form of MCPI2 has a significantly reduced ability to bind to MV. These data add 
weight to the hypothesis that the deglycosylation of MCP 12 disrupts its structure in 
some manner. 
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Figure 3:26 Virus overlay protein binding assay showing MCPI2 binding to 
measles virus. Lanes 1-3 represent positive internal controls to demonstrate that 
all components of the detection system perform as expected. Lane 7 is a negative 
test control and lane 8 is a positive test control. The three test lanes 4, 5, & 6 
indicate that hyperglycosylated MCP12 can bind measles virus, whereas 
deglycosylated MCPI2 and MCP1 cannot bind detectable levels of measles virus. 
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3.6. Discussion 
The results presented in this chapter demonstrate the successful cloning and 
expression of MCP12 in P. pastoris to levels that are sufficient for biophysical 
characterisation to be performed. Deglycosylated MCP12 was successfully purified 
to homogeneity as determined by SDS-PAGE, whilst a hyperglycosylated form of 
MCP 12 was purified to a homogeneous protein with heterogeneous glycoforms. 
N-terminal sequencing and mass spectrometry data confirmed the identity of the 
protein as MCP12, and that complete processing of the secretion signal had occurred. 
Mass spectrometry data also confirmed the integrity of the protein, showing no 
modifications and only trace amounts of proteolysis, which occurs only in the region 
of the protein left by cloning artefacts. Preliminary NMIR experiments indicate that 
both the glycosylated and deglycosylated forms of MCP 12 show the good dispersion 
indicative of a structured protein. There is, however, a larger area of overlap in the 
centre of the 1 H-' 5N HSQC for deglycosylated MCP12 than would normally be 
expected for a protein of this size. Moreover there are insufficient peaks in the 'H-
' 5N HSQC to account for all the amino acids in the protein. Possible explanations as 
to why this is the case included: aggregation, regions that are locally unfolded, the 
presence of contaminants or unfolded material, or the protein being flexible. 
Comparison of the 'H-' 5N HSQC spectra of deglycosylated MCP12 and 
deglycosylated MCP 1, shows the presence of MCP 1 in a similar state in MCP 12 as it 
is alone. Aggregation would not appear to be the main cause of the overlapped 
region of the 'H-' 5N HSQC spectrum, since it remains largely unchanged under a 
variety of sample conditions. 
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Functional data suggest that only glycosylated forms of MCP12 are active. It is 
possible therefore that removal of the N-linked glycans may locally disrupt the 
structure of MCP12. The NIVIR data acquired do not contradict this hypothesis and 
indeed suggest that removal of the N-linked glycans results in an increase in the 
protein's flexibility. The DSC data obtained from both glycosylated and 
deglycosylated MCP12 indicate that the glycans have a destabilising effect on one of 
the modules. The DSC data provide no evidence as to which module is potentially 
destabilised, since the two modules of MCP 12 appear to be behaving independently, 
and the technique is unable to provide the location specific information required to 
ascribe the different properties to one module or the other. That the DSC data appear 
to suggest that the glycans destabilise one of the modules is not necessarily 
contradictory to the NMR data since DSC records thermal stability, whereas NMR is 
able to investigate a protein's dynamics. Moreover, this destabilising effect may 
merely be an artefact of hyperglycosylation as opposed to physiological 
glycosylation. 
The requirement of N-linked glycans for structural integrity appears to be only a rare 
occurrence, however, the crystal structure of MCP12 also indicates that this might be 
the case (Casasnovas et al., 1999). Proving this hypothesis is potentially difficult due 
to the inherent difficulties associated with producing highly purified proteins with 
defined glycosylation patterns. 
It is difficult to delineate the regions of MCP 12 that are unstable and therefore, it was 
decided to express the two modules individually. Since MCP1 had already been 
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expressed and its solution structure solved (O'Leary, 2000), further efforts were 
concentrated on MCP. It was anticipated that analysis of the MCP2 single module 
would provide valuable information about this module, and potentially its behaviour 
in the MCP12 pair. Expression and characterisation of MCP2 is the subject of the 
following chapter. 
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4. Recombinant MCP2 from P. pastoris 
4.1. Preliminary remarks 
The work described in the following section describes the successful expression and 
purification of the second module of MCP (MCP2) in P. pastoris. P. pastoris was 
chosen for expression of MCP2 for the same reasons as it was chosen for expression 
of MCP12, and because of the success already achieved using this organism in the 
case ofMCP12. 
4.2. Cloning and expression of MCP2 in P. pastoris 
4.2.1. Cloning of MCP2 in pPlCZa 
The vector used for the expression of MCP2 in P. pastoris was the pPICZa vector, 
which is distinct from the pPIC9 vector used for the expression of MCP12. This 
vector, illustrated in Figure 4:1, is also a shuttle vector, but it uses resistance to the 
antibiotic zeocin as a selective maker in both E. coli and P. pastoris. One of the 
primary advantages of using zeocin as a selective marker is that using only a single 
selective marker for both E. coli and P. pastoris results in a significantly smaller size 
of vector (3.6 kb for pPICZ(x compared to 8.0 kb for pPIC9). The resulting smaller 
vector size leads to more straightforward downstream DNA manipulations. 
Moreover, using zeocin as a selective agent in yeast provides the ability to directly 
select the multicopy integration events that are often associated with higher levels of 
expression (Vassileva et al., 2001). Taken in concert these attributes makes zeocin 
an ideal selective marker for P. pastoris expression. For these reasons pPICZa was 
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chosen as the vector for the expression of MCP2 rather than the pPIC9 vector (which 
was used for the expression of MCP 12). 






Figure 4:1 The pPICZa expression vector. The features of this vector are similar 
to pPIC9 but with the use of zeocin selection in both E. co/i and P. pastoris rather 
than ampicillin and histidine. This results in a smaller vector size, fewer false 
positives, and the ability to directly select multicopy integration events (taken from 
Invitrogen, 2002b). 
As before, PCR was used to amplify the region coding for MCP2, and asymmetric 
restriction sites (5' EcoRl & 3' Notl) were incorporated into the primers to facillitate 
directional cloning. The PCR reaction showin in Figure 4:2 shows a single band of 
approximately 250 bp, which corresponds well with the predicted size of 233 bp for 
the MCP2 fragment (allowing for all extra sequences included for restriction sites 
and stop codons). This PCR product was digested with EcoRl and Notl and was 
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subsequently ligated into pPICZa using a similar strategy to that used for ligating 
MCP12 into pPIC9. 
500h 
20Oh 
Figure 4:2 PCR amplification of MCP2, showing a single band of the correct 
size for MCP2 
The recombinant plasmid thus genereated was then used to transform chemically 
competent Top 10 E. coli cells. The transformation of the E. coli cells produced 
numerous colonies, and plasmids from ten clones that grew on the selective medium 
(low salt LB agar containing 25 g.ml-1 zeocin) were prepared by miniprep and 
digested with X7o1 and Xbal. The reason why plasmids were digested with )7io1 
and Xbal, whose restriction sites flank the region containing the insert, rather than 
the restriction enzymes incorporated into the PCR product (EcoRl and Notl), was to 
allow concatamers to be detected and rejected. A clone that gave an insert of the 
predicted size was selected, and its DNA sequenced in order to confirm  the identity 
and integrity of the insert. 
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After confirming that the DNA sequence of the insert was correct this recombinant 
plasmid was prepared on a larger scale by a midiprep procedure. The plasmid was 
subsequently linearised with Sacl and used to transfrom the P. pastoris KM7 1-His 
strain. The KM7 1-His strain was genetically modified in-house by transforming the 
original KM71 strain with 'empty' pPIC9 vector, in the AOX1 region, to convert the 
His phenotype of KM71 to a His phenotype (data not shown). This modified strain 
had been used previously in our laboratory for the expression of several proteins, and 
had been shown to behave as expected, i.e. display the predicted His M utS 
phenotype (data not shown). This strain was chosen for the initial expression 
attempts because of the success that was achieved using the KM7 1 strain for the 
expression of MCP12, and because, it negated the requirement to supplement the 
growth and induction media with histidine. The latter point resolves the potential 
future problems associated with subsequent isotopic enrichment. This cloning 
strategy would be expected to yield recombinant P. pastoris with a His MutS 
phenotype. 
The transformation of KM7 1-His with the Sacl linearised MCP2-pPICZa yielded 
numerous colonies that could grow on the selective medium (YPDS + 100 g.ml' 
zeocin). In the absence of an assay for MCP2, or antibodies for this module, 
screening of the colonies was performed by using small-scale test inductions 
followed by SDS-PAGE. Five colonies were picked, grown and induced for 4 days, 
deglycosylated, and screened for expression of MCP2 by SDS-PAGE. The results 
shown in Figure 4:3 indicate a good level of expression that is better than was 
achieved with MCP12. The gel also shows that the level of expression of all clones 
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with the exception of clone I is approximately the same to within experimental error. 
and for this reason clone 4 was chosen at random and used in further analysis. On 
the basis of the previous observation that MCPI2 had been hyperglycosylated by P. 
pastoris, the samples of MCP2 were deglycosylated prior to SDS-PAGE. 
Subsequent TCA precipitation of the culture supernatant is inefficient, and only a 
faint smear could be observed on an SDS-PAGE gel. 
Clone I Clone 2 Clone 3 Clone 4 Clone 5 
low 
quo imp ______ - 	---I - - EfldOH f 
4M 	 0 
6.5 kDa 
AWPAMNaft 
Figure 4:3 SDS-PAGE showing deglycosylated MCP2 test inductions. All of the 
clones tested express a species of approximately the correct size for MCP2. 
Moreover, with the exception of clone 1, the clones appear to express this species 
to approximately the same level. 
In order to determine whether MCP2 is in fact been glycosylated by P. pastoris, both 
untreated and deglycosylated samples were subjected to SDS-PAGE. In order to 
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circumvent the TCA precipitation step, 4 ml of induced culture supernatant was 
concentrated down to 40 p1 using a centrifugal concentrator (5 kDa MWCO). The 
sample was exchanged into water by three 10 fold dilutions and concentrations. Of 
this. 10 lii was deglycosylated, and the remainder mock deglycosylated by 
incubation at 37 °C for the same length of time as the deglycosylated sample. The 
result of the SDS-PAGE for the glycosylated and deglycosylated samples of MCP2 
is shown in Figure 4:4. 
Non- 





Figure 4:4 SDS PAGE showing the effect of deglycosylating the MCP2 
expressed in P. pastoris with EndoHf. The glycosylated sample shows a large 
smear that extends between 16 and 30 kDa. This is in contrast to the 
deglycosylated sample, which runs as a single band slightly lower than would be 
expected. 
Three times more of the glycosylated MCP2 was loaded onto SDS-PAGE to 
compensate for its high degree of heterogeneity. This SDS-PAGE result shown in 
Figure 4:4 shows that the sample produced by P. pastoris, is both hyperglycosylated 
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and highly heterogeneous. This result is not surprising given the experience with 
MCP 12 described in the previous chapter. This result also demonstrates that the N-
linked glycans can be cleaved by EndoHf. Furthermore this observation implies that, 
as is the case with MCP12, the glycosylation of recombinant MCP2 did not comprise 
complex type glycans, since EndoH f is unable to cleave complex N-linked glycans. 
4.3. Preparative expression and purification of P. pastoris MCP2 
4.3.1. Large scale growth and expression of MCP2 P. pastoris 
In order to obtain sufficient protein for subsequent studies, the expression of MCP2 
was scaled up in a similar way to that used for the scale up of MCP12. Growth and 
induction of MCP2 was performed in buffered minimal media. This was done to 
with the requirement for future isotopic labelling of the recombinant protein module 
in mind. Typically the initial growth phase was carried out in BMG (2 1) at 29 °C 
until A600 =16. The recombinant yeast were then induced by harvesting the cells by 
centrifugation and resuspending them in BMM (11). The cells were incubated in this 
inducing medium for a total of 5 days at 29 °C and were fed daily with undiluted 
methanol (I % v/v). Optimisation of the length of induction was not performed in 
the case of MCP2, since it seemed likely that it would have similar properties to 
MCP12 as far as proteolysis was concerned. The temperature for growth and 
induction was set to 29 °C since it has been demonstrated that expression is greatly 
inhibited by growth at temperatures significantly above 30 °C and therefore to 
compensate for possible inaccuracies in the incubator's temperature control. 
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Moreover it has been demonstrated that whilst growing on methanol at high cell 
densities, P. pastoris produces a significant amount of heat which may result in the 
temperature of the culture rising above that set by the incubator. During both the 
growth and induction phases, the culture was agitated vigorously to achieve the high 
levels of oxygenation required for efficient expression of heterologous proteins. In 
the induction phase, however, the culture volume in each flask was reduced to 250 
ml from 500 ml per 2 1 conical flask, to compensate for the culture's increased 
requirement for oxygen. Following the induction phase, the supernatant was 
harvested by centrifugation, and PMSF (to 0.5 mM), and EDTA (to 5 mM) added to 
reduce the likelihood of proteolysis. A sample of the harvested culture supernatant 
(1 ml) was deglycosylated with EndoHf, TCA precipitated and subjected to SDS-
PAGE to determine whether the scale-up had been successful. The resulting band on 
the SDS-PAGE gel was of a higher intensity than that obtained from the test 
inductions, presumably because the more favourable growth conditions had resulted 
in higher levels of expression. Following harvest, all subsequent manipulations prior 
to purification were carried out either on ice or at 4 °C in a cold room. The culture 
supernatant was filter sterilised in order to remove any remaining yeast cells, which 
could subsequently act as a source of proteases. The now clarified culture 
supernatant was then concentrated to a final volume of 20 ml using ultra filtration (3 
kDa MWCO), after which time a further dose of PMSF (0.5 mM) was added. This 
second dose is required because PMSF is unstable in even slightly acidic aqueous 
environments. This concentrate was subsequently purified as is described in the 
following section. 
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The production of the ' 5N samples of MCP2 was achieved in a similar way to that 
described above, with the sole exception that both the growth and expression phases 
were carried out on media containing 0.2 % (w/v) ' 5N ammonium sulphate as the 
sole nitrogen source. These media were prepared by using YNB with neither amino 
acids nor ammonium sulphate, and then supplementing the media with 2 g.F 1 ' 5N 
ammonium sulphate. This protocol resulted in the production of MCP2 samples with 
greater than 90 % incorporation of 15N in the final protein (see section 4.4.1.1 for 
details). 
4.3.2. Initial purification of MCP2 
Hydrophobic interaction chromatography on a Resource Iso column was selected as 
the initial purification step in the purification of MCP2, because this method had 
proved successful for the purification of MCP12. Once again, the high level of 
heterogeneity of the MCP2 sample due to the different glycoforms present, meant 
that the initial purification of MCP2 gave a broad peak covering several fractions - 
numbers 16-19 in the chromatogram shown in Figure 4:5-A. This chromatogram 
shows a large unbound fraction that contains only traces of very highly glycosylated 
MCP2, and a single broad peak of the bound material. SDS-PAGE of the non-
deglycosylated fractions from the HIC purification (Figure 4:5-13) shows that the 
more highly glycosylated forms of MCP2 elute earlier from the column, although 
each fraction still remains highly heterogeneous. Following deglycosylation with 
EfldOHf, each of the bound fractions gave predominantly a band of the same size on 
SDS-PAGE, as shown in Figure 4:5-C. It can be seen from these SDS-PAGE gels 
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that this purifications step effectively removes significant quantities of contaminating 
proteins. Moreover, it effectively removes almost all the contaminating species that 
turns the yeast medium a deep green colour. Whilst this cannot be observed easily 
by looking at the SDS-PAGE gels, it can clearly be seen when one compares the 
colour of the unbound fractions with the bound fractions. 
4.3.3. Purification of deglycosylated MCP2 
As with the recombinant MCP12 sample, the pooled fractions corresponding to the 
central portion of the main peak from the HIC chromatography of MCP2 (fractions 
16-18) were concentrated, and deglycosylated by treatment with EndoH f. Based 
upon the success obtained with MCP12, MCP2 was also purified, following 
deglycosylation, by affinity chromatography using ConA sepharose. This step 
removes any non-deglycosylated MCP2 along with the contaminating cleaved 
glycans. As with MCP12, the deglycosylated MCP2 passed straight through the 
column in the unbound fractions, whereas the cleaved glycans and any MCP2 still 
glycosylated, bound to the column, and was subsequently eluted with 1 M methyl-a-
D-glucopyranose. The result of this purification step is illustrated in Figure 4:6. 
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Figure 4:5 HIC purification of crude MCP2 on a Resource iso column. A: 
chromatogram showing a large unbound fraction and single broad peak of bound 
material. B: SIDS PAGE of non-deglycosylated fractions. C: SDS PAGE of non-
deglycosylated fractions. The gels show than the majority of the bound material is 
glycosylated MCP2 and that more highly glycosylated species elute from the column 
earlier. 
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Figure 4:6 ConA purification of deglycosylated MCP2. Deglycosylated MCP2 
remains unbound, whereas the cleaved glycans and any non-deglycosylated MCP2 
that remained were retained on the column. 
Following ConA purification of deglycosylated MCP2 the breakthrough fractions 
from the ConA column were pooled, concentrated and further purified using anion 
exchange chromatography on a Poros20Q (Applied Biosystems) column The MCP2 
was exchanged into 50 mM Tris, pH 8.0, using a PD1O gravity-fed gel filtration 
column (Amersham-Pharmacia Biotech), and applied to the Poros20Q column in 
aliquots of approximately 1 mg. The chromatogram shown in Figure 4:7 shows that 
the deglycosylated MCP2 elutes from the column as a single peak indicative of a 
homogeneous protein. Fractions 18 and 19 from this column, that represented the 
central portion of the single peak, were pooled and used for subsequent analyses. 
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Mlon Exchange Purification of Oeglycoaylated MCP2 on a Poros200 Column 
Figure 4:7 Anion exchange purification of deglycosylated MCP2 on a 
Poros20Q column. The chromatogram shows that deglycosylated MCP2 elutes as 
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Figure 4:8 SDS-PAGE of purified deglycosylated MCP2. The gel shows that 
deglycosylated MCP2 has been purified to homogeneity as judged by SIDS-PAGE. 
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The SDS-PAGE of the pooled fractions, as shown in Figure 4:8, demonstrates the 
purification of deglycosylated MCP2 to homogeneity as judged by this method. The 
identity of the protein sample was further confirmed using N-terminal sequencing. 
This shows the presence of extra N-terminal EA sequences. These residues are 
occasionally present at the beginning of proteins secreted from P. pastoris, and are 
the result of inefficient cleavage of the secretion signal. A secondary sequence 
lacking extra E and A residues was also observed by N-terminal sequencing. These 
N-terminal sequences were determined to be: EAEFYRETCP and EFYRETCPYI. 
With the native MCP2 sequence starting YRET... 
4.3.4. Purification of glycosylated MCP2 expressed in P. pastoris 
In addition to the production of a deglycosylated sample of MCP2, a glycosylated 
sample was required in order to compare the behaviour of glycosylated and 
deglycosylated MCP2 with a view to better understanding the effects of the N-linked 
glycans. Purification of glycosylated MCP2 had many of the problems associated 
with heterogeneous glycosylation that were observed during the purification of 
glycosylated MCP12. The purification of the glycosylated sample of MCP2 was 
achieved in a similar way, namely an initial HIC purification step, followed by 
reverse phase chromatography. The chromatogram obtained from reverse phase 
chromatography of glycosylated MCP2 is shown in Figure 4:9, and demonstrates that 
much of the glycosylated module elutes as a single peak similar to the one for 
glycosylated MCP12. Demonstrating the purity of the highly heterogeneous 
glycosylated form of MCP2 is difficult, simply by virtue of its inherent 
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heterogeneity. In this case it seems reasonable to compare SDS-PAGE of the same 
sample both before and after treatment with EfldOHf. For the untreated sample, this 
method would be expected to yield the heterogeneous smear previously observed. 
On the other hand, for the treated sample two bands would be expected, one running 
at approximately 70 kDa corresponding to the EndoHf used for deglycosylation, and 
one at 6 kDa which corresponds to deglycosylated MCP2. This expected profile 
was indeed observed on the SDS-PAGE shown in Figure 4:10 
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Figure 4:9 Reverse phase purification of glycosylated MCP2. 	The 
chromatogram shows that glycosylated MCP2 elutes as a single peak with a slight 
shoulder, which is unsurprising given the heterogeneity of glycoforms observed. 
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Figure 4:10 SOS-PAGE of purified glycosylated MCP2 after treatment with 
EndoHf. The gel of the EndoH 1  treated sample shows two bands, one runs around 
the 6.5 kDa marker as would be expected for deglycosylated MCP2 and the other 
runs at —70 kDa which corresponds to the expected mass of the EfldoH f. The 
untreated sample shows a highly heterogeneous smear extending primarily between 
16 kDa and 32.5 kDa. 
The proteins purified as described in this section were then used for subsequent 
analysis as described in the following section. 
4.4. Biophysical Characterisation of MCP2 expressed in P. pastoris 
4.4.1. Mass spectrometry analysis of MCP2 
In the absence of an assay, evidence was sought to confirm that the species expressed 
and subsequently purified was indeed chemically intact and correctly folded MCP2. 
Plasmid DNA sequencing and N-terminal protein sequencing were encouraging but 
further validation was required. This was achieved using electrospray ionisation 
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(ES)-MS; the mass spectrum of MCP2 deglycosylated with EndoH f is shown in 
Figure 4:11. It reveals two major species that are within 1 Da (lower) of the 
expected mass of MCP2 with its two disulphide bonds formed, the single remaining 
G1cNAc residue following EndoH f treatment, and an N-terminus of either EF... or 
EAEF.... Each of these two major peaks has two associated minor peaks 
corresponding to masses +23 Da and +38 Da. It is most likely that these arise from 
the presence of sodium and potassium adducts respectively. In addition each of the 
two major peaks is associated with a -18 Da species. Modifications that could 
explain this difference include succinimide formation from aspartic acid residues, 
dehydration, and formation of dehydroalanine from serine. Regardless of which of 
these possibilities is correct, the fraction of the sample that contains this modification 
is small. It proved impossible to perform ES-MS on the non-deglycosylated form of 
MCP2 proved due to the high heterogeneity resulting from the presence of different 
glyco forms. 
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Figure 4:11 Mass spectrum of EndoHf deglycosylated MCP2. The two species 
at 8127 kDa and 8327 kDa are within 1 Da of the predicted mass for the protein with 
two disulphide bonds, a single GlcNAc residue, and N-terminal residues of EF and 
EAEF respectively. This is the result of incomplete processing of the secretion 
signal and was also observed with N-terminal sequencing. 
4.4.1.1. 	Verification of ' 5N incorporation into the 15N deglycosylated MCP2 
A sample of each of the glycoforms of MCP2 was uniformly labelled with ' 5N by 
growing up the P. pastoris cells with ' 5N ammonium sulphate as the sole nitrogen 
source, as described elsewhere (Wiles, 1996). ES-MS was used to verify that the 
MCP2 had been 15N-labelled and to check the level of ' 5N incorporation. The mass 
spectrum shown in Figure 4:12 once again shows two main peaks - presumably 
corresponding to the different N-termini. 
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Figure 4:12 Mass spectrum of 15N labelled EndoHf deglycosylated MCP2. The 
peaks correspond to masses for the major species which are 82 Da greater than the 
unlabelled equivalents. This indicates that 82 out of the possible 89 nitrogen atoms 
have 15N nuclei. 
The peak corresponding to the major species (N-terminus EAEF... ) is 82 Da larger 
than its counterpart in the unlabelled sample. This mass difference presumably 
represents the incorporation of 82 15N atoms out of a possible 89 nitrogen atoms per 
MCP2 molecule, which would correspond to 92 % incorporation of 15N. The peak 
corresponding to the minor species (N-terminus EF ... ) is also 82 Da greater than its 
unlabelled counterpart. Thus82 out of 87 ' 4N nuclei have been replaced by ' 5N 
nuclei in this case corresponding to 94 % 15N enrichment and consistent within 
experimental error with the percentage incorporation calculated for the larger 
species. 
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4.4.1.2. Verification of the number of disulphide bonds in MCP2 
In order to verify that both disulphide bonds had formed the protein was subjected to 
carboxymethylation using neutralised iodoacetic acid. This reagent would be 
expected to react with any free sulthydryls present in the protein. To reduce the 
ambiguity resulting from the presence of the single G1cNAc residue remaining after 
EndoHf treatment, this procedure was performed on PNGaseF-deglycosylated 
MCP2. Like EfldOHf, PNGaseF is an endoglycosidase that cleaves N-linked glycans. 
Unlike EfldOHf, PNGaseF cleaves glycans between the first GlcNAc residue and the 
asparagine residue of the NXS/T glycosylation sequon. This type of cleavage 
therefore leaves no sugar residues on the protein, which may be useful when 
attempting to interpret a mass spectrum. The use of PNGaseF-deglycosylated MCP2 
also permits a less ambiguous confirmation that the two major species observed 
(Figure 4:11) are due to the ragged N-terminus (expected difference 200 Da), rather 
than the presence or absence of a single G1cNAc residue (predicted mass difference 
203 Da). 
The PNGaseF-treated sample was subjected to ES-MS (i) prior to any further 
treatment; (ii) following carboxymethylation; and (iii) following denaturation with 
urea, reduction with DTT and carboxymethylation. The inclusion of the denatured, 
reduced, and alkylated sample acts as a positive control to prove that the 
carboxymethylation reaction progresses as would be expected. The purpose of the 
denaturing agents was to disrupt any tertiary structure that could bury free —SH 
groups. 
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Figure 4:13 Mass spectrum of 15N-labelled PNGaseF-deglycosylated MCP2. 
The spectrum shows the expected two peaks that correspond to the mass of MCP2 
with two disulphide bonds, no GIcNAc residue and the ragged N-terminus (± EA). 
The mass spectrum in Figure 4:13 shows two peaks that are within 1 Da of the 
predicted mass of deglycosylated MCP2 containing two disulphide bonds, the now 
expected ragged N-terminus, and minus the G1cNAc residue not removed by Endoll f, 
but cleaved by PNGaseF. These masses can be compared to those obtained with the 
EndoHf-treated sample. The mass of MCP2 after treatment with PNGaseF is 204 Da 
lower than that observed for EndoHf-deglycosylated MCP2. This mass difference 
corresponds to the loss of a 15N-abelled GIcNAc residue (expected mass difference 
204 Da). Therefore, these data provide confirmation that the two peaks are indeed 
due to the presence of the ragged N-terminus, rather than the presence of a 
proportion of MCP2 that had never been glycosylated. 
173 
Results and Disucssion 




Figure 4:14 Mass spectrum of carboxymethylated 15N labelled MCP2 
deglycosylated with PNGaseF. 
The mass spectrum of MCP2, treated with neutralised iodoacetic acid, shown in 
Figure 4:14 reveals no change in mass when compared to the non-
carboxymethylated sample (Figure 4:13), indicating that all four cysteines are 
oxidised, and therefore presumably involved in disulphide bonds. The mass 
spectrum of denatured, reduced, and alkylated MCP2 shown in Figure 4:15 shows an 
increase in mass of 235 Da and 236 Da for the smaller and larger peak respectively. 
This increased mass is in good agreement with the prediction of 232 Da expected for 
the carboxymethylation of 4 cysteines. Each of the carboxymethylation reactions is 
predicted to add 58 Da for each free cysteine. It appears, however, that the observed 
mass is 3 Da larger than would be predicted. This is probably the result of 
deamidation of the three asparagine residues in the protein. This is not entirely 
surprising since the reduction reaction is carried out at high pH, and at an elevated 
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temperature, making deamidation more likely. When taken in concert these data 
indicate that MCP2 has both its predicted disulphide bonds formed, and that these are 
reduced following denaturation and treatment with DTT. That two disulphides are 
present in MCP2, in line with expectations, provides further evidence that the core of 
the protein may indeed be folded as would be expected. 







Figure 4:15 Mass spectrum of denatured, reduced, and carboxymethylated 
PNGaseF-deglycosylated, 15N-labelled MCP2. The spectrum shows an increase 
in mass of 235 and 236 when compared to non-alkylated MCP2. 
The results described in the preceding sections demonstrate the successful expression 
and purification of MCP2, and subsequent verification that the isolated species 
contains its predicted two disulphide bonds. These data further indicate that the core 
of the protein should be folded in a similar way to that found naturally. Following 
these observations, the protein was subjected to NMR spectroscopy in order to gain 
further information and therefore a deeper understanding of its structure and 
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dynamics. The results of the NIvIR spectroscopy carried out on this protein will be 
the subject of the following section. 
4.4.2. NMR spectroscopic analysis of MCP2 
As previously discussed high field NMR can provide a wealth of information about a 
protein's structure and dynamics. Following the purification of a sample of EndoHr 
deglycosylated MCP2, a 1 D 'H spectrum was acquired at 25 °C under the conditions 
optimised for MCP12. This is shown in Figure 4:16. 
\W 
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Figure 4:16 ID 1 H spectrum of Endol-l f deglycosylated MCP2. The spectrum 
was acquired at 25 °C. The sample was 0.9 mM in 20 mM potassium 
phosphate pH 6.0. 
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The spectrum shows good dispersion, and narrow line-widths, both of which are 
associated with folded proteins. A spectrum of the same sample was then acquired at 
37 °C as shown in Figure 4:17. 
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Figure 4:17 ID 1 H spectrum of EndoHrdeglycosylated MCP2. The spectrum 
was acquired at 37 °C. The sample was 0.9 mM in 20 mM potassium phosphate pH 
6.0. 
The spectrum acquired at 37 °C shows several significant differences compared to 
that acquired at 25 °C. These include the appearance of broad peaks at 10.1 ppm, 9.7 
ppm, 5.7 ppm, 0.1 ppm, and -0.5 ppm. Such changes could result from temperature-
sensitive differences in the rates of inter-conversion between multiple conformers. 
For example an intermediate exchange rate that causes extreme broadening (effective 
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disappearance) of a signal is likely to become more rapid at a higher temperature 
resulting in a reappearance of the signal in the spectrum. To explore this further, 1 D 
'H spectra were also acquired at 42 °C and 10 °C (as shown in Figure 4:18 and 
Figure 4:19 respectively). Both of these spectra appear to exhibit the same trend, 
with the broad peaks becoming more prominent as temperature is increased. 





Figure 4:18 ID 1 H spectrum of EndoHrdeglycosylated MCP2. The spectrum 
was acquired at 42 °C. The sample was 0.9 mM in 20 mM potassium phosphate, 
pH 6.0. 
It is interesting to note that the broad peaks eventually disappeared completely 
following prolonged (>2 weeks) incubation in the fridge. It therefore seems that the 
fresh sample of deglycosylated MCP2 was not fully folded - but over time (at 4° C) 
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the folding process reached completion. A possible reason for very slow folding of 
this protein could be the presence of several X-Pro bonds that might settle into a 
preferred cis or trans configuration over an extended time. All subsequent spectra 
were acquired at 25 °C. 
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Figure 4:19 ID 1 H spectrum of EndoHrdeglycosylated MCP2. The spectrum 
was acquired at 10 C. The sample was 0.9 mM in 20 mM potassium phosphate pH 
6.0. 
Following the acquisition of the 1 D 'H spectra, and the selection of 25 °C as a 
suitable temperature for data acquisition, a 2D 'H, 'H TOCSY spectrum was 
acquired on deglycosylated MCP2, and the result is shown in Figure 4:20. This 
spectrum shows the expected extent of dispersion for a protein of this type. For 
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many side-chains, the TOCSY transfer appears to extend through to the Wy nuclei. 
There appears, however, to be significantly fewer peaks in this spectrum than would 
normally be expected for a protein of this size. This deficit may arise from 
inefficient magnetisation transfer due to aggregation or conformational exchange on 
an intermediate time-scale, both of which can result in shorter 'H-T 2 relaxation 
times. The excessively large quantities of sugars present in glycosylated MCP2 
rendered its 2D 'H 'H TOCSY s unusable. 
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Figure 4:20 2D 1 H 1 H TOCSY spectrum of EndoHf deglycosylated MCP2 
acquired at 25 °C. The sample was 0.9 mM in 20 mM potassium phosphate at pH 
6.0. 
A homonuclear NOESY was subsequently acquired of deglycosylated MCP2 and is 
shown in Figure 4:21. The spectrum shows a number of peaks with reasonable 
dispersion; however the shape of the peaks indicates that the sample may be in 
conformational exchange. Furthermore, it is noteworthy that there are no NOEs to 
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the consensus tryptophan residue. Were the protein well structured one would 
expect, to observe several such NOEs. 
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Figure 4:21 NOESY spectrum of deglycosylated MCP2 (100 ms mixing time). 
The spectrum was acquired at 25 °C on a 600 MHz Varian Innova spectrometer. 
The sample was 0.9 mM in 20 mM potassium phosphate, pH 6.0 
Following the production of a 15N-labelled sample of EndoHrdeglycosylated MCP2 
(see Figure 4:12), a more detailed NIvIR analysis of MCP2 could be performed. 
Initially 'H ' 5N HSQC spectra were recorded on a deglycosylated sample of MCP2. 
The spectrum shown in Figure 4:22 shows good dispersion indicative of a folded 
protein. There is, however, a considerable amount of line-broadening and overlap in 
the random coil region of the spectrum. This might be caused by aggregation, the 
presence of unfolded (or mis-folded) protein, or conformational exchange taking 
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conformational mobility. This could provide one possible explanation for the 
functional requirement of the N-linked glycans for both the measles receptor activity 
and the natural complement activity, which has been recorded both in this study and 
by others. 
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Figure 4:22 1 H, 15N HSQC spectrum of deglycosylated MCP2. The spectrum 
was acquired on a 0.9 mM sample in 20 mM potassium phosphate, pH 6.0, at 25 °C. 
The spectrum shows a large degree of dispersion, however there is considerable 
overlap in the centre of the spectrum. 
It was therefore a logical next step to acquire a 'H, 15N HSQC spectrum of 
glycosylated MCP2. This spectrum, shown in Figure 4:23, is similar to that of 
deglycosylated MCP2, with a few interesting differences. Notably amongst these, 
are the considerably reduced amount of overlap in the random coil region, and the 
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difference in intensity of a small number of resonances, including increased relative 
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Figure 4:23 HSQC spectrum of glycosylated MCP2. This spectrum shows many 
features indicative of a tightly folded protein, with well defined peaks and a large 
degree of dispersion in both the nitrogen and proton dimensions. The sheer size of 
the glycoprotein and its heterogeneity, however, preclude the use of this version of 
MCP2 for structural studies. 
The differences between these HSQC spectra of MCP2 are subtle, however the 
spectrum of glycosylated MCP2 shows significantly less overlap in the random coil 
region. One such possible explanation is that the sugars indeed perform a structural 
role, as may be inferred from the crystal structure (Casasnovas et al., 1999). A 
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4.4.3. Differential scanning calorimetry analysis of MCP2 
To investigate the possibility that the N-linked glycans on module 2 have a 
stabilising effect, differential scanning calorimetry was performed on both 
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Figure 4:24 Differential scanning calorimetry of EndoHrdeglycosylated MCP2. 
The data were best fit to a model with two transitions with melting temperatures of 
51 C and 76'C. The sample was 0.63 mg.mr 1 . 
The DSC data for EndoHr-deglycosylated MCP2, shown in Figure 4:24, were fitted 
to a double transition model with T. values of 51 °C and 76 °C. Possible 
explanations for the presence of two transitions in the melting profile include the 
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process. The presence of two forms of MCP2 in the deglycosylated sample is 
consistent with two interpretations of the HSQC NMR data (i.e. line-broadening due 
to inter-conversion between conformers; or the presence of an improperly folded 
form of the protein). Bearing this in mind, one can attempt to interpret these data. 
The Tm value of 76 °C is indicative of a protein which is well folded and highly 
compacted. This transition therefore, probably represents the thermal denaturation of 
the native conformation of MCP2. The transition with a T m of 51 °C would represent 
a protein conformation that is considerably less stable. 
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Figure 4:25 Differential scanning calorimetry of glycosylated MCP2. The data 
were again fitted to a two transition model of unfolding, with melting temperatures of 
51 C and 74 C. The sample was o.54 mg.mr 1 . 
The DSC data for glycosylated MCP2 (shown in Figure 4:25) were also fitted to a 
two transition model of unfolding. In this case, melting temperatures of 51 °C and 74 
were obtained. That similar two transition DSC traces were obtained for both 
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glycosylated and deglycosylated MCP2 (Figure 4:26) implies that glycosylation is 
not having a very major affect either on the thermal stability, or the unfolding 
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Figure 4:26 Overlay of DSC of glycosylated (red) and deglycosylated (black) 
MCP2. 
4.5. Discussion 
The results presented in this chapter demonstrate the successful cloning and 
expression of MCP2 in P. pastoris at levels sufficient for biophysical 
characterisation. Deglycosylated MCP2 was successfully purified to homogeneity as 
determined by SDS-PAGE, whilst the hyperglycosylated form of MCP2 was purified 
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to a homogeneous protein species that is heterogeneous solely with respect to 
glycosylation. 
N-terminal sequencing and mass spectrometry data confirmed the identity of the 
protein as MCP2, and revealed that complete processing of the secretion signal had 
not occurred - an extra EA, or EAEA, sequence remained at the N-terminus of the 
recombinant protein following signal sequence processing. Mass spectrometry 
experiments also confirmed the lack of chemical modifications to the recombinant 
protein, and was further used to verify that the two predicted disulphide bonds had 
formed. Preliminary NMR experiments indicated that both the glycosylated and 
deglycosylated forms of MCP 12 show the good dispersion indicative of a structured 
protein. There was, however, a larger area of overlap in the centre of the 
1 H, 15NHSQC from deglycosylated MCP2 than would normally be expected for a 
protein of this size. In the case of glycosylated MCP2, on the other hand, this is not 
the case. While a possible explanation for this is transient aggregation of 
deglycosylated MCP2this seems improbable since the problem persisted over a range 
of sample conditions. A more likely explanation is that conformational exchange on 
an intermediate time-scale is responsible. Evidence for inter-conversion between 
conformers was observed in the 'H NMR spectra of fresh MCP2 samples recorded at 
various temperatures. While the broad peaks that appeared at higher temperatures 
failed to appear in older samples, implying that a slow folding process was involved, 
other dynamic events on this intermediate time-scale cannot be ruled out. CCP 
modules do not possess a high proportion of regular secondary structure and much of 
the main chain lies in flexible loops and turns. Further NIMR analysis was not 
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performed on deglycosylated since it was thought that the acquired spectra were not 
of sufficient quality for a full structural study to be undertaken. 
The question as to the affect of glycans could be better addressed through the 
production of a sample of MCP2 that has a more natural glycosylation pattern. This 
can best be achieved through the use of an alternative expression system that does 
not hyperglycosylate recombinant proteins. Moreover, it is possible that the act of 
deglycosylation is the cause of the apparently less ordered structure of 
deglycosylated MCP2. To determine whether this is the case, a sample of native 
sequence that has never been glycosylated is required. To achieve these goals, two 
other expression systems were employed. Drosophila melanogaster S2 cells were 
used to generate a more naturally glycosylated form of MCP2; and E. coli was used 
to generate a large amount of non-glycosylated protein that could subsequently be 
refolded. The use of these alternative expression systems will form the subject of the 
following chapter. 
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5. Recombinant Mcp2 from Other Organisms 
5.1. Preliminary remarks 
Given the problems encountered producing a sample well-folded sample of MCP2, 
two alternative approaches were tried. In order to discount the hypothesis that it was 
the act of deglycosylation that was responsible for the apparent differences between 
the spectra of glycosylated and deglycosylated MCP2, a sample with native sequence 
that had never been glycosylated was required. In this respect expression in E. coli 
appears to be a reasonable option. Furthermore, CCP modules have, in the past, been 
successfully expressed and refolded from material expressed in E. coli (Dodd et al., 
1995). The second approach was to attempt to express the protein in a host that is 
capable of attaching a far smaller and better defined glycosylation profile. The ideal 
host for this purpose would appear to be an insect expression system, and a D. 
melanogaster expression system in particular seems appropriate since expression 
levels of 10 - 35 mg.1-1 have been achieved (Ivey-Hoyle et al., 1991; Johanson et al., 
1995). The work described in the following sections describes the use of these hosts 
for the expression of MCP2. 
5.2. Cloning and expression of MCP2 in E. coIl 
5.2.1. The pET system 
The pET system was chosen as a starting point for expression studies of MCP2 in E. 
coli, since it has a proven record of generating large amounts of recombinant 
proteins. It also has several diverse vectors with different features that can help when 
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expressing difficult proteins. The pET system illustrated in Figure 5:1, is centred 
around the use of the bacteriophage T7 RNA polyinerase. In the pET system, the 
gene of interest is cloned behind the T7 RNA polymerase promoter. Under normal 
circumstances of course, E. coli doesn't produce 17 RNA polymerase, and wild type 
strains do not contain this gene. This facilitates the cloning of genes encoding toxic 
proteins, for example, since basal protein expression is negligible. The expression 
hosts used in the pET system are lysogens for the bacteriophage DE3, and contain 
the lacl gene and a copy of the T7 RNA polymerase gene under the control of the 
lacUV5 promoter. The lacUV5 promoter is inducible by the unmetabolisable lactose 
analogue, isopropyl thiogalactoside (IPTG). Therefore the DE3 lysogenic hosts 
produce T7 RNA polymerase after the addition of IPTG to the culture medium. The 
polymerase is then able to undertake transcription of the gene in a pET vector that is 
under the control of the T7 RNA polymerase promoter. Thus, this system is a simple 
and effective method of producing inducible recombinant protein in enabled host 
strains. 
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Figure 5:1 Overview of the pET system. The gene of interest is cloned in a pET 
vector behind the 17 RNA polymerase promoter. Following transformation into a 
DE3 host strain, expression is induced by adding IPTG to the culture medium. This 
induces the production of 17 RNA polymerase from a gene on the DE3 lysogen that 
is under the control of the lacUV5 promoter, (taken from Novagen, 2002) 
5.2.2. Cloning and expression of MCP2 in pET15b 
The expression vector pETI 5b shown in Figure 5:2 was chosen for initial work on 
production of MCP2 in E. coli. The resulting construct will henceforth be referred to 
as MCP2 pET15b. This vector is one of the simplest expression vectors in the pET 
expression system, with only the inclusion of a thrombin cleavable N-terminal His 
tag for purification. This vector uses ampicillin resistance as a selectable marker. 
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Figure 5:2 Vector map of pET15b showing the key features (taken from 
Novagen, 2002) 
The region coding for MCP2 was amplified by PCR, and the agarose gel shown in 
Figure 5:3 reveals a single band of approximately the correct size for MCP2. This 
fragment was then inserted into pET1 5b between the restriction sites Ncol and )c7iol. 
The plasmid was then sequenced to verify the identity and accuracy of the insert, and 
a plasmid containing an insert of the published sequence for MCP2 was used to 
transform E. coli BL21 DE3 cells. Transformation of E. coli was performed 
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immediately prior to every growth for all the following expression studies. A single 
colony from a transformation was used to inoculate LB and samples taken of both 
the soluble and insoluble fractions of induced and uninduced samples. 
Figure 5:3 PCR of MCP2 for cloning into pET15b. The gel shows a single band 





Figure 5:4 SDS PAGE of MCP2 pET15b. The gel shows that MCP2 is expressed 
in reasonable quantities, but is exclusively in the insoluble fraction (lanes 2 and 4). 
The presence of MCP2 in the uninduced fraction (lane 4) indicates that expression 
of the fragment is not dependant upon induction with IPTG. 
193 
Results and Disucssion 
The SDS PAGE shown in Figure 5:4 shows the soluble (lane 1) and insoluble (lane 
2) fractions from the induced samples of MCP2, alongside the soluble (lane 3) and 
insoluble (lane 4) fractions from the induced samples of MCP2. The gel shows a 
band of the correct size for the MCP2 fragment in the insoluble fractions from both 
the induced and uninduced samples. Since it had previously been observed that 
BL21 DE3 cells transformed with pETl5b without an insert do not produce a band of 
this size, it seemed probable that this band was MCP2. The fact that this band is also 
present in the induced samples (albeit at a lower level) indicated that the plasmid was 
"leaky" i.e. induction was not a prerequisite for expression. This phenomenon has 
previously been observed with other proteins expressed using the pET system and is 
usually the result of basal expression of the T7 RNA polymerase gene. If desired 
this basal expression can be reduced by using host strains containing pLysS or pLysE 
(Dubendorff et al., 1991; Studier, 1991). There seems little point in attempting to 
repress this basal expression in this case, however, since MCP2 is apparently not 
toxic to E.coli. 
5.2.3. Cloning and expression of MCP2 in pET32a 
Since the MCP2 expressed in pET15b was found entirely in the insoluble fraction, it 
was decided to explore alternative strategies with the aim of achieving expression of 
soluble material. One method of solubilising proteins expressed in E. coli is to 
express them as fusion proteins. One possible fusion partner is thioredoxin, which is 
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encoded in the pET32a vector illustrated in Figure 5:5. This fusion tag is particularly 
appropriate for the expression of disulphide bonded proteins since it has been shown 
to catalyse the formation of disulphide bonds in the cytoplasm of E. coli (Novagen, 
2002). In addition to its ability to aid the formation of disulphide bonds, thioredoxin 
has also been shown to increase the solubility of proteins expressed in E. coli 
(Garcia-Ortega et al., 2000; Sachdev et al., 1998). For these reasons it seemed 
reasonable to use pET32 to express MCP2 in a soluble and, potentially, disulphide 
bonded form. Another reason for choosing the pET32 vector was the ease with 
which the gene for MCP2 could be inserted into the pET32 plasmid. It had 
previously been observed that genes cloned into pET15b between Ncol and X7iol 
could be digested with Ndel and Xhol and inserted into pET32 (S. Blein, University 
of Edinburgh. personal communication). This would allow the direct insertion of the 
MCP2 construct into pET32 without the need for a further PCR step. The resulting 
construct will henceforth be referred to as MCP2 pET15_32. This method for 
inserting a gene into pET32 does, however, produce a fusion protein that contains 
two His tags and two thrombin cleavage sites. The presence of the two His tags 
poses no serious problems, and indeed may actually aid the purification. The 
presence of two thrombin cleavage sequences on the other hand, could result in a less 
efficient cleavage of the fusion tags. This potential problem could possibly be 
alleviated by cleaving the fusion tags using a larger amount of thrombin. If this 
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Figure 5:5 Vector map of pET32a showing the key features of the thioredoxin 
tag, ampicillin resistance, and multicloning region (taken from Novagen, 
2002). 
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Figure 5:6 1.4% agarose gel showing MCP2 pET15b _pET32 cut Xhol Xbal. 
The gel shows that all the clones tested contained an insert of the correct size for 
MCP2 with the thioredoxin tag, 2*  His tags, and 2*  thrombin cleavage sites 
The agarose gel shown in Figure 5:14 shows the digestion with Jt7zol and Xbal of 
pET32 plasmids thought to contain the MCP2 insert. The gel reveals the presence of 
the insert in all of the plasmids tested. These plasmids were then sequenced to varify 
the identity and accuracy of the insert, and a clone containing an insert of the 
predicted sequence for MCP2 was used to transform E. coli BL2 1 DE3 cells. The 
Origami strain of E. coli, which has also been shown to be effective at forming 
disulphides in the cytoplasm, was also transformed using this plasmid, but no 
positive clones were obtained using this strain. Soluble and insoluble fractions of 
induced and uninduced samples of MCP2 pET15_32 were prepared in a similar way 
to those for MCP2 pET15b, and subjected to SDS-PAGE. The gel shown in Figure 
5:7 reveals that in contrast to MCP2 pET15b all or most of the MCP2 is now found 
in the soluble fraction as a band of approximately 25 kDa. The use of a thioredoxin 
tag was therefore successful in producing a soluble form of MCP2 expressed in E. 
coli. It is also interesting to note that once again MCP2 is found in the uninduced 
samples albeit at a lower level. 
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Figure 5:7 Induction tests of MCP expressed in E. coil 131-2I. SOS PAGE 
showing a band at 25 kDa in the soluble fractions of both the induced and 
uninduced samples. This band is the correct size for MCP2 with the thioredoxin tag, 
two His tags and a thrombin cleavage sequences. This band was not present in 
either the gel for BL21 without the MCP2 pET15b32a plasmid (data not shown) or 
the BL21 containing MCP2 pET15b (Figure 5:4). It can also be seen that the band 
is present at only very small levels in either of the insoluble fractions. It therefore 
seems that the addition of the thioredoxin tag has converted all the expressed 
MCP2 from the insoluble to the soluble fraction. In addition as with MCP2 pET15b, 
induction with IPTG is not required for protein expression. 
5.2.4. Large scale expression of MCP2 pETI5_32 
Since it was observed that MCP2 was expressed by both induced and uninduced 
cells, it seemed prudent to exploit this property to develop a more efficient protocol 
for expression. It has been noted by others in our laboratory that E. coli can be 
grown satisfactorily by inoculating 250 ml of LB medium containing 100 .tg.mL' 
ampicillin (LB-amplOO) directly with a single colony from a freshly transformed 
plate. It therefore seemed reasonable to modify this procedure to express MCP2. 
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This was achieved by inoculating 4 x  250 ml LB-amp 100 each with a single colony 
from a freshly transformed plate of MCP2 pET15-32 BL21. This culture was 
incubated overnight at 37 °C with shaking at 250 rpm, and processed the following 
morning for purification of MCP2. This protocol offers significant advantages over 
the standard growth—induction protocols commonly used for expressing proteins in 
E. coli. Not least of these advantages are the time saving (almost two days) and the 
speed at which the harvested pellet is purified - thus reducing the chances of 
degradation. The cells expressing the MCP2 fusion protein were subjected to 
chemical lysis with the "Bugbuster" reagent (Novagen). Following lysis, the soluble 
fraction was applied to a charged nickel affinity column and bound protein eluted 
with a step gradient of 1 M imidazole. The chromatogram shown in Figure 5:8 
reveals that the MCP2 fusion protein elutes from the column as a single peak. 
Following the initial purification of MCP2 on nickel affinity resin, the thioredoxin 
and His tags were cleaved with thrombin, and then the sample was re-applied to the 
nickel affinity column. This last step removes the cleaved His tags, and some of the 
non-specifically bound proteins, whilst the cleaved protein passes through the 
column without binding. N-terminal sequencing yielded a sequence of 
GSHMYRETCP indicating that the thioredoxin and His tags had been 
completely removed. 
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Figure 5:8 Chromatogram showing the purification of MCP2 on a nickel affinity 
column. The rise and dip in A280 between 55 ml and 65 ml is due to the protein 
purification machine equilibrating to elution buffer with the column off line. 
The final purification step was gel filtration on a Superdex 75 column. The 
chromatogram shown in Figure 5:9 reveals that a small proportion of material elutes 
at approximately 78 ml. This compares to the gel filtration of MCP12 which elutes 
from the column at approximately 75 ml, and indicates that a small proportion of the 
sample exists as a dimer. This is presumably the result of non-specific dimerisation, 
since the protein had not been refolded at this stage, and this behaviour was not 
observed with MCP2 expressed by P. pastoris. Since the sample was soluble at this 
stage it was decided to acquire a 1D 'H NIMIR spectrum, in order to determine 
whether a refolding step was necessary. This spectrum, shown in Figure 5:10 shows 
almost none of the dispersion seen in the MCP2 produced by P. pastoris that is 
characteristic of folded proteins. It was therefore concluded that this form of MCP2 
was almost completely unfolded, and therefore requires a refolding step. 
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Figure 5:9 Purification of MCP2 expressed in E. coil on a Superdex 75 column. 
The chromatogram shows the existence of a small proportion of material that 
behaves as a dimer. 
___ ____________- 
H 	LI 
Figure 5:10 ID 1  NMR spectrum at 25°C of MCP2 expressed in E. coil before 
refolding. The sample was 0.8 mM in 20 mM potassium phosphate, pH 6.0. The 
spectrum shows almost no dispersion from random coil. 
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5.2.5. Refolding of MCP2 expressed in E. coil 
The refolding of proteins that contain disulphide bonds can prove problematic and 
even in favourable cases the process results in the loss of large amounts of protein. 
The problem is particularly challenging in proteins for which there is no easy 
functional assay of the correctly folded protein. In the case of MCP2, the refolding 
step was performed using a protocol similar to that used to successfully refold MCP1 
(O'Leary, 2000). The protein was purified as described above, and then denatured 
using 8 M urea, and the disulphide bonds disrupted by the inclusion of 2 mM 
reduced glutathione (GSH) and 0.2 mM oxidised glutathione (GSSG). The protein 
was then dialysed against 100 mM Tris, pH 8.0, 2 mM GSH, 0.2 mM GSSG 
containing 5 mM EDTA to help prevent possible metal catalysed oxidation, and 
proteolysis. The refolded sample was then further purified by anion exchange 
chromatography under the conditions used for the purification of MCP2 expressed in 
P. pastoris, and this chromatogram shown in Figure 5:11 is similar to that obtained 
for MCP2 expressed in P. pastoris. Following the refolding step a 1D 'H NIvIR 
spectrum was acquired as shown in Figure 5:12. This spectrum shows considerably 
more dispersion than that of the non-refolded sample, indicating that the refolding 
protocol had caused the protein to become more structured. Comparison of the 
spectra from the refolded material with deglycosylated MCP2 expressed by P. 
pastoris shows that the spectra are largely similar, however it appears that there is 
still more dispersion in the deglycosylated MCP2 than in the refolded MCP2. 
Possible reasons for this include the structure of MCP2 being further destabilised by 
having no glycans at all or that the initial steps of glycosylation are required in order 
to attain the correct fold. 
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Anion Exchange Purification of Refolded E. coil expressed MCP2 on a 
Poros20Q Column 
Figure 5:11 Purification of 'refolded' E. coil-expressed MCP2. The 
chromatogram appears to be very similar to that for the P. pastoris-expressed 
MCP2. 
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Figure 5:12 ID 1 1-1 spectrum of 'refolded' MCP2. The spectrum was acquired at 
25 °C. The sample was 0.8 mM in 20 mM potassium phosphate pH 6.0. 
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5.3. Cloning and expression of MCP2 in drosophila S2 cells 
It proved impossible to generate MCP2 with a small and relatively homogeneous 
glycosylation profile in P. pastoris. The choice then was to find a host capable of 
such a task. It is widely believed that the phenomenon of hyperglycosylation is more 
common in yeasts such as S. cerevisiae than it is in P. pastoris. It therefore seemed 
unnecessary to attempt to express this fragment another yeast host. Instead it was 
decided to express this fragment in a higher eukaryotic host. The choice of which 
host to choose rested on several factors, namely: the glycosylation profile produced; 
the level of expression expected; the media requirements of the host cell line; the 
equipment requirements of the technique; and the ease of mastering the technique. 
In each of these respects, one host appeared to be more suitable than the others 
available, namely S2 cells from the D. melanogaster expression system (DES). This 
is a non-lytic expression system where expression levels of 10 - 35 mg.r' have been 
recorded (Ivey-Hoyle et al., 1991; Johanson et al., 1995). Proteins expressed with 
the DES give a glycosylation profile of the high mannose type (typically 
Man9GlcNAc2). Whilst complex N-glycans cannot normally be produced in this 
host, this is unnecessary since it has been demonstrated that either complex, or high 
mannose, glycans are sufficient for functional activity. The S2 cells are able to grow 
in serum free medium, which can potentially be isotopically labelled, and are 
relatively easy to culture. The cells are cultured at room temperature either in 
loosely adherent or suspension cultures. Moreover transfections are generally 
relatively efficient. To allow glycosylation and disulphide bond formation, it is 
necessary that the protein enters the secretory pathway. With this in mind the, the 
expression vector pMT/BiPIV5-His shown in Figure 5:13 was used. This vector uses 
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the inducible drosophila metalothianein (MI) promoter, which is very tightly 
regulated, but can be induced to high levels by the addition of copper sulphate or 
cadmium chloride to the growth medium (Angelichio et al., 1991). Copper sulphate 
is the prefered choice as an inducer since it is less toxic to the cells. Additionally, 
this vector uses the secretion signal from the drosophila 'BiP' protein to target the 
heterologous protein to the secretory pathway and subsequently into the culture 
medium via the endoplasmic reticulum (Kirkpatrick et al., 1995). The pMT/BiPIV5-
his-A vector has ampicillin resistance as a selectable marker for cloning in E. coli, 
but it has no selectable marker for the drosophila S2 cells. This has the effect that 
generation of a stable cell line requires the expression vector to be co-transfected 
with a helper plasmid. In the case of MCP2, pCoHygro served this purpose. 
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Fram.-dependent variations  
Comments for pMT/BIPN5-His A 	 XbG I and Apal are found onty in versions Aand B. 
3642 nudcotides 	 Sat U Is found only in vetinon B. 
BE Ills found only in version C. 
Metallothlo,eln promoter: bases 412-778 
Start of transcription: base 778 
MT Forward priming site: bases 814-831 
BIP signal sequence: bases 851-904 
Multiple cloning site: bases 908-999 
V5epltopetag: bases 1003-1044 
Potyhistidine region: bases 1054-1074 
BGH Reverse priming site: bases 1094-1111 
SV40 late pdyadenylation signal: bases 1267-1272 
pUG origin: bases 1765-2438 (complementary strand) 
blapromoter: bases 3444-3542 (complementary strand) 
Ampidilin (bla) resistance gene ORF: bases 2583-3443 (complementary strand) 
Figure 5:13 Vector map of the drosophila secreted expression vector 
pMT/BiPN5-His. 
The MCP2 coding sequence was obtained by digestion of MCP2 pET 1 5b with Nco 1 
and Xho 1, thus leaving the N-terminal His tag and thrombin cleavage sequence from 
pET15b. This fragment was ligated into pMTIBiP/V5-his-A, and used to transform 
E. coli OneShot Top 10 cells, and positive transformants were selected using 
ampicillin resistance. The transformation was highly efficient due to the 'cut and 
paste' strategy, and therefore the plasmid from a single positive clone was prepared 
by "miniprep" and digested with Ncol and X7o1. Subsequent electrophoresis on a 
1.4 % agarose gel is shown in Figure 5:14 and indicates that the cloning was 
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successful. The identity and sequence of the clone was confirmed using automated 
DNA sequencing. 
Figure 5:14 1.4% agarose gel showing MCP2 pMT digested with Ncol and 
Xhol. The gel shows an insert of approximately 300bp. This agrees well with the 
predicted size of 320bp for MCP2 with a His tag and a thrombin cleavage sequence 
Plasmid was introduced into S2 cells according to the calcium phosphate transfection 
protocol from the DES manual. A stable cell line expressing MCP2 was required, 
therefore the S2 cells (3 x 10 6) were cotransfected with MCP2 pMT/BiP/V5-his-A 
and pCoHygro (19 .tg MCP2 pMT/BiP/V5-his-A and 1 lag pCoHygro). A stable cell 
line was achieved by selection with 300 .tg.mF' hygromycin-B for three weeks and 
three days, post transfection. Cells were induced for 24 hours using 500 tM copper 
sulphate. The supernatant was harvested by centrifugation, TCA-precipitated, and 
subjected to SDS-PAGE. No MCP2 could be observed on this gel. To determine 
whether any significant amount of MCP2 had been produced, purification on a nickel 
affinity columm was performed. Due to the presence of the N-terminal His tag 
carried over from pET15b, it should be possible to purify this protein on a nickel 
afinity column. Therefore a larger-scale growth was performed, and the cells 
induced as before once the culture had been expanded to 20m1. This medium was 
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then concentrated to 1.0 ml using centrifugal concentrators with a MWCO of 3 kDa. 
The medium was then exchanged into 20 mM sodium phosphate, 100 mM sodium 
chloride. pH 7, and applied to a charged nickel affinity column. Following washing 
the bound protein was eluted with 350 mM imidazole, concentrated and subjected to 
SDS-PAGE. Following SDS-PAGE the proteins were transferred to a nitrocellulose 
membrane, and immunostained using anti His tag antibodies. This immunoblot blot 
is shown in Figure 5:15, and shows a faint band of approximately the correct size for 






Figure 5:15 Western blot of MCP2 expressed in drosophila S2 cells. The blot 
shows a faint band of approximately the correct size for this MCP2 construct 
This suggested the level of expression achieved using the DES was very low. It is 
possible that the expression levels are in fact higher than they first appear to be due 
to cleavage of the His tag, and a consequent reduction in sensitivity of the immuno- 
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detection system. The level of expression achieved using this system could only be 
estimated but was thought to be in the 10s of micrograms per litre range. Such 
expression levels would be considerably lower than those required for any 
biophysical analysis to be performed, and for this reason a larger scale-growth was 
not attempted. It was also presumed that the increases in expression levels required 
for biophysical characterisation (approximately 100-fold) would be unattainable. 
5.3.1. Discussion 
The results described in this chapter demonstrate the successful expression of MCP2 
in E. coil, at levels sufficient for the subsequently required refolding step. NIMR 
spectrOscopic analysis of the 'native' MCP2 expressed in E. coli yielded spectra that 
were consistent with an almost completely unstructured protein. Following refolding 
however, the spectra were considerable improved. Comparison of the spectra 
generated by deglycosylated MCP2 with refolded MCP2 showed a number of 
similarities including the appearance of the dispersed peak at 11.1 ppm that is 
presumed to be the consensus tryptophan residue. Other similarly well dispersed 
peaks were also observed following refolding, however the spectra from refolded 
MCP2 suggest that refolded MCP2 is less well ordered than that of deglycosylated 
MCP2. This observation may imply a trend, whereby having no glycans results in a 
protein with a less ordered structure than one with a single G1cNAc residue, which in 
turn has a less well ordered structure than the protein with a native glycosylation 
profile. One cannot discount however, the possibility that the difference in the 
quality of these spectra is due to inefficient refolding of the E. coil material. 
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MCP2 was also successfully expressed in drosophila S2 cells, although in this case 
the quantities of protein obtained were insufficient for any significant analysis to be 
performed. It may have been possible to increase the levels of protein obtained using 
this system; however this was not attempted since the necessary increases (-j 100 
fold) were thought to be unrealistically high. 
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6. SLAMI 
6.1. Preliminary remarks 
The recent discovery that, in addition to MCP, SLAM could serve as a receptor for 
measles virus (MV) prompted interest in the structural characterisation of the 
relevant region of SLAM. A direct comparison of the interactions of MV with 
SLAM and MCP could shed light on the nature of the initial virus-receptor 
interaction. The initial aim was to produce significant quantities of the domain of 
SLAM that interacts with MV. This work is described in the following sections. 
6.2. Cloning of SLAM into pGEM-T 
Since no direct source of the SLAM cDNA was readily available, a cDNA library 
was used as a template for amplification. Difficulties associated with using a cDNA 
library, include the complexity of the template, and the low abundance of the target 
cDNA. This results in increased risk of generating non-specific amplification 
products, both from mispriming, and due to contamination. Jr addition, commercial 
cDNA sources are expensive, and cannot be regenerated in house. 
In an attempt to address some of these drawbacks, it was decided to clone the whole 
cDNA region encoding SLAM into a suitable cloning vector. The cDNA clone 
generated using this approach, once sequenced, would serve as a template for 
amplification of the required fragments of SLAM in all subsequent expression 
experiments. This approach permits the production of a copious supply of SLAM 
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cDNA from a single aliquot of a commercial cDNA library. In addition, this strategy 
facilitates improved primer design, since the primer sites are far less restrictive than 
those required for expression. A vector map of the cloning vector chosen for this 
purpose, pGEM-T, is shown in Figure 6:1. This vector has the advantage that it 
requires no restriction sites to be incorporated into the primers. Instead the insert is 
ligated by means of A-T base pairing. The vector is linear, with a single overhanging 
T at each 5' end, and pairing is achieved with the presence of a single overhanging A 
on the 3' ends of the PCR product. PCR products generated using Taq DNA 
polymerase, naturally have this 3' overhanging A (Clark, 1988), while PCR products 
generated by most of the popular proof-reading polymerases lack this overhang 
(Newton et al., 1997). The proof-reading DNA polymerase used in this case 
produces blunt-ended PCR products and therefore the 3' overhanging A must be 
added artificially by incubation with Taq in the presence of dATP (Promega, 2002). 
The pGEM-T vector also has the advantage of using blue-white screening as a result 
of the cloning region being located in the lac Z gene. Colonies not containing an 
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Figure 6:1 Vector map of the cloning vector pGEM-T showing its major 
features. The vector uses ampicillin resistance for selection in E. co/i, and PCR 
products are inserted by means of A-T base pairing (taken from Promega, 2002). 
The gene encoding SLAM, was amplified from the QuickClone cDNA library using 
PCR alongside a negative control as shown in Figure 6:2. The negative control was 
performed under exactly the same conditions, with the exception that no primers 
were included in the reaction mix. Surprisingly the negative control yielded a band 
of 1.5 kb, which was also present in the experimental reaction and was probably the 
result of contamination in the PCR mixture. In addition to the band found in the 
negative control, a band of just less than 1 kb was also seen. This band agrees well 
with the predicted length of the SLAM fragment, which was 936 bp. 
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Figure 6:2 Agarose gel showing the amplification of SLAM from the 
QuickClone cDNA library. The gel shows the presence of a band of the predicted 
size for the gene encoding SLAM, in the test reaction, which is absent from the 
negative control. 
Figure 6:3 Digestion of SLAM pGEM-T with Ncol and Ndel. The digested 
plasmids 3 and 5 give an insert of the predcted size for SLAM. 
This band was purified from the gel, A-tailed using Taq DNA polymerase in the 
presence of dATP, ligated into the cloning vector pGEM-T, and used to transform 
chemically competent E. coli ToplO cells. 	The transformation yielded 
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approximately 500 colonies of which approximately 40 % were white colonies, 
signifying that they contain an insert. Six of these colonies were subjected to 
"miniprep", and the plasmids digested with Ncol and Ndel to reveal the size of the 
insert, as shown in Figure 6:3. Whilst it is clear that the digests did not go to 
completion, inserts of several different sizes can be seen. Representatives of each 
fragment length were sequenced, and clone 3 gave the published sequence for 
SLAM. This plasmid construct was then used as a template in the subsequent 
attempts to clone the SLAM! fragment for expression in P. pastoris. 
6.3. Expression of SLAMI in P. pastoris 
6.3.1. Cloning of SLAMI in pPICZa 
The N-terminal domain of SLAM had previously been shown to be necessary and 
sufficient for measles virus binding (Ono et al., 2001b). By comparing SLAM-1 
both functionally and structurally to MCP12 it should be possible to understand 
better the initial steps of a measles virus infection. 
The N-terminal immunoglobulin (Ig) domain of SLAM contains a putative 
disulphide bond, and is predicted be N-glycosylated at several sites. Therefore, for 
the reasons already described in chapter 3, initial attempts to express this domain of 
SLAM were performed in P. pastoris. The region encoding the N-terminal domain 
was amplified by PCR using the sequenced SLAM pGEM-T clone 3 as a template. 
Primers that incorporated asymmetric restriction sites (5' EcoRl and 3' Not 1) were 
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used to facilitate directional cloning required for the insert to be cloned in-frame with 
the alpha-factor secretion signal. The PCR product was then ligated into the P. 
pastoris expression vector pPICZa (see Figure 4:1), and used to transform 
chemically competent E. coli Top 10 cells. The expression vector pPICZa was 
chosen over pPIC9 for the reasons detailed in section 4.2.1. The transformation 
yielded a large number of transformants, eight of which were selected for miniprep, 
and the plasmids were digested with EcoRl and Not 1, to determine the presence and 
size of any insert. The result shown in Figure 6:4 demonstrates that all the plasmids 
contained an insert of the correct size for SLAM I. Clones 2 and 6) were sequenced 
and both contained an insert of the published sequence for SLAM 1. Clone 6 was 
taken and used in subsequent experiments. 
Clone I Clone 2 Clone 3 Clone 4 Clone 5 Clone 6 Clone 7 Clone 8 
1 kbp 
500 b bp 
bp 
bp 
Figure 6:4 Agarose gel showing SLAM1 pPICZa clones digested with EcoRl 
and Notl. The gel shows that each clone contained an insert of approximately 400 
bp which corresponds well with the predicted size of 420 bp for the SLAM1 
fragment. 
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The SLAM1 pPICZa plasmid was then linearised using Sacl and 10 .tg used to 
transform P. pastoris X33 cells by electroporation (1.5 kV, 200 0, 25 tF). The X33 
strain of P. pastoris is a wild type strain that exhibits Mut growth characteristics on 
methanol. The P. pastoris transformation yielded approximately 100 colonies that 
were able to grow on the selective medium (YPDS + 100 jtg.m1 1 zeocin). As is 
always the case for protein expression in P. pastoris it is useful to screen a number of 
colonies in search of a multi insertion event that often results in higher levels of 
expression (Higgins, 1998). Expression testing was performed using test inductions 
followed by SDS-PAGE. The induced culture supernatant was treated with EndoHf 
prior to SDS-PAGE in light of the experiences of hyperglycosylation gained with 
MCP. The SDS-PAGE gel is shown in Figure 6:5. It shows a band of approximately 
the predicted size for SLAM1 (15.6 kDa), however significant degradation is 
observed with each clone. Clone 12 was chosen for further analysis since it appeared 
to offer the optimum balance between expression level and degradation. It is 
possible that the observed degradation takes place during the deglycosylation 
reaction rather than during the induction phase, since the deglycosylation reaction 
requires incubation of the crude culture supernatant at 37 °C for extended periods. 
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Figure 6:5 Test inductions for SLAMI. The gel shows a significant amount of 
degradation and apparent differences in expression levels. Clone 12 was chosen 
since it appeared to have the optimum balance between expression level and 
degradation. 
6.3.2. Optimisation of expression conditions for SLAMI in X33 
As previously alluded to, the growth characteristics for the X33 strain are 
significantly different from the KM71 strain. These differences occur due to the 
methanol utilisation phenotype of X33 being MuC compared to the MutS phenotype 
of the KM7 I strain. Muts  strains of P. paswris exhibit considerably faster growth on 
methanol, compared to Mu( strains, and therefore it is worthwhile, in this strain, 
optimising the growth conditions for the induction phase. This was investigated 
using four induction flasks, each containing 250 ml of SLAM I X33 in BMM. Each 
of these cultures originated from the same resuspended cells obtained during the 
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growth phase. In each flask the starting methanol concentration was kept at only 
0.5% (v/v), to prevent cell death due to methanol poisoning before the cells had time 
to express the alcohol oxidase gene. The culture was subsequently induced for four 
days with daily feeds of methanol at concentrations of 0.5 %, 1 %, 2 % and 4 % 
(v/v). Samples were taken at regular intervals and A 600 's measured to follow growth. 
The culture supernatant was retained in each case to determine the level of 
expression by SDS-PAGE and the growth curves are shown in Figure 6:6. These 
indicate that growth rate and extent of growth are highest for the culture grown on 2 
% methanol, and that increasing the methanol concentration between 0.5 % and 2 % 
results in significantly higher growth. Furthermore, 4 % methanol results in less 
growth than 1 % methanol, indicating that growth is inhibited by the higher levels of 
methanol. The optimum methanol concentration appears to lie between 2 % and 4 
%. The level of SLAM 1 expression for each of the methanol concentrations tested 
was also monitored based on estimates using SDS-PAGE following treatment of the 
relevant culture supernatants with EndoHf. The gel shown in Figure 6:7,indicates 
that SLAM1 expression also happened to be optimal at 2 % Further growths were 
thus performed using a methanol concentration of 2 % during the induction phase. 
219 
Results and Disucssion 
Growth Curves for the Induction Phase of SLAMI X33 with Different Concentrations of Methanol. 
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Figure 6:6 Growth curves for the induction phase of SLAMI in P. pastoris 
X33, with different concentrations of methanol. The graph shows that both the 
rate and extent of growth of the cells increases with increasing methanol 
concentration, until at 4 % methanol the growth becomes inhibited. This result 
suggests that the optimum concentration of methanol for the growth of SLAM 1 X33 
cells during induction is 2 %. 
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Figure 6:7 SDS-PAGE showing optimisation of SLAMI. The gel shows that the 
optimum methanol concentration for induction of SLAM1 is 2 % and that the 
optimum induction time is four days. 
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Degradation, as had been observed in the test inductions, was also observed during 
the growth optimisation test. While expression levels increased with increasing 
induction time, the proportion of SLAM! that is degraded remains relatively constant 
throughout the induction period. This suggests that the optimum induction time for 
SLAM1 is four days, and therefore subsequent growths were performed using this 
induction time. The level of expression of SLAM 1 was estimated on the basis of 
SDS-PAGE to be in the region of 10 mg per litre of BMM. This estimate suggests 
that SLAM1 is expressed at a comparable level to that achieved for the MCP 
fragments. 
6.3.3. Verification that the expressed species was indeed SLAMI 
To determine that the species observed on SDS-PAGE was indeed SLAM, an 
immuno-blot was performed. Following SDS-PAGE, the gel was blotted onto a 
nitrocellulose membrane, and immuno-stained using anti-SLAM antibodies as the 
primary antibody (Nakamura et al., 2001). Antibodies were raised against was the N-
terminal ten residues of human SLAM. The immuno-blot shown in Figure 6:8 
clearly demonstrates that deglycosylated SLAM 1 is recognised strongly, and that the 
non-deglycosylated samples give little or no reaction. This supports the notion that 
the protein expressed is indeed SLAM 1. Moreover, the fact that the epitope used to 
raise primary antibody was mapped to the N-terminus of human SLAM, implies that 
the expressed protein must have an intact N-terminus. 
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Figure 6:8 Immunoblot of SLAMI. The blot shows that the expressed species is 
recognised strongly by anti-SLAM antibodies. The deglycosylated samples yield a 
single, strongly stained band of the correct size for SLAM 1, whereas the untreated 
sample either stains only poorly or the band is highly diffuse. 
In addition the observation that non-deglycosylated SLAM 1 does not react with anti-
SLAM antibodies, whereas deglycosylated SLAM I reacts strongly provides 
reasonable evidence that the recombinant SLAM I expressed by P. pastoris is 
glycosylated. Moreover, these data further suggest that the recombinant SLAM 1 is 
hyperglycosylated for the following reason. If it were not hyperglycosylated, one 
would expect to observe a reasonably discrete band, with a lower mobility on SDS-
PAGE, which is not observed in this case. The almost complete absence of an 
observable reaction to anti-SLAM antibodies could result from the glycans masking 
the epitope for the anti-SLAM antibodies. Since there is no glycosylation site in the 
epitope used to raise the antibodies, this would seem to be unlikely. The other 
possible explanation would be that hyperglycosylation of SLAM I results in a very 
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diffuse smear on a gel, like that observed with MCP, and that the concomitant 
reduction in the quantity of protein in each band reduces the signal from the 
immuno-staining procedure to below the threshold of detection. 
6.4. Attempts to purify the recombinant SLAM 
6.4.1. Purification of SLAMI on ConA sepharose 
Before describing the purification of SLAM 1 it is worth recapping what is already 
known about this protein. It is highly glycosylated, of approximately 15.5 kDa, and 
has a predicted p1 close to 9 (using the Expasy protparam protein parameter 
calculator - http://us.expasy.org/tools/protpararn.htmI) . One can attempt to exploit 
any of these properties during purification. Based on the fact that SLAM 1 expressed 
in P. pastoris is highly glycosylated, and that the glycosylation pattern found in P. 
pastoris proteins is of the high mannose type, it was decided that the use of ConA 
sepharose could make a useful first step of purification. It should allow the protein 
to undergo partial purification prior to deglycosylation, thus reducing the risk of 
proteolysis and degradation. The culture supernatant was concentrated to 20 ml 
using ultrafiltration (5 kDa MWCO) as described for the MCP fragments. The 
protein was then exchanged into the ConA binding buffer (500 mM NaCl; 50 mM 
Tris, pH 7.5) using a PD10 desalting gel filtration colunm. This solution (2 ml) was 
applied to a gravity-fed ConA sepharose column (5 ml) (Amersham Pharmacia 
Biotech), and 2 ml fractions collected. Unbound protein was washed away with 
binding buffer, and bound proteins eluted with a step-gradient of elution buffer (500 
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Figure 6:9 ConA purification of SLAMI. The chromatogram shows a significant 
amount of protein in both the bound and unbound fractions, indicating that a degree 
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mM NaCl; 50 mM Tris pH 7.5; 2 M methyl-a-D-gluco-pyranoside). The presence 
of protein was traced using absorbance at 280 nm. 
Purification of SLAMI on a ConA column 
The chromatogram shown in Figure 6:9 initially appears promising, with a 
significant amount of protein in the unbound fractions, and a proportion bound to the 
column and eluted subsequently with elution buffer. The presence of SLAM 1 was 
confirmed for the fractions numbered in the chromatogram (Figure 6:9), by using 
SDS-PAGE after EndoHrdeglycosylation of the fractions The resulting gel is shown 
in Figure 6:10, and appears to indicate that there is significant SLAM1 present in 
both the bound and unbound fractions. Moreover, there is a significant quantity of a 
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larger, contaminating protein (-j 65 kDa), present in the bound fractions. The 
quantity of crude concentrate applied to this column (estimated to be less than 1 mg 
of total protein) should be easily within the binding capacity of the column (— 30 mg 
of porcine thyroglobulin per nil of gel). 









Figure 6:10 SDS-PAGE showing the result of purification of SLAMI on ConA. 
The gel shows that significant amounts of SLAM1 are present in both the bound and 
unbound fractions. Moreover, large amounts of a - 70 kDa protein are present as a 
contaminant in the bound fractions. 
It was speculated that the reason for poor binding of SLAM 1 to ConA sepharose was 
the presence of non-covalently attached carbohydrates that have previously been 
found on proteins expressed by P. pastoris (Denton et al., 1998). In order to 
determine whether this was the case, a protein blot was prepared with glycosylated 
and deglycosylated SLAM 1. This blot was stained using the glycoprotein detection 
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kit (Sigma) which is an adaptation of the periodic acid-Schiff method (Devine, 
1990). This staining method effectively stains vicinal diol groups that are found on 
many of the glycans found in glycoproteins resulting in a deep magenta colour. 
Markers SLAMI SLAMI SLAMI SLAMI 
CRUDE PNSase Er,doH PHOase 
Endo H 
16.5k Da 
Figure 6:11 Blots of SLAMI stained using the glycoprotein detection kit from 
Sigma. The blot shows the presence of significant amounts of glycans, whose 
mobility on SDS-PAGE remains relatively unchanged following treatment with 
EndOH f and I or PNGaseF. 
The blot shown in Figure 6:11 indicates that the samples indeed contain large 
amounts of glycans that have a low mobility on SDS-PAGE. That the mobility of 
these glycans is largely unaffected by treatment with EndoHf and /or PNGaseF, may 
imply that the glycans are non-specifically bound to proteins; that they are 
unattached to any proteins; or that the glycoprotein to which they are attached is 
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insensitive to either Endoll f or PNGaseF. That glycans may co-purify with proteins 
expressed in P. pastoris has previously been observed in the case of bovine beta-
lactoglobulin (Denton et al., 1998). It is interesting , however, that the glycans 
appear to have a similar mobility to the contaminating protein found in the bound 
fractions from the ConA purification step. Together with the lack of sensitivity to 
EndoHf and PNGaseF, this implies a different form of glycosylation (eg 0-linked 
glycosylation). The presence of such large quantities of glycans in the crude SLAM 1 
samples, which may be binding to the ConA column in preference to SLAM1, could 
cause a dramatic reduction in the capacity of the column. For this reason it may 
prove useful to attempt to remove some of these glycans prior to purification with 
ConA sepharose. 
6.4.2. Reverse phase purification of SLAMI 
It still remains a goal to use ConA affinity chromatography as a purification step for 
the production of SLAM1, but it appears that the majority of the non-covalently 
attached glycans need to be removed first. Reverse phase chromatography is a 
suitable method for this initial purification step since glycans are generally less 
hydrophobic than most proteins. Moreover, reverse phase chromatography could in 
any case provide a useful means of purifying SLAM 1 from other contaminating 
proteins. Crude, concentrated SLAM1 was applied to a C4 reverse phase 
chromatography column pre-equilibrated with 90 % H20 (0.05 % v/v TFA), 10 % 
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acetonitrile (0.05 % TFA). Bound proteins were eluted with a linear gradient to 60 
% acetonitrile. 
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Figure 6:12 Purification of SLAMI on reverse phase chromatography. 
Fractions of 1 ml were collected deglycosylated and subjected to SIDS-PAGE. 
The reverse phase chromatogram shown in Figure 6:12 appears to show that several 
species have been separated. The fractions were lyophilised, deglycosylated with 
EndoHf and subjected to SDS-PAGE. This gel shown in Figure 6:13, indicates that 
the SLAM 1 co-elutes with large amounts of a protein of approximately 80 kDa, 
which appears to resemble the protein that co-purifies with SLAM 1 following ConA 
purification. Further attempts to purify SLAM I. by reverse phase chromatography 
used stationery phases with different hydrophobicities, but the fraction containing 
SLAM 1 always co-purified with this protein (data not shown). 
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Figure 6:13 SDS-PAGE showing the purification of SLAMI on a C4 reverse 
phase column. 
The difficulties experienced purifying SLAM I using reverse phase chromatography 
necessitated the exploration of other chromatography techniques. 
6.4.3. Hydrophobic interaction chromatography purification of SLAMI 
Given the success achieved in purifying MCP fragments using HIC, it was thought 
that this type of chromatography could also prove useful for purifying SLAM 1. 
Although HIC works on similar principles to reverse phase chromatography, the fact 
that the protein is probably unfolded in the latter but not in the former provides the 
potential for differential results. To this end a number of different 1-IIC stationery 
phases were explored, including phenyl, octyl, butyl, and isopropyl substituted 
media. Mobile phases containing 2 M, 1.5 M, and 1 M (NH4)2 SO4 were also tested, 
and of these binding to a phenyl Resource column (Amersham Pharmacia Biotech) in 
2 M (NH4)2SO4 50 mM Tris, pH 7.5, yielded the most promising results. 
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Figure 6:14 Hydrophobic interaction chromatography purification of SLAMI 
on a phenyl resource column 
Fr 	Fr4 	 Fr 18 Fr 19 Fr 23 Fr 24 Fr 25 Fr 26 





Figure 6:15 SDS-PAGE showing hydrophobic interaction chromatography 
purification of SLAM I on a phenyl resource column 
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The crude SLAM 1 concentrate was applied to a phenyl Resource column pre-
equilibrated with 2 M (NH4)2SO4 50 mM Tris pH 7.5. The chromatogram shown in 
Figure 6:14 appears promising, as it resembles the chromatogram obtained for the 
MCP fragments. The bound peak is broad, but this would be expected given the 
heterogeneity of the glycosylation profile. The SDS-PAGE gel shown in Figure 6:15 
reveals, however, that once again the SLAM 1 fragment co-purifies with abundant 
quantities of a protein of 80 kDa. This contaminating protein is presumably the 
same material that had co-purified with SLAM 1 during the previous purification 
attempts. 
6.4.4. Cation exchange purification of SLAMI 
Given the unusually high predicted p1 of the SLAM 1 fragment, cation exchange 
chromatography appeared to be a potentially useful method of purification. The 
SLAM 1 was deglycosylated prior to cation exchange chromatography to reduce its 
heterogeneity, and thus to facilitate uniform behaviour during cation exchange. 
Initial attempts at cation exchange on a MonoS HR 515 column (Amersham 
Pharmacia Biotech) were performed in 50 mM MES pH 6.0, and the chromatogram 
shown in Figure 6:16 indicates that the SLAM1 fragment did not bind to the column; 
indeed this was subsequently confirmed by SDS-PAGE of the flow-through fractions 
(shown in Figure 6:17). 
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Figure 6:16 Cation exchange purification of SLAMI on a MonoS Hr 5/5 column. 
The protein was applied to the column in 50 mM MES pH 6.0. It can be seen from 
the chromatogram that negligible quantities of protein are present in the bound 
fractions. 





Figure 6:17 SDS-PAGE of the flow-through fractions from the MonoS HR 5/5 
run under a number of different pH conditions 
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Since the SLAM1 fragment did not bind to the MonoS HR 5/5 column under a range 
of conditions, it was decided to attempt cation exchange. Sodium acetate buffers (20 
mM) at pH 5.0; 4.5; and 4.0 were used to equilibrate the column. SDS-PAGE 
showing the flow through fractions at each of these different pH conditions is shown 
in Figure 6:17, and demonstrates that the SLAM  passed through and did not bind to 
the resin. 
6.5. Discussion and future work 
The results presented in this chapter describe the cloning and expression of SLAM1 
in P. pastoris. Following optimisation of the growth and induction conditions, 
SLAM1 was expressed at levels of approximately 5 - 10 mg per litre of induction 
medium. Confirmation that this material was indeed SLAM1 was through the use of 
anti-SLAM antibodies during immuno-blot analysis. As was the case with the MCP 
fragments, it was determined that SLAM 1 was hyperglycosylated - this is perhaps 
not surprising given the number of glycosylation sites present in the protein. 
Despite the success achieved with the expression of SLAM1, a detailed analysis of 
this protein was negated by the difficulties encountered during the subsequent 
purification attempts. Under all of the conditions tested SLAM1 either failed to bind 
to the column, or co-purified with abundant quantities of a contaminating protein of 
80 kDa. To address this problem, gel filtration chromatography on a Superdex 75 
column (Amersham Pharmacia Biotech) was considered; however the viscosity of 
crude material from P. pastoris would have a detrimental effect on both the 
resolution and integrity of the column and was therefore not attempted. 
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Following the failure of the battery of chromatographic techniques tested above, it is 
probable that a purification tag may be required. A number of factors, however, 
complicate the use of such tags in this instance. The available tags in the pPICZa 
vector is a C-terminal (His) 6 tag, that follows the C-myc antibody epitope. This tag is 
uncleavable, and would result in the addition of a minimum of 23 extra amino acids, 
adding approximately an extra 20 % to the size of the protein. In addition, (His) 6 
tags, or the subsequent immobilised metal ion adsorption chromatographic (IIMAC) 
purification have been shown to affect the quality of a number of proteins expressed 
for structural biology (for a review see Ramage et al., 2002). Moreover, the 
successful use of such tags for the purification of proteins expressed in P. pastoris is 
not widely documented. It may also be possible to express SLAM 1 in E. coli, as it 
only has one putative disulphide bond and may be amenable to refolding; however 
time constraints prevented this from being attempted. 
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7. CONCLUSIONS AND FUTURE WORK 
The current debate as to the possible identities of the measles virus receptor is still 
on-going. A detailed appreciation of the initial processes in a measles virus 
infection, however, will only be realised with an in depth understanding of the 
structure and physiochemical behaviour of the viral receptor. 
It was the aim of this study to express and characterise the candidate receptors, as a 
first step in a larger effort to elucidate both their 3D structures, and their precise 
modes of interaction with the binding partners on the virus. In the process 
fundamental questions were addressed regarding the functions of the N-linked 
glycans of the second module of MCP. 
Initial efforts were directed towards a study of the region of MCP identified as being 
necessary and sufficient for measles virus binding - MCP12 (residues Fl— 1,131). 
The methylotrophic yeast, P. pastoris was selected as the most appropriate host, and 
was successfully engineered to secret MCP12 at levels sufficient for biophysical 
characterisation ('-10 mg MCP12 per litre of induction medium). 
The recombinant protein was hyperglycosylated. The excessive extent and 
heterogeneity of glycosylation rendered a detailed NMR spectroscopic analysis of 
this glycosylated form impractical. For such a study to be performed on MCP12, 
either the glycosylation sites would have to be removed by mutagenesis, or the 
glycans would require removal post-expression. The former route was not explored 
since it had already been demonstrated that mutation of the glycosylation site in 
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module 1 of MCP had a detrimental effect on the protein conformation and resulted 
in a largely undefined structure (O'Leary, 2000) - this is despite the lack of any 
known functional effect of the glycan on module 1 of MCP. Preliminary NItvIR 
analysis of enzymatically deglycosylated MCP12 indicated that this protein was not 
fully folded. Comparison with NIVIR spectra of recombinant MCP1 revealed that 
while the first module appeared to be properly folded, the second module was not. 
This observation fits with the known functional requirement of glycosylation in 
module 2 of MCP (Maisner et al., 1996), and with the observation in the crystal 
structure of relatively extensive contacts between these glycans and the polypeptide 
chain (Casasnovas et al., 1999) in module 2. It would have been possible to pursue 
further NMR studies of this sample of MCP12. Further efforts, however, were 
considered unlikely to advance significantly understanding of the structure of 
MCP12. The crystal structure is already known, and a solution structure of MCP1 
has been solved - therefore the main benefit of a solution structure of MCP 12 would 
lie in the information it could provide on the intermodular interface and this relies on 
properly folded protein that yields high quality NMR spectra. 
The observation that glycosylation might be critical for structural integrity merited 
further investigation. To this end, a glycosylated sample was analysed in a similar 
manner to that used for the deglycosylated protein.. Whilst detailed NMR analysis of 
glycosylated MCP12 could not be performed for the reasons given above, several 
experiments were nevertheless possible. The data acquired from these experiments 
implied that glycosylated MCP12 had a better defined structure than did 
deglycosylated MCP12 and that therefore the glycans play a structural role. Whilst 
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uncommon similar findings have been reported with other proteins (De Beer et al., 
1996; van Zuylen et al., 1997; Wyss et al., 1995). Further analysis of the 
hyperglycosylated and deglycosylated forms of MCP 12 by DSC indicated that these 
glycans did not directly stabilise the protein fold. The lack of a stabilising effect 
could be an artefact of hyperglycosylation as opposed to physiological glycosylation. 
When taken together these data led to the conclusion that producing the component 
modules of MCP separately would be useful for further progress. Since MCP1 has 
been characterised in isolation, further efforts were focussed on MCP2. 
The success achieved with the expression of MCP12 in P. pastoris led to its use for 
expression of the single module fragment of MCP2. The fragment was also 
successfully secreted, although at slightly higher levels than those obtained for 
MCP12. As predicted the MCP2 fragment was also hyperglycosylated, with 
approximately a three fold greater mass of sugar than protein. The NMR 
experiments performed on glycosylated MCP2 yielded spectra indicative of a highly 
structured protein. Detailed analysis of hyperglycosylated MCP2 by NMR 
spectroscopy could not be performed for the reasons given above. The NIMR 
experiments performed on deglycosylated MCP2 on the other hand yielded spectra 
that were indicative of a protein with a more poorly defined structure, and was 
potentially overly flexible. DSC analysis on both hyperglycosylated and 
deglycosylated MCP2, however indicated that the glycans have no significant effect 
on the thermal stability of MCP2. At first analysis, these data appear to be 
inconsistent with the NMR data, however the lack of a significant stabilising effect 
of these glycans could also be an artefact of hyperglycosylation. Additionally it is 
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possible that the flexibility of a protein can be reduced without necessarily increasing 
its thermal stability. 
To discount the hypothesis that it is the deglycosylation reaction itself that is 
responsible for the observed differences between the spectra of glycosylated and 
deglycosylated MCP2, a sample with native sequence that had never been 
glycosylated was required. Refolding a protein is often associated with high protein 
losses, and therefore it is desirable to express a large quantity of potentially unfolded 
protein prior to refolding. This end is usually most successfully achieved through 
expression in E. coli which generally gives higher levels of recombinant protein than 
other organisms. Initial expression attempts for MCP2 in E. coli produced MCP2 in 
sufficient quantities, however the protein was found entirely in inclusion bodies, 
which can cause significant downstream problems. Using molecular biology to 
prevent the protein going into inclusion bodies, can often prove more successful than 
attempting to solubilising inclusion bodies. Efforts were therefore focused on 
generating soluble protein through the use of the thioredoxin fusion tag. Expression 
of the subsequently generated fusion protein resulted in the fragment being found 
entirely in the soluble fractions. NvIR spectroscopic analysis of the purified soluble 
protein, revealed a spectrum with almost no dispersion from random coil. The NMR 
experiments performed on refolded B. coli MCP2 however yielded spectra with 
considerably more dispersion, indicating that the refolded MCP2 has acquired some 
structure. Comparison of the spectra from refolded MCP2 and deglycosylated MCP2 
shows that whilst the spectra are similar indicating that refolding was largely 
successful. 
238 
Conclusions and Future Work 
Expression of MCP2 from D. melanogaster S2 cells, proved successful, however the 
quantities of protein produced were insufficient for any significant characterisation to 
be performed. Moreover, the requirement to increase expression levels by 
approximately 100 fold appears unfeasible. It therefore remains a goal to produce 
MCP with a small and well defined glycosylation profile on module 2. In light of the 
experience gained through using different expression systems, it seems likely that 
some non-recombinant method may prove more successful. One such possibility is 
through the use of N-(beta-saccharide) haloacetamides (Wong et al., 1994) to 
specifically attach synthetic glycans to free cysteines in a recombinant protein. In 
this case, of particular interest would be the use of this type of system to attach the 
chitobiose saccharides, to a mutant protein where the asparagine residue of the 
glycosylation site has been replaced with a cysteine. This approach could potentially 
mimic the interactions seen in the crystal structure. 
It appears to be an intrinsic property of certain CCP modules to exhibit high 
flexibility. The failure to produce a CCP module containing proteins that give the 
very high quality spectra required for structural studies is a problem that has been 
encountered previously in our and other laboratories. Examples of these include 
VCP12, CR2-42, and GABAB receptor 1A modules 1-2. Other, CCP module 
proteins prove readily amenable to structural studies including VCP23 (Henderson et 
al., 2001), and fHl9-20 (A. Herbert, University of Edinburgh, unpublished results). 
The work carried out on SLAM was performed in an attempt to gain a fundamental 
understanding of the mode of action of measles virus binding. This insight would be 
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the result of considerable characterisation and preferably structural data, on both of 
these proteins. Whilst this goal was perhaps beyond the scope of this thesis, 
recombinant P. pastoris has been generated that expresses SLAM 1 at significant 
levels. Its purification proved troublesome due to both the continued presence of a 
large contaminating protein, and the heterogeneity associated with 
hyperglycosylation. The use of purification tags and alternative expression systems 
could potentially provide a route to the generation of this fragment with the yields 
and purity required for biophysical studies. 
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Appendix A: Buffers and Media Recipies 
Towbin buffer: Tris Base 
Glycine 
Methanol 
TAE (Tris Acetate EDTA) buffer Tris Base 
Glacial acetic acid 
0.5M EDTA 
TGS (Tris Glycine SDS) buffer Tris base 25 mM 
Glycine 250 	m 
SDS 0.1%(w/v) 
2* SDS PAGE loading buffer TrispH 6.8 100mM 
Dithiothreitol 200 mM 
SDS 4% (w/v) 
Bromophenol blue 0.2% (w/v) 
Glycerol 20% (v/v) 
LB (Launa Bertani) medium Tryptone 1% (w/v) 
Yeast Extract 0.5% (w/v) 
NaCl 1% (w/v) 
pH 7.0 
Low salt LB medium Tiyptone 1% (w/v) 
Yeast Extract 0.5% (w/v) 
NaCl 0.5%(w/v) 
pH 7.0 
YPD (Yeast Extract, Peptone, Dextrose) mediun Yeast extract 1% 
Peptone 2% 
Dextrose 2% 
BMG (Buffered Minimal Glycerol) medium potassium phosphate p 100mM 
YNB 1.34% 
Biotin 4* 10 -5% 
Glycerol 1% 
BMM (Buffered Minimal Methanol) medium potassium phosphate p 100mM 
YNB 1.34% 
Biotin 4* 10-5% 
Methanol 1% 
MD (Minimal Dextrose) medium 	 YNB 1.34% 
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